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Abstract 
Strategies for the Mitigation of Oxysterol-
Induced Cytotoxicity 
By 
Jacques M. Mathieu 
Chronic exposure to some oxysterols might contribute to deterioration of 
human or environmental health. Oxysterols are both biomarkers of oxidative 
stress as well as mediators of its damage, and play a central role in many 
independent, but converging, disease processes, such as atherosclerosis, 
Alzheimer's disease, and age-related macular degeneration. Therefore, the aim 
of this thesis was to identify enzymes capable of transforming oxysterols to either 
reduce their toxicity or facilitate their metabolism or excretion. 7-ketocholesterol 
(7KC), being amongst the most cytotoxic and recalcitrant of these compounds, 
was the main focus of this work. 
We isolated various bacteria capable of utilizing 7KC as a sole carbon and 
energy source. One of these, Rhodococcus jostii RHA 1, was subjected to 
rigorous transcriptomic and mutational analysis to elucidate its 7KC degradation 
pathway, which was similar, but not identical, to that of cholesterol. Metabolite 
screening revealed the reduction and subsequent removal of the 7 -keto moiety 
prior to the step catalyzed by HsaC, the enzyme responsible for cleavage of 
sterol ring A. Furthermore, cloning and expression of a number of reductases 
from two gene clusters that were highly up-regulated during growth on 7KC 
identified three reductases that are active against several closely related 
structural analogs, though not 7KC itself. 
7KC and a number of analogs were assayed for toxicity against human 
fibroblasts. Several enzymes were overexpressed in these fibroblasts by 
transient transfection with mammalian expression vectors to screen for their 
ability to mitigate 7KC-induced cytotoxicity. A LAMP1/choiesteroi oxidase 
chimera was found to be significantly cytoprotective to exposure to up to 50 IJM 
7KC compared to mock transfection as well as 7KC-transforming enzymes 
targeted to either the mitochondria or cytosol. Additionally, transfection with 
LAMP1 alone and treatment with 0.9% hydroxypropyl ~-cyclodextrin also 
reduced toxicity. Therefore, it seems likely that addressing 7KC toxicity within the 
lysosome is critical for cytoprotection. This work provides preliminary evidence to 
support this approach, and may have implications for the treatment of oxysterol-
associated diseases. However, further research is needed to evaluate the effects 
and safety of heterologous gene expression within the lysosome, both in vitro 
and in vivo. 
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Chapter 1 
Introduction 
Recognition of the deleterious effects of some oxysterols has led to 
increasing concern that chronic exposure might contribute to deterioration of 
physical or environmental health. Oxysterols are both biomarkers of oxidative 
stress as well as mediators of its damage, and play a central role in many 
independent, but converging, disease processes. High oxysterol levels in 
humans have been associated with seemingly disparate conditions such as 
atherosclerosis [4, 5], Alzheimer's disease [6, 7], Parkinson's disease [8], 
diabetes [9], iron and copper toxicity [10-12], age-related macular degeneration 
[13-15], osteoporosis [16], multiple sclerosis [6], and Niemann-Pick disease [17]. 
Additionally, oxysterol concentrations are determined by a combination of 
genetics, age, nutrition and physical environment, and consequently serve as a 
link between different risk factors. However, while a vast body of literature exists 
documenting the effects of various oxysterols, there is an overall deficiency in the 
knowledge of how to control their levels and mitigate their toxicity. 
The aim of this thesis is to identify and characterize enzymes capable of 
transforming oxysterols in a manner that reduces their toxicity or promotes their 
metabolism. 7-ketocholesterol (7KC), being amongst the most toxic and 
recalcitrant of these compounds, is the main focus of this work. Though strong 
evidence exists for the detrimental effects of 7KC, and other oxysterols, in 
various biological processes, questions remain regarding the extent of their role 
in the initiation and progression of pathogenic or endocrine disrupting processes, 
both in the environment and in vivo. Therefore tools capable of the selective 
transformation of these oxysterols serve two purposes: to verify or reject 
hypotheses concerning the effects of oxysterols and as potential catalysts to 
control oxysterol levels and mitigate their impacts in various media. 
1.1. General Background 
Though eukaryotic cells possess several mechanisms to facilitate the 
detoxification and elimination of oxysterols, these processes regularly fail in 
higher organisms, resulting in cell- and tissue-specific accumulations. One 
reason for this is a lack of sufficient catabolic capacity; many multicellular 
eukaryotes do not have the enzymes necessary to degrade the steroid nucleus 
or reverse sterol autoxidation. However, a number of bacteria and fungi are 
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capable of partial or complete sterol degradation, with some achieving complete 
mineralization in the absence of other carbon or energy sources [18-20]. Indeed, 
the microbial transformation of sterols and steroids has been exploited by the 
pharmaceutical industry since the 1950s for the development of novel 
compounds and synthesis routes [21). Research into microbial sterol 
biodegradation may therefore be beneficial in uncovering enzymes capable of 
specific oxysterol transformations. 
Microbial cholesterol degradation has been continuously and extensively 
studied for almost a century [18, 22-24]. Partial pathways for testosterone [25], ~­
sitosterol [26], and cholic acid degradation [27] have also been identified, and 
share many similarities. However, most research into microbial steroid 
conversions have focused on hydroxylations and side-chain cleavage [28, 29]; 
reactions that are used in the pharmaceutical industry for the production of 
natural or modified steroid analogs [30). Other bacterial steroid transformations 
that have been identified include both the hydrogenation of C=C bonds and 
dehydrogenation of C-C bonds within the steroid nucleus [31, 32], oxidation of 
alcohols to ketones [33, 34], and the oxidation of ketones to esters or lactones 
[35]. However, little is known about the enzymes involved, and a complete 
degradation pathway for any sterol has yet to be elucidated. 
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1.2. Objectives, Hypotheses and Significance 
This thesis investigates both the microbial degradation of the cholesterol 
derivative 7 -ketocholesterol and potential strategies to mitigate its toxicity. 
Specific objectives include to: 
1. Determine whether bacteria capable of metabolizing 7KC exist in the 
environment and assess their diversity. 
We hypothesize that the capacity to transform oxysterols is widely 
prevalent amongst indigenous microorganisms. Sterols are essential 
components of animal, plant, and fungal cells, and are therefore common in the 
environment, where the lack of their accumulation is indicative of their 
degradation. 
2. Determine the genetic basis of 7-ketocholesterol degradation in a 
microorganism. 
We postulate that the diversity of organisms capable of transforming 7KC 
is broad enough that we will discover a species amenable to laboratory culture 
for subsequent study. The transcriptomic analysis of an organism grown solely 
on TKC (relative to growth on alternative substrates) should discern the catabolic 
genes and associated enzymes involved in the catabolism of this compound. 
3. Characterize candidate enzymes for their ability to transform 7KC, and 
assess their feasibility for use in controlling oxysterol levels. 
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Once we have identified candidate enzymes for 7KC transformation, 
standard molecular biology techniques can be used to clone, express, and assay 
these enzymes. The feasibility of using any enzyme for therapeutic purposes 
depends on the toxicity of its product. Accordingly, we hypothesize that the 
enzymatic oxidation of TKC (e.g., by oxidation of the 3f3-hydroxyl group or side-
chain hydroxylation) or reduction of the 7-keto group (forming 7a-
hydroxycholesterol) will reduce the potential toxicity of TKC metabolites. 
However, due to the low prevalence of TKC in comparison to cholesterol, it may 
be difficult to isolate enzymes that are specific for 7KC. This is important as 
unintended transformation of cholesterol could have detrimental consequences in 
regard to membrane integrity, or the accumulation of more toxic intermediates, 
such as cholest-4-en-3-one. 
The significance of this research relates to the fact that, whereas a large 
number of studies have extensively detailed the physiological impact of 7KC, 
none have addressed the microbial degradation of this compound. Addressing 
this knowledge gap should provide information valuable for the purpose of 
selectively manipulating oxysterol levels in various matrices while avoiding 
unintended transformation of other compounds that may playa beneficial role. 
The ability to accomplish this is particularly relevant due to the high prevalence 
and cytotoxicity of 7KC, and would have potential implications for a number of 
fields. Specifically, oxysterols are of concern in environmental toxicology as 
several environmental contaminants, such as ozone and iron, contribute to their 
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formation in vivo. Additionally, oxysterols may accumulate to high levels outside 
of pulp mills and other industrial discharge zones where they cause endocrine 
disruption in susceptible aquatic species. Mitigation of the effects of these 
pollutants would therefore have implications for human health and safety as well 
as wildlife. Since oxysterols are rapidly formed during the cooking and 
processing of food, their concentrations may be unusually high in certain 
foodstuffs. Controlling dietary levels may therefore be of benefit to the food 
industry. And in the medical field, the ability to alter oxysterol levels could provide 
a means to either halt the progression of, or potentially treat, many different 
diseases. 
1.3. Thesis Outline 
Chapter 2 provides a summary of the sources, formation, and effects of 
oxysterols. It also illustrates how the human body metabolizes these compounds, 
discusses what environmental risk factors exist, and establishes a framework for 
understanding their relevance in disease processes. Some of the information 
present in this chapter was published in the form of a review paper [36]: 
Mathieu, J.M., J. Schloendorn, B.E. Rittmann, and P.J. Alvarez, Medical 
bioremediation of age-related diseases. Microb Cell Fact, 2009. 8: p. 21-
39. 
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Chapter 3 addresses the microbial degradation of 7KC; investigating the 
phylogenetic diversity of bacteria involved as well as the rate and extent of 
degradation [37], and was published as: 
Mathieu, J.M., J. Schloendorn, B.E. Rittmann, and P.J. Alvarez, Microbial 
degradation of 7-ketocholesterol. Biodegradation, 2008. 19(6): p. 807-13. 
Specific pathways in one model organism, Rhodococcus jostii RHA1, are 
explored in Chapter 4 using mutational analysis, transcriptomics, and metabolite 
screening as reported in [38]: 
Mathieu, J.M, W.W. Mohn, L.D. Eltis, J.C. LeBlanc, G.R. Stewart, C. 
Dresen, K. Okamoto, and P.J. Alvarez, 7-ketocholesterol catabolism by 
Rhodococcus jostii RHA 1. Appl Environ Microbiol, 2010. 76(1): p. 352-5. 
Chapter 5 is unpublished work that describes our efforts cloning, 
expressing, and assaying candidate enzymes from RHA 1 as well as several 
other sources. Chapter 6 is research being submitted for publication that details 
our investigation into 7KC cytotoxicity and strategies to mitigate its effects in vivo. 
Some of the basis for this chapter was previously published as a collaborative 
effort [39]: 
Schloendorn, J., T. Webb, K. Kemmish, M. Hamalainen, D. Jackemeyer, 
L. Jiang, J. Mathieu, J. Rebo, J. Sankman, L. Sherman, L. Tontson, A. 
Qureshi, P. Alvarez, and B. Rittmann, Medical bioremediation: a concept 
moving toward reality. Rejuvenation Res, 2009. 12(6): p. 411-9. 
7 
-----------------------------
Chapter 7 concludes with comments on the engineering significance of the 
final results, recommendations for future work, and addresses the overall impact 
of the thesis. 
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Chapter 2 
Literature Review 
Sterols are hydrophobic lipids present in appreciable quantity in both 
animal and plant tissue where they serve essential physiological roles as 
membrane components, hormones or hormone precursors, and modulators of 
signal transduction. They are characterized by a tetracyclic ring structure (steroid 
nucleus), a 3~- or 3a-hydroxy group, and a C-17 positioned aliphatic side chain 
(Figs. 2-1, 2-2). Oxidative modification of the steroid nucleus or side chain may 
occur through enzymatic or spontaneous mechanisms, forming oxysterols. 
Although these compounds normally represent a minor fraction of total sterol, 10-
6 to 10-3 in most cases [40], they are uniquely classified due to the alteration in 
biophysical properties generated by the additional oxygen substituent, which 
often results in substantial changes in functionality. The effect of these changes 
is dependent on many factors, though increased concentrations of oxysterols 
have generally been associated with disruption of cellular homeostasis, 
decreased cell viability, and increased cell death [41]. This may lead to 
dysfunction and injury at the histological level, resulting in the development or 
exacerbation of several pathological conditions. Indeed, oxysterols have been 
implicated in atherosclerosis [5, 40, 42], Alzheimer's disease [43, 44], age-related 
macular degeneration [14, 15, 45], and Parkinson's disease [46]. Recent findings 
also indicate that some oxidized phytosterols have endocrine disrupting 
capabilities that result in alterations to the reproductive capacity of certain 
species [47, 48]. 
Although considerable research has been performed on the biological 
effects and fate of a number of oxysterols within mammalian systems (for a 
thorough review see [49]), to date there is very limited research on the 
biotransformation of most oxysterols, and a scarcity of peer-reviewed 
publications regarding their microbial degradation. Knowledge of how these 
compounds are transformed and degraded by bacteria could prove beneficial for 
a number of reasons. For example, most oxysterols with C-7 bound oxygen 
groups have deleterious effects in vivo, and the identification and use of microbial 
enzymes that degrade C-7 oxidized sterols has been proposed as a possible 
therapeutic approach for the treatment of certain age-related diseases [50]. 
Furthermore, dietary intake of oxysterols has been reported to result in significant 
accumulation within human plasma [51], potentially contributing to the elevated 
oxysterol levels associated with increasing age [52-54]. Thus, information 
concerning their microbial transformation could also be used to identify enzymes 
useful in food processing and other biotechnological applications. Finally, the 
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endocrine disrupting potential of some oxysterols also motivates research on 
their biodegradation to mitigate their potential ecological and agricultural impact. 
2.1. Sources of oxysterols and mechanisms of formation 
Cholesterol, l3-sitosterol, and ergosterol are the three most abundant 
sterols, representing the animal, plant, and fungal kingdoms respectively. These 
three sterols, therefore, serve as parental compounds for the majority of 
oxysterol species, though cholesterol oxidation products (COP) are by far the 
most studied of the three (Fig. 2-2). By contrast, very little appears in the 
literature concerning oxyphytosterols, and even less for oxidized ergosterol 
derivatives. 
The presence of a /15 double bond in cholesterol and l3-sitosterol affects 
the conformation of both rings A and B, and increases the susceptibility of the 
unsaturation and adjacent allylic positions to a variety of radical as well as non-
radical oxidation reactions. Furthermore, as major components of the plasma 
membrane of cells, these sterols are in a position to encounter reactive oxygen 
species that cross this barrier. Autoxidation is initiated through hydrogen 
abstraction creating a carbon-centered radical, predominately at C-7 due to the 
lower dissociation energy of the carbon-hydrogen bond at this position (Fig. 2-1) 
[55]. This radical further reacts with oxygen to form a peroxyl radical and, after an 
additional hydrogen abstraction, yields either 7a- or 713-hydroperoxide (7a/l3-
OOHC). These hydroperoxides are further decomposed to 7a/l3-alkoxy radicals, 
11 
'iO 
7KC S,6EC 7(3HC 
ROS ROS 
Cholesterol 
HO 
CYP27Al 1 CYP7Al CYP46Al 
27HC 7aHC 24HC 
Figure 2-1. Oxysterol formation pathways. 7 -ketocholesterol (7KC), 7~­
hydroxycholesterol (7~HC), and 5,6-epoxycholesterol (5,6EC) are formed by 
reaction of reactive oxygen species (ROS) with cholesterol. 7a-
hydroxycholesterol (7aHC) is produced primarily in the liver by CYP7A 1 
during bile acid synthesis, 27 -hydroxycholesterol (27HC) is generated in 
many different tissues through the action of the mitochondrial enzyme 
CYP27 A 1, and 24-hydroxycholesterol (24HC) is produced mainly in neural 
tissue by CYP46A 1. 
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with subsequent reactions generating 7a/~-hydroxysterols and 7-ketosterols [56-
58], the major species formed by autoxidation. To a lesser extent, sterol ring 
oxidation yields the 5a,6a- and 5~,6~-epoxides, which are the result of lipid 
hydroperoxy radical attack on the /15 double bond with formation of a radical 
adduct at C-5 or C-6 and subsequent loss of an alkoxyl lipid radical [59]. Though 
generally a non-enzymatic process, ring oxidation of sterols may also occur 
through enzymatic processes. The generation of 7a-hydroxycholesterol by 
CYP7A is the most common example (Fig. 2-1). 
In general, side-chain oxidation of cholesterol derivatives occurs through 
enzymatic modification, with the predominant species being 24-, 25-, and 27-
hydroxycholesterol [60]. As an exception to this rule, 25-hydroxycholesterol may 
also be formed through auto-oxidative processes, but this is less common. 25-
hydroxycholesterol is normally a product of cholesterol 25-hydroxylase, a non-
heme iron containing protein localized in the endoplasmic reticulum (ER) and 
Golgi that is expressed in many tissues, albeit at low levels [61]. 24- and 27-
hydroxycholesterol are products of the cytochrome P450s cholesterol 24-
hydroxylase (CYP46A 1) and sterol 27 -hydroxylase (CYP27 A 1), respectively (Fig. 
2-1). CYP46A1 is highly expressed in neural cells and localizes to the ER while 
CYP27 A 1 is expressed primarily in the liver and macrophages and found in the 
mitochondria [62, 63]. 
~-sitosterol and ergosterol, in comparison to cholesterol, seem more 
susceptible to side chain autoxidation. The additional ethyl group at C-24 allows 
for 
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Cholesterol Ergosterol j3-sitosterol 
7 -ketocholesterol 7j3-hydroxycholesterol 5j3,6j3-epoxycholesterol 
27 -hyd roxycholesterol 25-hydroxycholesterol 24S-hydroxycholesterol 
atheronal-A atheronal-B 
Figure 2-2. Structures of common sterols and oxysterols. Panel A, the three 
most abundant animal, plant, and fungal sterols. Panel B, cholesterol oxidation 
products found in the highest concentrations in vivo. Atheronal-A and -8 are 
cholesterol 5,6-secosterols formed by the oxidative cleavage of the steroid 
nucleus. 
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a broader range of oxidation products from ~-sitosterol, which forms 24-, and 25-
hydroxysitosterol [64]. Ergosterol contains not only an additional methyl group, 
but a double bond in the side chain that increases vulnerability to auto-oxidative 
forces (Fig. 2-2) [65]. Ergosterol also contains a conjugated diene in ring B that is 
known to react with singlet oxygen to form ergosterol epidioxide (EEP) and 7-
hydroperoxide (EHP). EEP then undergoes immediate enzymatic isomerization 
to yield 5a,6a-epoxy-(22E)-ergosta-8,22-dien-3~,7a-diol (8-DED), the most 
predominant ergosterol oxidation product. 9(11)-dehydroergosterol (DHE) is also 
generated to a lesser extent by decomposition of EHP [66]. 
2.1. Occurrence of oxysterols 
Analytical measurements of oxysterols are experimentally demanding and 
commonly show great variability between labs. Accurate quantitation may suffer 
from losses during processing, the presence of interfering materials, artifact 
formation, the lability of particular species, and insufficient sensitivity of detection 
[58, 67, 68]. Additionally, losses may occur during separation or hydrolysis steps. 
Isotope dilution has been found to effectively overcome problems with artifact 
formation through the use of deuterium-labeled internal standards [69-71]. Solid 
phase extraction to separate sterols from oxysterols also benefits quantitation as 
does the use of electrospray ionization mass spectrometry [72, 73]. 
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2.1.1. Environmental oxysterol concentrations 
The environmental accumulation of oxysterols may occur in aquatic 
environments where waste discharge from pulp mills or fat processing facilities 
takes place. In the pulp and paper industry, lipophilic extractives containing high 
levels of sterol result in so-called "pitch deposits". Pitch deposition causes 
several problems including reduced production, higher equipment and operating 
costs, and the release of toxic compounds [74]. For 22 US pulp and paper mills 
tested, total sterol discharge rates ranged from 0.2 gfT to 25 gfT [75]. 
Approximately 70% of the sterols remaining in bleached pulp were determined to 
be oxidation products of ~-sitosterol [76]. 
~-sitosterol was also detected in sewage plant effluent in concentrations 
up to 402 ng/L, and in German rivers and tap water from 60 ng/L [77]. 
Additionally, it has been found that some natural sterols are not removed from 
treated wastewater at all [78]. Continuous exposure to these low levels of sterols 
and oxysterols is enough to elicit endocrine disrupting activity as demonstrated 
by both field data and experiments with zebrafish [79-81], though no studies have 
provided definitive evidence as to the identity of the responsible compound(s) 
[82]. Interestingly, it was found that microbial conversion of phytosterols results in 
enhanced bioactivity of the transformed fraction [80, 83, 84]. Considering sterol 
degradation in bacteria is predominantly an oxidative process, it is possible that 
phytosterol oxidation products may playa role in this phenomenon. 
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Sterols, and their oxidized derivatives, also accumulate in soil. In three 
agricultural soils tested, ~-sitosterol levels were the highest, with a range from 
0.9 to 30 mg kg-1. Ergosterol levels were similar at 0.3 to 24.2 mg kg-1, though 
cholesterol levels were lower, ranging from 0.2 to 2.4 mg kg-1 [85]. The relevance 
of excessive sterol or oxysterols levels in soil has not been considered, however 
extreme acidity, lack of aeration, and excessive water content have all been 
determined as factors that may inhibit the decomposition of sterols, resulting in 
elevated concentrations [86]. 
2.1.2. Food oxysterol concentrations 
Oxysterols have been found in a variety of foods of both plant and animal 
origin, including dairy products, liquid eggs and dried egg products, meat and 
meat products, fried foods, flour, potato products, and vegetable oils [51, 87-90]. 
In most food, levels are typically low, but their concentrations may be significantly 
increased due to processing and storage. In particular, heating and exposure to 
either air or radiation may increase oxysterol concentrations [91, 92]. Studies 
have shown that both temperature and heating time affect sterol oxidation. Other 
determining factors are sterol structure and lipid matrix composition. Interactions 
between different lipid matrices and temperatures have strong effects on 
oxysterol formation and the reaction pathways of oxidation. Specifically it was 
found that at low temperatures « 140°C) sterols were less stable in an 
unsaturated matrix than in a saturated matrix, while at high temperatures (> 
140°C) the reverse is true [93]. It has been shown that the oxysterol percent of 
cholesterol in meat increases between 0.3 to 0.8% during normal cooking, and 
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that oxysterol content doubled after storage for three months at -20°C [94]. In 
fact, several studies have indicated oxysterol levels in excess of 1 % total 
cholesterol [91] from food of animal origin. This has been found true of oxidized 
phytosterols as well, with concentrations routinely found in excess of 1 % total 
sterol [90]. Ghee, a clarified butter product used in Indian cooking, contains over 
12% oxysterols as a percent of total sterol [95]. The most common oxysterols in 
food are the major products of autoxidation, namely the 7-oxygenated 
derivatives. 
2.1.3. Dietary Intake of Oxysterols 
Oxysterol concentrations in vivo are a combination of endogenous 
sources and dietary supply. Mean intake for a cholesterol-low diet has been 
estimated at 3.0 mg/day and 0.7 mg/day for cholesterol and phytosterol oxidation 
products respectively [87, 89, 96]. However, the use of phytosterol-enriched 
foods may increase intake dramatically, with certain consumers ingesting an 
average of 3 to 6 g/day of phytosterol [97]. This would result in approximately 30 
to 60 mg/day of phytosterol oxidation products. 
After ingestion, sterols, along with any oxysterols, are absorbed by 
enterocytes and incorporated into chylomicrons which are secreted into the 
lymph and circulation via the thoracic duct. Ingestion of cholesterol-rich food has 
been found to cause a maximal increase in free plasma COP concentrations 
after 3 h and total plasma COP after 8 h, though no change in the total COP:total 
cholesterol ratio was observed. Analysis of COP in the chylomicron fractions 
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revealed an identical composition but with differing proportions as compared to 
diet, indicating different absorption rates for each oxysterol. In particular, 7-
ketocholesterol (7KC), cholestanetriol, and cholesterol-a-epoxide were 
underrepresented in the chylomicron as compared to 7a- and 7~­
hydroxycholesterol, which were present in greater proportion [51). Though the 
literature contains little data for COP absorption in humans, studies in rats have 
shown 7KC rates to be only 12% over 24 h, while those of 7a- and 7~­
hydroxycholesterol were 30% and 42% respectively [98). Phytosterol absorption 
rates are generally lower than those of their cholesterol analogs « 10%), but it 
has been found that a diet containing oxidized phytosterols increases the 
concentration of absorption of cholesterol oxidation products [99]. 
In the plasma, free COP may serve as a substrate for lecithin:cholesterol 
acyltransferase (LCAT). Esterification by LCAT promotes the incorporation of 
COP into lipoproteins, and movement of esters between different lipoproteins is 
facilitated by cholesteryl ester transfer protein [100, 101). The extent of 
esterification varies substantially for each cholesterol derivative, though 
approximately 90% of total COP in the plasma is in the form of acyl esters [51, 
70). Esterification of oxysterols decreases their solubility in the plasma and 
immobilizes them in the lipoprotein fraction. This has significant implications 
regarding the plasma clearance of these oxysterols and their associated 
lipoproteins. Normal metabolism of chylomicrons involves their extra-hepatic 
conversion to chylomicron remnants by endothelial lipoprotein lipase. During this 
transformation, lipids and fat-soluble antioxidants are retained and subsequently 
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transported to the liver for incorporation into VLDL [102]. However, it has been 
found that inclusion of oxysterols into chylomicrons reduces their metabolism and 
uptake by extra-hepatic tissue through alterations to chylomicron structure and 
composition. This results in increased delivery to, and retention of these particles 
by, the arterial wall [103, 104], and it has been found that their increased 
antioxidant content may further enhance uptake in macrophages [105, 106]. This 
implies that oxysterols may be selectively concentrated in certain cells and 
tissues relative to levels throughout the rest of the body. 
2.1.4. De novo synthesis and intracellular transport of cholesterol and 
oxysterols 
In higher eukaryotes, all nucleated cells are able to synthesize cholesterol 
through the melavonate pathway. The initial step in cholesterol biosynthesis is 
the formation of acetoacetyl-CoA from two acetyl-CoA molecules. Condensation 
of a third acetyl-CoA results in production of 3-hydroxy-3methylglutaryl coenzyme 
A (HMG-CoA). The reduction of HMG-CoA yields melavonate, which undergoes 
a series of phosphorylations and a decarboxylation to produce isopentenyl 
pyrophosphate (IPP). IPP polymerizes to form geranyl pyrophosphate (GPP) and 
farnesyl pyrophosphate (FPP). Since FPP is utilized in several biosynthetic 
pathways, the first dedicated step of sterol synthesis is condensation of two 
molecules of FPP to yield squalene. Further cyclization and demethylation yields 
cholesterol [107]. 
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De novo synthesis is estimated to account for 70% of total body 
cholesterol [108], with a production rate of approximately 9 mg/day/kg body 
weight [109]. While most cells are capable of endogenous cholesterol synthesis, 
the liver is the primary site of production and turnover, producing as much as the 
rest of the body does collectively. Excess hepatic cholesterol may be excreted as 
bile, used for steroid hormone synthesis, or secreted in the plasma through 
incorporation into VLDL. VLDL is processed into IDL, and subsequently LDL, by 
endothelial lipoprotein lipase. The smaller size of LDL particles allows them to 
penetrate the endothelium, where they may be assimilated by cells expressing 
LDL receptor (LDLR) or through pinocytosis. 
LDLR-mediated uptake is estimated to account for 65-80% of the 
clearance of LDL in humans [109]. LDLR is present on the plasma membrane of 
most cells, where it binds particles containing apolipoproteins B or E. Bound 
particles are endocytosed by clathrin-coated vesicles and transported to 
endocytic compartments for hydrolysis. Acid lipase hydrolyzes cholesteryl esters 
transported by the LDL, allowing the free sterol to exit the compartment. 
Besides being a carrier of cholesterol, LDL may incorporate oxysterols in 
the liver or undergo oxidative modification in the sub-endothelial region [110]. 
Extracellular oxidized LDL (oxLDL) undergoes receptor-mediated uptake by 
macrophage type I or type II class A scavenger receptors (MSR-A) [111], CD36 
[112] and lectin-like oxLDL receptor-1 (LOX-1) [113, 114]. Unlike the normal 
route of LDL uptake, these receptor-mediated pathways are not regulated by 
cellular cholesterol content and may lead to high intracellular levels of oxLDL and 
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its associated oxysterols. LDL is also susceptible to oxidative modification within 
the lysosome, resulting in the production of free or esterified 7KC and 7r3-
hydroxycholesterol [115, 116]. 
2.1.5. Environmental risk factors 
Environmental exposure to certain toxins or pollutants may also increase 
oxysterol concentrations in vivo. Ozone exposure has been found to increase the 
levels of 5r3,6r3-epoxycholesterol and secosterol in lung epithelium through 
reactions with cholesterol [117, 118]. Secosterols are unique cholesterol 
oxidation products in that they are formed via the oxidative cleavage of the 
steroid nucleus, whereas all other oxysterols are products of peripheral oxidation. 
Atheronal-A and -B (Fig. 2-2) are two such secosterols that have been detected 
in human lung surfactant, plasma, and atherosclerotic plaques. Plasma levels of 
atheronal-B vary from 20 to 500 nM, though ranges between 3 and 25 IJM are 
thought to exist within atherosclerotic plaques, with effects similar to 7KC at 
these concentrations [119]. 
Exposure to high levels of either iron or copper is strongly correlated with 
increased levels of oxysterols. While iron and copper are both essential to life, 
they are also transition elements that catalyze the formation of reactive oxygen 
species through Fenton chemistry: 
(1) Fe2+ + H20 2 ~ Fe3+ + OH· + OH-
(2) Fe3+ + H20 2 ~ Fe2+ + OOH· + H+ 
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In vivo, excess metals are normally stored and transported bound to other 
molecules; by ferritin and transferrin in the case of iron, and metallothioneins and 
ceruloplasmin for copper. However, saturation of these metal-binding proteins 
may occur, increasing the labile iron and copper pools, and consequently ROS 
levels as well. ROS subsequently react with sterols to produce oxysterols. 
Interestingly, it has also recently been discovered that iron nanoparticles, while 
displaying limited toxicity of their own, significantly enhance the cytotoxic and 
pro-inflammatory action of 7KC towards cardiac cells [10]. 
Smoking has also been found to increase the levels of circulating 
oxysterols [9]. The same study reported similar increases in patients suffering 
from diabetes mellitus. It is likely that any process which results in increased 
ROS generation will consequently raise oxysterol levels. 
2.2. Effects of oxysterols 
The proper proportion of sterol in the plasma and organellar 
membranes is essential for many cellular functions. Therefore, understanding 
intracellular sterol dynamics is critical to understanding how excessive levels of 
oxysterols can disrupt cellular homeostasis. Compared to other lipids, the 
atypical structure of sterols provides them with unique transport properties that 
allow them to quickly reach a state of chemical equilibrium within the cell. This 
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characteristic provides sterols, and their oxidation products, with an influential 
role in determining membrane properties [120]. 
2.2.1. Intracellular sterol dynamics 
In a typical mammalian cell, there exist approximately 6 x 108 sterol 
molecules, 35% of which are located in the endocytic compartment, and 50% 
contained in the plasma membrane. Sterol equilibration between the plasma 
membrane and the endocytic compartment occurs within 2-3 minutes, at a rate of 
106 sterol molecules per second. This process is thought to be facilitated by 
soluble lipid transfer proteins (L TP), which may interact with membrane proteins 
in the targeted bilayer. However, it was found that most sterol is still delivered to 
the endocytic compartment in preference to other organelles even when targeting 
capability was lacking. This may imply that the cytosolic leaflet of the endocytic 
compartment is maintained in a state thermodynamically favorable for sterol 
acceptance [120, 121]. 
The "umbrella model" has been used to describe the biophysical basis for 
sterol membrane stabilization. This model suggests that the mismatch between 
the hydroxyl group of cholesterol and the size of its non-polar region necessitates 
protection from exposure to water by other membrane lipids (Fig. 2-3). Therefore 
phospholipids with larger heads, such as phosphatidylcholine or sphingomyelin 
(-70 A\ preferentially associate with cholesterol, as compared to those with 
smaller heads such as phosphatidylethanolamine (-40 A2). As membrane sterol 
levels increase, the phospholipid heads are stretched and the acyl chains 
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become more tightly packed with cholesterol. This increased density is also the 
reason for the decrease in membrane permeability associated with elevated 
cholesterol concentrations. However, too large of a cholesterol concentration 
results in exposure of some molecules to water. These unshielded sterols have a 
greater chemical activity, or availability for a chemical or physical transition, and 
as such have a greater propensity to leave the membrane [120, 122, 123]. Acyl 
chain unsaturation is also important within this framework because of the effects 
it may have on lipid geometry in the bilayer. A larger degree of unsaturation 
results in a greater cross-section of the acyl chain, providing less space for 
cholesterol. Based on this, it is apparent that the phospholipid composition of a 
membrane helps determine its sterol concentration. Some evidence of this can 
be seen by comparing the acyl chain saturation of the plasma membrane to the 
endoplasmic reticulum (ER). Only 25% of phosphatidylserine acyl chains are 
saturated in the ER, while almost 90% are saturated in the plasma membrane. 
Accordingly, the ER retains only 5% of total cell cholesterol while the plasma 
membrane holds 35% [120]. 
The chemical activity coefficient is useful in explaining the asymmetric 
distribution of sterols in different subcellular locations: 
a = yc [1] 
where a is chemical activity, y is the chemical activity coefficient, and c is the 
sterol concentration [120]. From Eq. 1 it is easy to see how the chemical 
activities of different membranes can be in equilibrium while maintaining different 
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Figure 2-3. Sterol membrane interactions. Various sterol/phospholipid 
configurations are shown to illustrate the effect of oxysterols on membrane 
properties. A. Cholesterol preferentially associates with phosphatidylcholine 
(PC) due to its larger head size, which shields the hydrophobic body of 
cholesterol. B. The spacing between phospholipids is partially determined by 
the degree of acyl chain saturation. Greater saturation results in less room for 
cholesterol, and therefore increases its chemical activity and propensity to leave 
the membrane. C. Smaller phospholipid heads, such as that of 
phosphatidylethanolamine, can shield fewer cholesterol molecules, also 
increasing chemical activity. D. 7KC, due to its additional oxygen moiety, inserts 
in the membrane at a tilt with respect to cholesterol, increasing the distance 
between phospholipids with resultant depletion of cholesterol and increased 
membrane permeability. 
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concentrations of sterols (due to differing phospholipid composition). The 
coefficient may be lowered by favorable interactions, resulting in an increased 
membrane capacity of sterol. 
One of the principal roles of cholesterol is organization of membrane 
structure, which it accomplishes through increasing bilayer thickness, decreasing 
interfacial hydration, decreasing membrane permeability, restricting acyl chain 
movement, and formation of liquid-ordered (Lo) domains [124-128]. Lo domains, 
or lipid rafts, are regions of laterally organized lipid that exist within the bilayer. 
Proteins are hypothesized to target these regions due to interactions with 
cholesterol and sphingolipid, which encase the protein in a lipid shell [129, 130]. 
Several important roles are attributed to Lo domains, including endocytosis and 
signal transduction events [131]. 
2.2.2. The impact of oxysterol enrichment on ce"ular membranes 
Oxysterols that are incorporated into cellular membranes effectively 
displace cholesterol and may alter the biophysical properties of the membrane 
[128, 132]. Additionally, they are capable of passing between membranes orders 
of magnitude faster than cholesterol and may inhibit cholesterol-mediated 
processes [133]. The exact effect a given oxysterol has is dependent on the 
location and extent of oxidation, though side-chain oxidized sterols favor a 
horizontal orientation to the membrane surface, while nucleus oxidized sterols 
adopt a tilted orientation [128, 134, 135]. These differences in orientation, as 
compared to cholesterol, would tend to increase the chemical activity of 
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membrane sterol, resulting in depletion of cholesterol with corresponding 
changes in membrane organization. Results have indicated that 7 -oxygenated 
sterols do not insert as far into the lipid bilayer as cholesterol, and are less 
efficient at forming Lo domains [128]. Enrichment of Lo domains with 7KC, for 
example, results in reduced cholesterol efflux [136], increased apoptosis due to 
Ca2+ influx [137], and increased intercellular communication which may disrupt 
differentiation and proliferation [138, 139]. Although it has been suggested that 
normal oxysterol levels are too low to cause significant effects, recent evidence 
has indicated that in high-cholesterol membranes the difference in cholesterol 
between Lo and Ld domains is small [140, 141]. Additionally, some oxysterols 
preferentially partition to Lo domains, increasing their concentration beyond what 
would normally be expected [136, 137]. The effect of oxysterol displacement, 
therefore, could be substantial. Differences in interactions between phospholipids 
and oxysterols may also have effects on membrane curvature, with implications 
for transmembrane proteins [132, 142]. Furthermore, due to their increased 
hydrophilicity, many oxysterols have reduced membrane condensing activity with 
consequent increases in permeability [143], and have also been found to partition 
to organellar membranes that are typically low in cholesterol. 
Some oxysterols, notably 7KC, are potent inducers of phospholipidosis, a 
lysosomal storage disorder characterized by the presence of cytosolic lamellar 
bodies containing phospholipids as well as lipoprotein and other lipids [144, 145]. 
Currently, however, it is uncertain whether this is a defense response, or part of 
the cell death pathway. Incubation of U937 cells with 7KC caused lysosomal and 
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mitochondrial membrane permeabilization in a sequential manner, ultimately 
inducing either apoptosis or necrosis [146]. Eukaryotic cells contain at least two 
separate calcium-dependent apoptotic pathways: one modulated by calpain and 
the other calpain-independent [147]. Calpain has also been implicated in 
neuronal death following ischemic insult by initiating lysosomal rupture and 
subsequent cathepsin B release [148, 149]. The ability of 7KC to disrupt cellular 
Ca2+ homeostasis is likely integral to its toxicity [137, 150, 151]. Evidence for this 
is also supported by the prevention of 7KC-induced mitochondrial damage 
through the addition of calmodulin inhibitors [152]. How 7KC induces Ca2+ influx 
is still a matter of research, though it was found that it and several other 
oxysterols could increase ion conductivity in membranes lacking proteins [143]. 
2.2.3. The role of oxysterols in disease 
Due to the ability of oxysterols to dysregulate normal physiological 
function, they are also potential contributors to the initiation and development of 
disease. The most commonly encountered oxysterols are those with either a keto 
or hydroxyl group at the C-7 position of the steroid nucleus, and these also tend 
to be the species most detrimental to cell viability. C-7 modified sterols commonly 
have pro-apoptotic, pro-oxidative, and pro-inflammatory activities [40, 41, 146, 
153]. Amongst these compounds, 7KC is one of the most predominant and 
widely studied, principally due to its suspected involvement in various human 
pathological conditions such as atherosclerosis [5, 40, 154] and Alzheimer's 
disease [6, 7, 44, 72]. Oxysterols are also suspected to play a role in the 
progression of age-related macular degeneration [15, 45] and cataract formation 
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[155]. Levels of oxysterols in the lens and retinal pigment epithelial cells are 
known to accumulate to quantifiable levels with advancing age and may trigger 
cytotoxic effects. Furthermore, structural analogues of 7KC, such as 7-
ketositosterol and 7~-hydroxysitosterol which are derived from ~-sitosterol, have 
been found to be cytotoxic to a number of cell lines [156] and accumulate 
intracellularly [99]. 
While many of the diseases affected by oxysterols are independent of 
each other, they share convergent processes. Many only manifest at an 
advanced age, presumably due to the associated increase in oxidative stress or 
inflammation. This leads to increased in vivo oxysterol production which 
accelerates cell death, and consequently may initiate or accelerate the 
development of disease. Moreover, oxysterols have been found to increase ROS 
production [146], thereby creating a positive feedback loop for their own 
production. Several diseases in which oxysterols play a prominent role are 
explored in the following sections. 
2.2.3.1. Atherosclerosis 
Atherosclerosis is a progressive disease of the arterial blood vessels and 
the principle contributor to the pathogenesis of myocardial and cerebral 
infarction. As such, it is the leading cause of all mortality in the United States, 
Europe, and Japan [157]. Though the disease is highly ubiquitous, it has an 
extremely complex etiology that hinders the development of effective treatments. 
The earliest symptoms are lesions known as "fatty streaks," an aggregation of 
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lipid-rich macrophages and T-Iymphocytes within the sub-endothelial matrix that 
may be a result of arterial injury [158]. Remarkably, these early-stage lesions 
were found to exist in half of autopsy samples from children aged 10 to 14 [159]. 
Initiation and progression of "fatty steaks" to fibrous plaques is an inflammatory 
process that increases cell influx and proliferation at the site of injury, finally 
leading to the development of the advanced lesions that precede heart attack or 
stroke. 
A major component of atherosclerotic plaques is the foam cell: 
macrophages or smooth muscle cells containing large amounts of lipid derived 
from low-density lipoprotein (LDL). LDL is capable of diffusing passively through 
endothelial cell junctions, and its accumulation is a primary event in 
atherosclerosis, though its uptake in native form is not rapid enough to generate 
foam cells [111]. Native LDL, however, is oxidized in the sub-endothelial region 
[110] or within the lysosome [116] by various processes likely mediated by free 
radicals or reactive oxygen species (ROS). Extracellular oxidized LDL (oxLDL) 
undergoes receptor-mediated uptake by macrophage type I or type" class A 
scavenger receptors (MSR-A) [111], CD36 [112] and lectin-like oxLDL receptor-1 
(LOX-1) [113, 114]. Unlike the normal route of LDL uptake, these receptor-
mediated pathways are not regulated by cellular cholesterol content and may 
lead to high intracellular levels of oxLDL. Inhibition of MSR-A and CD36 has 
been shown to reduce atherosclerotic plaque size [160] and foam-cell formation 
[161]. Conversely, normal macrophages treated with oxLDL quickly become 
foam cells, accumulating free cholesterol (FC) and displaying reduced lysosomal 
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cholesteryl ester (CE) hydrolysis [162]. OxLDL is now widely regarded as a 
primary factor contributing to the development of atherosclerotic lesions, having 
been found cytotoxic to a variety of cell types. OxLDL also possesses a number 
of other atherogenic properties, such as inhibition of cholesterol efflux, increased 
expression of cellular adhesion molecules, and stimulation of macrophage 
proliferation [5, 40, 163, 164). Taken together, these properties may lead to 
plaque instability, increasing the chance of rupture. 
After endocytosis, LDL is delivered to the lysosome, where CE may be 
hydrolyzed and FC released. Lysosomal FC egress is mediated by Niemann 
Pick C proteins Type 1 and 2 (NPC) [165], which are believed to transfer FC to 
acceptor vesicles or directly to the plasma membrane before proceeding to the 
endoplasmic reticulum [166). Typically macrophages are protected from excess 
FC accumulation through acyl-coenzyme A:cholesterol acyltransferase (ACAT) 
re-esterification in the cytosol and cholesterol efflux. In atherosclerosis, however, 
intralysosomal FC accumulation occurs, followed by CE accumulation [167). 
This series of events has been observed not only in macrophages treated with 
oxLDL, but in aggregated LDL (aggLDL) and CE dispersion particles (DISP) 
[168). Acetylated-LDL (acLDL), however, is not able to achieve FC 
accumulation, instead forming cytosolic CE inclusions [169). This is curious, 
because acLDL is endocytosed by MSR-A, as is oxLDL. AcLDL is not 
endocytosed by LOX-1, however [113], and was not found to induce apoptosis at 
the concentration of oxLDL. Similarly, native LDL and cholesterol could not 
initiate apoptosis at as low of a level as oxLDL [170). 
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Recent research shows that intra-lysosomal FC accumulation inactivates 
the vacuolar-ATPases that maintain lysosomal pH, likely by partitioning to the 
lysosomal membrane and exerting a direct effect on the proteins [162]. This drop 
in pH subsequently inactivates acid lipase and other hydrolases, leading to CE 
accumulation. And while it may seem obvious that the unregulated uptake of 
modified LDL through scavenger receptors could provide the excess FC, the 
question arises as to why acLDL does not cause the same accumulations, 
especially considering aggLDL and DISP are unoxidized as well. Answers to this 
may lie in the resistance of oxLDL to lysosomal degradation [171] and to the 
observation that acLDL is degraded even more rapidly than native LDL [172]. 
OxLDL is also more resistant to degradation than either aggLDL or DISP [168], 
and it is also possible that aggLDL and DISP are oxidized within the lysosome 
[116]. 
Many of the effects of oxLDL, including cytotoxicity, can be attributed to 
one of its primary components, 7KC [5]. The average LDL particle contains 
approximately 600 molecules of cholesterol and 1600 molecules of cholesteryl 
ester (CE), all of which are susceptible to oxidation prior to and during uptake 
[173]. Non-enzymatic oxidation of cholesterol predominately occurs at the 7-
carbon of the steroid nucleus, a region associated with the greatest cytotoxicity 
[5, 40, 41, 146, 153]. Similar to cholesterol, 7KC partitions intracellularly to the 
plasma and organellar membranes [174], though its slightly higher polarity alters 
their biophysical properties [128, 175]. Several studies have found 7KC to 
increase disorder in membrane structure, altering curvature and the properties of 
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nearby membrane-bound proteins [132, 142]. In smooth muscle cells, 7KC was 
discovered to increase ROS production through up-regulation of NAD(P)H 
oxidase [176]. 7KC is also known to induce several pro-inflammatory cytokines, 
including interleukin-1~ [177], interleukin-6 (IL6) [178], and interleukin-8 (IL8) [53, 
179]. 
Due to its high concentration in atherosclerotic plaques [180-182], 
cytotoxicity, and other pro-atherogenic properties, 7KC is a prominent target for 
attenuation of atherosclerosis. Contributing to the rationale for its elimination is 
that 7KC has also been associated with Alzheimer's disease by several studies 
[7, 43, 183]. These two diseases share many similar risk factors, notably many 
involving cholesterol homeostasis. While FC alone has the ability to destabilize 
Iysosomes and hinder CE hydrolysis, the etiology of atherosclerosis is clearly a 
complex process, and 7KC certainly contributes. Reducing levels of 7KC may 
subsequently reduce the rate of LDL uptake and apoptosis, slowing 
atherosclerotic prog ression. 
2.2.3.2. Alzheimer's Disease 
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that 
increasingly affects millions worldwide and is the greatest cause of dementia in 
Western society. It is estimated that US annual incidence rates will surpass 
950,000 by 2050, affecting 62% of those 85 and older [184]. It has also been 
estimated that delaying the onset of AD by just two years would decrease the 
number of cases in the US in 50 years by approximately two million [185]. 
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AD is characterized by two neuropathological hallmarks: senile plaques 
composed primarily of extracellular amyloid beta (A~) deposits [186, 187] and 
neurofibrillary tangles (NFT) generated from intraneuronal accumulations of 
abnormal tau protein. A~ is a peptide of 39-43 amino acids formed by 
successive cleavage of amyloid precursor protein (APP) by ~- and v-secretases. 
While A~40 is the most common isoform, A~42 is most typically associated with 
progression of AD, accumulating first intracellularly, where it alters the normal 
metabolism of APP and promotes lysosomal APP accumulation [188]. Tau 
proteins are microtubule-associated proteins with six isoforms that exist in brain 
tissue. Hyperphosphorylation of tau causes self-assembly into paired helical 
filaments that are present in AD and several other tautopathies [189]. 
It should be noted that many factors involved in AD have also been found 
determinate of other pathologies. For example, over 100 genes have been found 
to be associated with AD, and many of these are also highly correlated with 
atherosclerosis [7, 183]. In fact, APP and A~ can oxidize cholesterol to 7~­
hydroxycholesterol, which can be subsequently oxidized to 7KC [44]. Another 
association between atherosclerosis and AD are the parallels found between 
Niemann-Pick disease and both aforementioned diseases [190]. Lysosomal 
dysfunction likely has a primary role in all of these processes [191]. 
Relationships between frontotemporal dementias, Parkinson's disease, and AD 
have also been discovered [192]. These may be a result of inflammatory 
processes, increased tissue transglutaminase [193], or some other factor, but 
usually the causes of pathogenesis are attributed to just a few compounds. In 
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AD, this is most often A~ or tau proteins, both of which may be useful targets for 
therapy, however 7KC may playa vital role as well, and reducing its levels could 
help stall AD progression. Apolipoprotein D, a neuroprotective protein that 
attenuates 7KC formation by binding cholesterol, is highly expressed in AD, as 
well as Parkinson's, Niemann-Pick, and other types of brain injury [194]. This 
may be indicative of the need to protect from 7KC formation. While total 
membrane cholesterol turnover is typically only 0.7% per day, this rate is much 
lower in the central nervous system, averaging approximately 0.03% per day 
[195]. The implication of this is that oxysterols may persist longer in the brain. 
Granted, oxidation should increase the efflux of these compounds, but this may 
not be enough to overcome an overall accumulation of oxysterols to 
concentrations that are cytotoxic. The ability to control oxysterol levels in the 
CNS may therefore be beneficial in the case of many neurodegenerative 
disorders where oxidative stress is a hallmark. 
2.2.3.3. Age-related macular degeneration 
Age-related macular degeneration (AMD) is a complex group of diseases 
that are the leading cause of blindness in people over 50 years of age in the 
developed world [196]. It currently affects approximately 8 million adults in the 
US, with an expected increase of over 50% by the year 2020 [197]. The first 
signs of AMD are typically deposits of protein and lipid, called drusen, which form 
between the retinal pigment epithelium (RPE) and Bruch's membrane. Damage 
to the RPE, as well as a chronic inflammatory response, lead to retinal atrophy, 
and subsequent choroidal neovascularization. These newly formed blood vessels 
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are often malformed and fragile, allowing blood to contact photoreceptors and 
other retinal cells, resulting in massive damage to the surrounding tissue [198]. 
7KC is present in appreciable quantity in the retina, where it is believed to 
be formed through iron-catalyzed free radical oxidation [199-201]. The retina 
contains high levels of iron that is normally bound to either ferritin or cytochrome 
c. However, light is known to liberate iron from ferritin [202], and hydrogen 
peroxide may cause iron release from cytochrome c [203], leaving the iron free to 
participate in Fenton chemistry. Additionally, drusen may accumulate significant 
levels of 7KC, which promotes macrophage migration, and consequent secretion 
of vascular endothelial growth factor and metalloproteinases. The former may 
lead to neovascularization while the latter can initiate membrane disruption [14]. 
Therefore, reduction of 7KC levels in the retina may help slow the progression of 
AMD, or help reduce the chance of its onset. 
2.2.4. Other diseases 
While atherosclerosis, Alzheimer's, and AMD are the most commonly 
cited diseases with regard to oxysterols, recent research is revealing a broader 
pathological role for these molecules. We have already mentioned the ability of 
oxysterols to perturb normal membrane structure and increase ROS formation. 
ROS, in turn, are capable of damaging many cell components, including DNA, 
lipids, and proteins. Accumulating damage can cause changes in gene 
expression with further consequences. Additionally, several studies have labeled 
particular oxysterols (commonly including 7KC) as mutagenic, as their levels are 
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correlated to both nuclear and mitochondrial DNA damage [204, 205]. 
Subsequently, these same oxysterols were determined to play a role in 
carcinogenesis [206]. And, as shown by Smith et al., normally non-mutagenic 
cholesterol that is heated in air becomes mutagenic to Salmonella typhimurium. 
This indicates a direct role for oxysterols, instead of an indirect role, regarding 
DNA damage. Oxysterols have also been found to cause an increase in protein 
ubiquitination and elicit changes in proteosomal degradation [207). Clearly the 
etiology of oxysterol-induced toxicity is complex and may affect almost every 
area of cell function. 
2.3. Elimination and detoxification of oxysterols 
Many enzymes that transform cholesterol are also able to utilize 
oxysterols as substrates (Fig. 2-4). Both ACAT and LCAT esterify oxysterols, 
which helps mitigate their cytotoxicity [100, 208]. In fact, the majority of both 
circulatory and intracellular oxysterols are esterified [70, 174, 209). Esterification 
of intracellular free cholesterol is necessary for proper regulation of membrane 
cholesterol levels, and the additional use of oxysterols as substrates allows for 
their incorporation into the same metabolically inert cytoplasmic pool. 
Side chain hydroxylation is effective in facilitating reverse cholesterol 
transport, and the same process may also help control intracellular oxysterol 
levels. Sterol 27-hydroxylase (CYP27A1) is known to act on some ring-oxidized 
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Figure 2-4. Mammalian pathways of 7KC detoxification. 7KC undergoes 
several transformations in mammalian cells, including reduction to 7~HC by 
11 ~-hydroxysteroid dehydrogenase; side chain hydroxylation by CYP27 A 1; 
sulfation of the 3~-OH moiety by SUL T28 1 b; and esterification by ACAT. 
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sterols, resulting in reduced cellular toxicity [210]. Elimination of oxysterols also 
proceeds via sulfation, catalyzed by cholesterol sulfotransferase enzyme 
(SUL T2B1 b). Expression of SUL T2B1 b has been found to attenuate the toxicity 
of some ring-oxidized sterols as well as suppress cholesterol biosynthesis [211, 
212]. 
Oxysterol export may occur via lipophilic acceptors such as HDL, a 
process mediated by membrane lipid transporters. ATP-binding cassette, 
subfamily A, member 1 (ABCA 1) has been found to export 7KC to apolipoprotein 
A1 (apoA1), though at a much lower rate than cholesterol [136, 213]. ABCG1 is 
also thought to promote export of both 7KC and 7J3-hydroxycholesterol to HDL, 
and there is evidence that it can protect against apoptosis and impaired 
endothelial cell function [214, 215]. However, mass transfer of 7KC is also seen 
from HDL to cells if the oxysterol content of HDL is sufficiently elevated. This 
mechanism of traffic is more consistent with scavenger receptor BI-mediated 
transport. In fact, cholesterol and oxysterol transport may occur in opposite 
directions simultaneously depending on the state of sterol loading [216, 217]. 
So how would it be possible to mitigate the effects of 7KC in vivo? A 
number of transformations may reduce its toxicity, with the most obvious 
example being side-chain hydroxylation. The addition of an oxygen-containing 
group to the 24- or 27 -carbon of the cholesterol side chain increases its ability to 
traverse cell membranes and allows migration through the blood-brain barrier for 
easier excretion [218, 219]. Sterol 27-hydroxylase catalyzes the formation of 27-
hydroxycholesterol, the most abundant oxysterol found in atherosclerotic 
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plaques, and is present in macrophages as well as the liver and several other 
organs [220-222]. It was also found to utilize 7KC as a substrate, facilitating its 
secretion [223]. Unfortunately, high levels of 270H-7KC still accumulate in 
lesions and foam cells. This may indicate that expression of sterol 27-
hydroxylase alone is not sufficient to overcome atherosclerotic progression or 
that the enzyme is not expressed highly enough to compensate for the increased 
cholesterol and oxysterol burden. Further testing of this enzyme is warranted. 
Another potential route of remediation would be removal of the 7 -keto 
moiety, which generates cholesterol, reducing toxicity to corresponding levels. A 
mechanism was recently discovered through which 7KC is reduced to 7P-
hydroxycholesterol (7P-OH-Ch) by 11 P-hydroxysteroid dehydrogenase type 1 
[224]. 7p-OH-Ch, however, is more cytotoxic than 7KC; thus, hydrolysis of the 
hydroxyl group would be necessary. Conversion of 7KC to 7a-OH-Ch is 
preferable, as the latter has a much reduced toxicity and is normally formed as 
an intermediate in the production of bile acid in the liver by cholesterol 7a-
hydroxylase [225]. Because an enzyme catalyzing the removal of the 7-0H 
group is not endogenous to humans, this function would have to be supplied 
exogenously. Our lab recently found evidence of a hydrolase in Rhodococcus 
jostii RHA 1 capable of removing a 7 -OH group from 7 -hydroxycholesterol and a 
number of its metabolites. Research is being performed to see if this enzyme will 
be an effective catalyst in human foam cells. 
Many microorganisms that catabolize cholesterol are able to cleave the 
steroid nucleus [20, 31, 226]. Steroid ring fission may facilitate endogenous 
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enzymatic attack in humans, though this is a purely speculative idea and it is 
unclear what effect the byproducts would have. Another possibility is 
manipulation of esterification. It has been theorized that oxLDL could accentuate 
accumulation of CE through inactivation of lysosomal acid lipase (LAL). In fact, 
exogenous supplementation with lysosomal acid lipase was previously shown to 
reduce the size of atherosclerotic plaques in mice [227]. Therefore, controlling 
the esterification of oxysterols may help reduce toxicity or facilitate efflux. 
2.4. Summary 
Oxysterols are a large class of compounds that were previously regarded 
as minor sterol metabolites with little physiological impact. Research over the 
past two decades has exposed their role as important, biologically active 
compounds that affect a wide variety of intracellular processes despite their low 
concentrations. The delay in understanding the effects of oxysterols is likely due 
to the difficulties encountered during their analysis, however new analytical 
techniques and research into the effect of different oxysterols on membrane 
properties has yielded promising results and accelerated the pace of research. 
Nevertheless, critical gaps in our knowledge still exist regarding 
oxysterols. For example, most cytotoxicity studies have used exogenously added 
oxysterols, often simply solubilized in ethanol, assuming that this method 
replicates conditions found in vivo. However, many oxysterols are formed 
intracellularly, and those of dietary origin usually enter the cell as oxLDL. 
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Additionally, many studies assay oxysterols individually while, in fact, they have 
been shown to work synergistically. 
Perhaps one of the most limiting factors in oxysterol research is an 
inability to selectively control their levels, whether in vitro or in vivo. Few studies 
have examined the subcellular distribution of these compounds, though where 
and how they accumulate is of paramount importance. For example, lysosomal 
accumulations of 7KC can lead to apoptosis, while accumulation in the ER 
initiates the unfolded protein response. Developing methods to reduce oxysterol 
levels in specific subcellular compartments would be invaluable in helping 
elucidate their effects, especially their association with age-related disease. In 
this thesis we investigate both novel methods of transforming 7KC and strategies 
for reducing its concentration intracellularly, particularly the lysosome. The broad 
diversity of organisms displaying the ability to degrade oxysterols provides a wide 
range of enzymatic mechanisms that can not only effect the transformation of 
7KC, but also cholesterol or other sterols that may contribute to pathogenesis. It 
is our hope that in mining the catabolic capacity of these organisms we are able 
to discover enzymes capable of transforming oxysterols, and that we can 
successfully apply this knowledge to controlling intracellular levels of 7KC. 
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3.1. Introduction 
Chapter 3 
Microbial Degradation of 7-
Ketocholesterol 
Oxysterols are oxidized derivatives of cholesterol that are widely 
distributed in nature and often exert potent and diverse biological effects. 
Although these compounds normally make up only a minute fraction of total 
sterol present when found naturally, usually 10-6 to 10-3 in most cases [228], 
oxysterols display high biological activity with synergistic effects observed even 
at low concentrations [229]. 
Many of the most commonly encountered oxysterols are those with either 
a keto or hydroxyl group at the C-7 position of the steroid nucleus. Amongst 
these compounds, 7-ketocholesterol (7KC) is one of the most predominant and 
widely studied, principally due to its suspected involvement in various human 
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pathological conditions such as atherosclerosis [5] and Alzheimer's disease [44]. 
There is considerable evidence suggesting that 7KC promotes these conditions 
through various cytotoxic modes of action, including induction of apoptosis [170]. 
In addition, 7KC has been found to increase Na+/K+ ATP-ase activity in 
fibroblasts [154], decrease Ca2+ uptake in human erythrocytes [230], stimulate 
monocyte differentiation [231], inhibit proliferation and stimulate differentiation in 
lens epithelial cells [155], and promote oxidative stress through reactive oxygen 
intermediate generation in murine macrophages [232]. Many oxysterols, 
including 7KC, have also been shown to inhibit HMG CoA-reductase [233], the 
first enzyme in the mevalonate pathway which controls a multitude of cellular 
processes such as cholesterol and sterol biosynthesis, proliferation, apoptosis, 
and possibly inflammation. 
In addition to human pathogenicity, some plant-derived sterols 
(phytosterols) are endocrine disruptors that can adversely affect environmental 
health. For example, ~-sitosterol (a phytosterol commonly present in pine pulp 
and paper mill effluents [234]) has been linked to the masculinization of resident 
fish populations [79], possibly through its microbial conversion to 
androstenedione [83]. Furthermore, structural analogues of 7KC, such as 7-
ketositosterol and 7~-hydroxysitosterol which are derived from ~-sitosterol, have 
been found to be cytotoxic to a number of cell lines [156] and accumulate in the 
bodies of animals [99]. 
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While microbial degradation of cholesterol has been extensively studied 
[18, 23, 24], and considerable research has been performed on the biological 
effects and fate of a number of oxysterols within mammalian systems, to date 
there is very limited research on the biotransformation of most oxysterols, and no 
peer-reviewed publications regarding the microbial degradation of 7KC. 
Knowledge of how these compounds are transformed and degraded by bacteria 
could prove beneficial for a number of reasons. For example, most oxysterols 
with C-7 bound oxygen groups have deleterious effects, and the identification 
and use of microbial enzymes that degrade 7KC has been proposed as a 
possible therapeutic approach for the treatment of certain age-related diseases 
[50]. Furthermore, dietary intake of oxysterols, the largest percent of which was 
7KC, has been reported to cause significant accumulation within the plasma of 
humans [51]. Thus, information concerning the microbial degradation of 7KC and 
other oxysterols could also be used to help remove some of these substances 
from food. Finally, the endocrine disrupting potential of some oxysterols also 
motivates research on their biodegradation to mitigate their potential ecological 
and agricultural impact. 
In this paper, we report the isolation of diverse bacteria capable of using 
7KC as a sole carbon and energy source. Thus, this study serves as a stepping 
stone to understand the microbial degradation of oxysterols for potential 
applications in wastewater treatment, food technology, and medical 
bioremed iation. 
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3.2. Materials and Methods 
3.2.1. Media and substrate. 
7KC was obtained from Sigma (St. Louis, MO) (97.1 % pure as determined 
by gas chromatography). A modified Hunter's Mineral Base medium (MSB) 
consisting of a dilution of three stock solutions was used in all experiments. The 
medium consists of 40 ml of solution A (141.2 9 Na2HP04 and 136 9 KH2P04 per 
liter, pH 7.25), 20 mL of solution B (10 9 nitrilotriacetic acid, 14.45 9 MgS04, 3.33 
9 CaCI2·2H20, 9.25 mg (NH4)6Mo7024·4H20, 99 mg FeS04·7H20, and 50 ml 
Metals 44 per liter) and 5 ml of solution C (200g (NH4hS04 per liter). Metals 44 is 
composed of 2.50 9 EDTA, 10.95 9 ZnS04·7H20, 1.54 9 MnS04·7H20, 5.00 9 
FeS04·7H20, 392 mg CuS04·5H20, 248 mg Co(N03h·6H20, and 177 mg 
Na2B40 7·10H20 per liter (final pH 7). 
3.2.2. Enrichment and isolation of bacteria. 
Activated sludge samples were acquired from the 69th Street Wastewater 
Treatment Plant and the Shell Westhollow Technology Center, both in Houston, 
TX. Soil samples were collected from numerous sites within Houston. Both the 
activated sludge and soil were exposed to 7KC within two hours of sampling. 
Enrichment cultures (100 ml) were created by transferring 1 ml of activated 
sludge (10-3 dilution with sterile water) or 1 ml of soil seed (suspended 10 9 100 
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mr1 into 100 ml of MSB amended with 7KC (1 g r1 or 0.0025 M) as the sole 
carbon source. Because 7KC is relatively insoluble (Table 1), the medium was 
sonicated prior to inoculation for 30 minutes in a bath sonicator to homogenize 
the solution and decrease 7KC particle size. 7KC initially floats on top of the 
medium until saturated and subsequently settles to the bottom of the flask. 
Sonication notably increases the turbidity of the solution and breaks up larger 
aggregates. Each culture was incubated at 30°C and 150 rpm in a gyratory 
shaking incubator until growth could be determined through visual inspection, 
and positive cultures were aliquoted (100 I-II) onto MSB agar plates with 5.0 mg of 
7KC in methanol evaporated to dryness on the surface. Plates were then 
incubated for 72 hours at 30°C and all colonies were picked and grown in batch 
cultures as above. One-ml samples of that the pure cultures that grew on 7KC 
were then added to 1 ml of sterile 40% glycerol and stored at -70°C until needed. 
3.2.3. Carbon dioxide measurements. 
Heterotrophic activity was measured per CO2 accumulation and 
respiration rates using a MicroOxymax respirometer (Columbus Instruments, 
Columbus, OH). Batches were prepared as above, though the volume used was 
50 ml and the temperature was 25°C. Each batch was inoculated with 5 1-11 of 
cells that had been grown overnight in LB media, centrifuged at 10,000g for 10 
minutes and washed in MSB minimal media a total of three times. Cells were 
resuspended to an OD600 of 1.0 prior to inoculation. 
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3.2.4. HPLC analysis. 
High performance liquid chromatography (HPLC) was used to verify 7KC 
degradation by the strains isolated. 25 ml batches were prepared as above and 
incubated at 30°C and 150 rpm. Five 100 1-11 samples were taken from each batch 
using large bore pipette tips. The samples were pooled and each processed in 
triplicate. 7KC was then extracted from the pooled samples twice, using 3 ml of 
3:2 hexane/isopropanol, and 1.0 ml of the organic layer was filtered through a 
0.22 1-11 Whatman syringe filter and capped inside an analytical vial. This filtrate 
was analyzed by reverse phase HPLC (0.72 ml min-1, 85: 1 0:5 
methanol/water/acetonitrile) using a Waters 2695 Separation Module with a 
Waters 996 photodiode array (235 nm) and a Waters NovaPak C18 column (3.9 
by 150 mm). Chromatographic data was analyzed with the Empower 2 software 
suite (Waters, Milford, MA). 
3.2.5. Growth on 7KC in the presence of a surfactant. 
To overcome grow-rate limitation by the rate of dissolution of 7KC, growth 
experiments were also conducted in the presence of Tween 80, a surfactant that 
is widely used to enhance the solubility of hydrophobic compounds. 
Pseudomonas aeruginosa was grown in 100 ml batches containing 2mM 7KC in 
MSB (30°C, 150 rpm). The 7KC was first dissolved in 7 ml of methanol, filter 
sterilized, and the methanol was evaporated off, allowing a fine crystalline layer 
to form along the bottom of the flasks to which 0.5-ml Tween 80 and 99.5-ml 
MSB were added. Controls were prepared in the same manner without the 
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addition of 7KC. Optical density (600 nm) was measured at one hour time 
intervals until log phase was reached. Thereafter measurements were taken at 
30 minute intervals. Samples with 00 measurements over 0.4 were diluted and 
re-measured until readings were under 0.4. The final 00 in these cases was 
determined by multiplying by the dilution factor. 
3.2.6. DNA extraction and amplification. 
DNA extractions were performed using an UltraClean Microbial DNA 
Isolation Kit (Mo Bio, Solana Beach, CA) according to the manufacturer's 
protocol. Amplification of 16S rONA was performed by polymerase chain reaction 
(PCR) using extracted DNA with a Taq PCR Master Mix Kit (Qiagen, Valencia, 
CA) and DGGE primers (DGGE-F: 5' -ATGGCTGTCGTCAGCT- '3 and DGGE-
R: 5'-CGCCCGCCGCGCC CCGCGCCCGGCCCGCCGCCCCCGCCCCACGGG 
CGG TGTGTAC -3') on a Biometra T-Gradient thermocycler (Goettingen, 
Germany). Amplification mixtures had a final volume of 100 1-11 and contained 0.5 
I-IM of each primer, 200 I-IM dNTPs, 1X PCR buffer, and 2.5 units of Taq 
polymerase. The temperature cycle for the PCR was 1 minute of denaturation at 
94°C, 1 minute of annealing, and 3 minutes of primer extension at 72°C. The 
annealing temperature was initially set at 53°C and reduced 1°C each cycle until 
it reached 43°C. This was followed by 20 additional cycles at 43°C and a final 
primer extension for 10 minutes. 
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3.2.7. Phylogenetic analysis 
Denaturing gradient gel electrophoresis (DGGE) analysis of the 16S rDNA 
gene sequence was used to ensure strain purity and identify bacteria for which 
DNA had been extracted. Analysis was performed on a Bio-Rad DCode™ system 
(Richmond, CA) (35 volts, 14 hours) and the gel (using denaturing gradients from 
30% to 80%) stained in ethidium bromide before visualization under UV. 
Samples which displayed one or a small number of bands had those excised, the 
DNA reamplified, and were sequenced (LoneStar Labs, Houston, TX). The 
sequences were matched against the NCBI GenBank Database 
(http://ncbi.nlm.nih.gov/Blast) and the Sequence Match facility of the Ribosomal 
Database Project (http://www.cme.msu.edu/RDP) for phylogenetic identification 
of the bacteria. 
3.3. Results and Discussion 
3.3.1. Isolation and identification of 7KC-degraders. 
Numerous bacterial species were isolated from soil and activated sludge 
by virtue of their ability to grow on 7KC as sole carbon and energy source. Two 
of five soil sample enrichment cultures, and all of the activated sludge samples 
tested utilized 7KC. After incubating aliquots of the cultures on MSB agar plates 
with 7KC as the sole carbon source, numerous colony-forming units (CFUs) 
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could be observed with distinct morphology and color. Each of these CFUs was 
then transferred into batch culture as described above, and those that retained 
the ability to grow were analyzed for strain purity using DGGE. Typically, visual 
evaluation of growth occurred between five and ten days for any culture surviving 
transfer from the plates to enrichment culture. 16S rDNA gene analysis based on 
percent similarity from NCBI BLAST search revealed y-Proteobacterium Y-134 
(99%), Sphingomonas sp. JEM-1 (98%), Nocardia nova (99%), and 
Pseduomonas aeruginosa (97%). Another mixed culture which we have been 
unsuccessful at plating on 7KC and MSB agar, but which grows well in 
enrichment culture, could not be reliably identified and were most closely 
associated with Xanthomonas sp. (85%) and uncultured a-Proteobacterium sp. 
(79%). This mixed culture was isolated from an activated sludge sample as were 
the y-Proteobacterium Y-134 and Pseudomonas aeruginosa. Sphingomonas sp. 
JEM-1 and Nocardia nova were both isolated from soil samples. In addition to 
those isolated, Rhodococcus sp. RHA1 (provided by William Mohn, University of 
British Columbia) was also tested for growth on 7KC. All of these isolates are 
either from the Proteobacteria or Actinobacteria phyla. 
3.3.2. Evidence of degradation 
The results of the HPLC analysis for 7KC degradation are presented in 
Figure 3-1. The most rapid degradation was observed with Nocardia nova, a 
known producer of biosurfactants [235], which removed the 7KC below detection 
levels within 20 days. It is likely that the degradation rate was dissolution limited, 
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as is the case with many hydrophobic compounds that experience faster 
degradation in the presence of biosurfactants [236, 237]. All other cultures still 
contained measurable amounts of 7KC at 25 days. UV detection from 190 nm to 
400 nm revealed no measurable accumulation of metabolites within that range. 
The absorption maximum for 7KC is 233 nm, allowing accurate determination of 
7KC concentration. However, other oxysterols are generally not as strong UV 
absorbers, so the extracellular presence of degradation intermediates cannot be 
ruled out. 
CO2 accumulation and respiration rates were determined through 
respirometry as illustrated in Figure 3-2 and Figure 3-3 respectively. For the y-
Proteobacterium Y-134., Nocardia nova, and the Sphingomonas sp JEM-1, 
noticeable respiration did not begin to occur until approximately 100 hours after 
inoculation, and peaked at just past 200 hours for all three. Rhodococcus sp 
RHA 1, however, did not begin noticeable respiration until 150 hours' time, and 
peaked at approximately 250 hours. The percent mineralization over a 300 hour 
period was 43% for y-Proteobacterium sp., 24% for Sphingomonas sp., 21 % for 
Nocardia nova, and 14% for Rhodococcus sp. RHA1. The purity of the 7KC was 
97.1 %, allowing a maximum of approximately 100 IJmoles of CO2 generated from 
other potential co-substrates. Rhodococcus sp. RHA 1 gave the lowest amount of 
accumulated C02, which was 460 IJmoles. y-Proteobacterium sp. released the 
highest amount of CO2 at 1442 IJmoles. 
53 
.-.. 
--l 
....... 
OJ 
'-" 
C 
0 
:;::::; 
C\l 
.... 
+-' 
c 
Q) 
0 
C 
0 
0 
0 
:::s::: 
I'--
1.2 
-.- y-Proteobacterium Y-134 
-0- Pseudomonas sp. 
--.....- Sphingomonas sp. JEM-1 
1.0 --v- Rhodococcus sp. RHA 1 
___ Nocardia nova 
-0- Control 
0.8 
0.6 
0.4 
0.2 
0.0 +----,--------,.----------.------+=======----~ 
o 5 10 15 
Time (days) 
20 25 30 
Figure 3-1. HPLC analysis of 7KC degradation. 7KC degradation by y-
Proteobacterium Y-134, Sphingomonas sp. JEM-1, Nocardia nova, and 
Rhodococcus sp. RHA1. This experiment was conducted at 30°C, pH 7. 
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Figure 3-2. Evidence for 7KC mineralization. CO2 accumulation (IJmoles) in 
batch reactors by y-Proteobacterium Y -134, Rhodococcus sp. RHA 1, 
Sphingomonas sp. JEM-1, and Nocardia nova in mineral salts media with 0.1 % 
7KC as the sole carbon source. Controls contained no 7KC. This experiment 
was conducted at 25°C, pH 7. 
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3.1. Growth on 7KC in the presence of a surfactant 
Due to the hydrophobicity of 7KC, which results in polydispersed colloidal 
particles with a tendency to precipitate, it is difficult to measure optical density 
unless the solution is properly suspended and diluted. In order to achieve a fine 
suspension, 7KC was first dissolved in methanol and filter-sterilized and 
evaporated to form a crystalline layer before the addition of Tween 80 (0.5 %) 
and MSB. This surfactant enhanced bacterial growth on 7KC. As shown in Figure 
3-4, exponential growth was achieved within hours when 7KC was present while 
no growth occurred without 7KC. This proves that 7KC rather than the surfactant 
or residual methanol served as sole carbon and energy source to support growth. 
In contrast, the HPLC (Fig. 3-1) and respirometry data (Fig. 3-2) suggest that, in 
the absence of surfactant, overcoming the lag phase took much longer, normally 
at least five days. .These results support the notion that 7KC biodegradation 
might be dissolution limited, and that compounds that enhance its effective 
solubility and bioavailability are likely to enhance degradation kinetics. 
3.1. Conclusion 
A diversity of bacteria from the Proteobacteria and Actinobacteria phyla 
were isolated from soil and activated sludge from wastewater treatment plants, 
based on their ability to exploit the biodegradation of 7KC as a metabolic niche. 
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Figure 3-3. CO2 evolution rates during 7KC catabolism. Rates of CO2 
evolution (IJmoles/min) in batch reactors inoculated with y-Proteobacterium Y-
134, Rhodococcus sp. RHA1, Sphingomonas sp. JEM-1, or Nocardia nova in 
mineral salts media with 0.1 % 7KC as the sole carbon source. Controls 
contained no 7KC. This experiment was conducted at 25°C, pH 7. 
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Figure 3-4. Effect of surfactants on 7KC catabolism. Growth of Pseudomonas 
sp. in MSB media and 0.5% Tween 80 with and without 7KC (ca. 1 9 r\ Optical 
density was determined at 600 nm. This experiment was conducted at 30 oe, pH 
7. 
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Carbon dioxide evolution in incubations with 7KC (but not in unamended 
controls) indicated extensive mineralization. Growth on 7KC as sole carbon 
source was also demonstrated, and noted to proceed faster in the presence of a 
surfactant; this suggests that 7KC dissolution might be a rate-limiting step. 
Overall, these results support the notion that oxysterol levels might be controlled 
in different matrices by biodegradation processes, and motivate further 
investigation into the specific pathways involved in microbial 7KC degradation, 
with the goal of identifying novel enzymes capable of transforming oxysterols for 
potential environmental, industrial, pharmaceutical, and medical applications. 
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Chapter 4 
7 -Ketocholesterol Catabolism by 
RhodococcusjostliRHA1 
4.1. Introduction 
Oxysterols are oxygenated sterol derivatives with potent and diverse 
activities in a wide range of organisms. In organisms and environments where 
sterols occur, oxysterols occur as abiotic degradation products, comprising a 
small fraction of total sterols, typically much less than 0.1 %. Nevertheless, 
oxysterols may exert significant effects at low concentrations and act 
synergistically. The predominant oxysterol species form through free radical 
reactions involving oxidation of the C-7 position due to the unsaturated ring 
structure of many sterols [238]. 7-Ketocholesterol (7KC), one of the most 
abundant and most biologically active oxysterols, has been the focus of a large 
body of research. 7KC is cytotoxic in mammalian cells [5, 41, 152], induces 
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apoptosis [146, 170, 239], and is associated with the pathogenesis of 
atherosclerosis [5, 40], Parkinson's disease [46], age-related macular 
degeneration [15, 45] and Alzheimer's disease [43, 44]. 7KC and other oxysterols 
can also modify the biophysical properties of cellular membranes, decreasing 
their fluidity and increasing their permeability. In certain cases this increases the 
calcium influx, decreases cholesterol efflux, and disrupts eukaryotic lipid rafts 
[128, 175]. Oxysterols derived from phytosterols have similar cytotoxic properties 
as 7KC, increasing early apoptosis and decreasing cell viability in several cell 
lines [99, 156, 240]. Although oxysterols may be generated in vivo in humans 
and animals [116], a significant amount can also be absorbed through the 
intestinal tract when cholesterol-rich food is ingested [51]. 
Mammalian cells are typically not capable of degrading the steroid 
nucleus, and 7KC or other oxysterols may accumulate intracellularly to 
pathogenic levels [41, 174]. This has prompted interest in medical 
bioremediation, the targeted use of exogenous enzymes (or the genes that 
encode them) to supply missing, or augment insufficient, catabolic functions in 
human cells [36, 50]. The aim is to enhance the degradation of recalcitrant 
pathogenic substances such as 7KC to prevent or ameliorate associated 
diseases. Thus, enzymes that could safely and effectively transform 7KC to a 
metabolizable form may have significant therapeutic value. In addition, research 
into oxysterol degradation pathways could be useful in mitigating the potential 
ecological and agricultural impact of oxysterols. While oxysterols are presumably 
degraded by microorganisms during decomposition, mechanisms for this 
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degradation have not been previously reported. We recently identified a variety of 
bacteria that were able to mineralize 7KC [241]. Among these, Rhodococcus 
jostii RHA 1 was selected for further investigation of 7KC degradation due to the 
availability of the annotated RHA 1 genome sequence 
(http://www.rhodococcus.ca) as well as knowledge of its cholesterol degradation 
pathway [1]. 
RHA 1 belongs to the Actinobacteria, a diverse and ubiquitous group of 
gram-positive bacteria that are abundant in soil and other environments. The 9.7-
Mb genome of RHA 1 encodes the degradation of a broad range of organic 
compounds, including various steroids [242, 243]. Based on previous 
identification of genes encoding bacterial steroid catabolism [244-247], RHA 1 
appears to have several large gene clusters that encode steroid catabolism (Fig. 
4-1). These clusters encode a number of enzymes that may be isofunctional or 
catalyze analogous reactions with metabolites of different steroids. 
Transcriptional analysis indicated that many of the genes in Cluster 1 were up-
regulated during growth of RHA1 on cholesterol [1]. Further bioinformatic studies 
and analysis of gene deletion mutants permitted elucidation of several steps of 
cholesterol catabolism by RHA 1 (Fig. 4-3). However, it is not yet known whether 
enzymes encoded in Cluster 1 degrade other steroids. Furthermore, the possible 
roles of enzymes encoded in the other clusters in steroid degradation remains to 
be explored. 
This study compared cholesterol and 7KC catabolism by RHA 1, with the 
aim of identifying enzymes particular to 7KC metabolism. We utilized microarray 
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transcriptomic analysis to compare gene expression in RHA 1 cells grown 
separately on pyruvate, cholesterol, or 7KC as the sole organic substrate. 
Reverse-transcriptase quantitative PCR (RT -qPCR) was used to verify selected 
microarray results. To assess the roles of selected enzymes, gene deletion 
strains were tested for growth and metabolite accumulation. 
4.2. Materials and Methods 
4.2.1. Bacterial Growth 
RHA 1 was cultivated at 30°C on a shaker (200 rpm) in a modified mineral 
salts medium (pH 7.2) consisting of NaNH4HP04-4H20 1.74 g/l, NaH2P04·H20 
0.54 g/l, MgS04·7H20 0.2 gIl, KCI 0.04 g/l, FeS04·7H20 5.0 mgll, and trace 
mineral solution 1 mLlI [248]. The composition of the trace mineral solution was 
H3B03 2.86 gIl, MnCb·4H20 1.81 g/l, ZnS04·7H20 0.22 gIl, CuS04·5H20 0.08 gIl, 
CoCI2·6H20 0.06 gIl, and Na2Mo04·2H20 25.0 mg/\. All media were 
supplemented with 20 mM pyruvate, 2 mM cholesterol, or 2 mM 7KC. Bath 
sonication was used to reduce particle size and facilitate suspension of both 7KC 
and cholesterol in the media. Continuous shaking was sufficient to prevent 
aggregate formation. 
Triplicate cultures were used for all experiments, including measurement 
of specific growth rate, growth of mutants, RT-qPCR, and microarray analysis. 
Growth rates were measured by protein assay for 7KC and cholesterol, and 
63 
optical density (00600) for pyruvate. Total protein content was measured in cells 
disrupted by alkaline lysis using the microBCA (bicinchoninic acid) protein assay 
(Thermo Scientific, Rockford, IL). 
For both microarray and RT-qPCR analysis, cells were harvested from 
cultures in mid-log phase, corresponding to total protein values of 60, 80 and 40 
IJg/ml for cultures grown on pyruvate, cholesterol and 7KC, respectively. Prior to 
harvesting cells, a 1/10 volume of "stop solution", consisting of 1 0% phenol in 
ethanol, was added to the cultures to preserve RNA. Cells were then centrifuged 
at 7,000 x g for 10 min at 4°C and resuspended in 1 mL of supernatant. 2 mL of 
RNAProtect (Qiagen) was added to the suspension, which was incubated for 5 
min at room temperature. The mixture then underwent additional centrifugation at 
14,000 x g for 2 min, after which the supernatant was removed and the cells 
frozen at -80°C. 
4.2.2. RNA Extraction and Microarray Analysis. 
Total RNA was isolated from RHA1 as previously described [249]. Briefly, 
this consisted of vortexing cells with glass beads (3 mm), phenol and sodium 
dodecyl sulfate (SOS), after which debris was removed with phenol and 
chloroform. Nucleic acids were precipitated using isopropanol and treated with 
DNase I (15 U/225 IJI RNA sample)(lnvitrogen). Samples used for RT-qPCR 
were subjected to an additional treatment of TURBO DNase (2 U per 225-1J1 RNA 
sample; Ambion, Austin, TX). The RNA was purified by phenol-chloroform 
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extraction, isopropanol precipitation, and an RNeasy kit using the manufacturer's 
protocol (Qiagen, Valencia, CA). 
Transcriptomic analysis was done using indirectly labeled cDNA and an 
8,313-gene microarray with 70-mer probes. The current array (GEO platform 
reference GPL7627) is an expansion of a previously described version [250]. 
cDNA synthesis, labeling and microarray hybridizations were performed as 
described [249], and data analyzed by GeneSpring (Agilent Technologies, Palo 
Alto, CA) using Locally Weighted Linear Regression (Lowess). 
4.2.3. RT -qPCR 
In order to validate the microarray data, the expression ratios of ten genes 
(Table 4-1) were determined relative to the expression of a housekeeping gene, 
DNA polymerase IV (Gene ID ro01702). DNA polymerase IV is steadily 
expressed under a variety of growth conditions and therefore serves as a 
suitable endogenous control [249]. RNA prepared for RT-qPCR, was reverse 
transcribed using a First Strand cDNA Synthesis Kit (Fermentas, Hanover, MD) 
and random hexamers according to the manufacturer's instructions. 
Amplification of RT-qPCR products was carried out using SYBR Green as 
a detection system. Primers were designed using PrimerQuest 
(http://www.idtdna.com/Scitools/ Applications/PrimerquestlDefault.aspx) with 
real-time PCR as the parameter set. Each reaction mixture contained 25 1-11 
Power SYBR Green PCR Master Mix (2X), 0.5 I-IM forward and reverse primers, 
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50 ng template cDNA, and RNase-free water to bring the final volume to 50 1-11. 
The conditions for RT -qPCR were 2 min at 50°C, 10 min at 95°C, 40 cycles of 15 
sec at 95°C and 1 min at 60°C, followed by a final step of 1 min at 60°C. The Ct 
values were normalized (/1 Ct) by subtracting those of the endogenous control, 
and confidence levels were tested using a two-sample t-test. Relative expression 
results were compared using the zMCt method [1]. Purity of the amplified 
products was determined by the presence of a single band of the correct size in a 
2% agarose gel stained with ethidium bromide. 
4.2.4. Gene deletion and replacement 
Two RHA 1 strains with unmarked deletions of the supAB and 
mce4ABCDEF genes as well as one strain in which the hsaC gene was replaced 
by an apramycin resistance gene were previously described (Table 4-2). 
Unmarked deletions of hsaA and cyp125 were performed using the sacB counter 
selection system [246]. GeneRunner software was used to design 
oligonucleotides with appropriate restriction sites that amplified flanking regions 
of each gene. Vector plasmids were transformed into E. coli DH5a by 
electroporation, verified, and then transformed into 817 E. coli competent donor 
cells maintained with 25 I-1g mr1 kanamycin. Conjugative plasmid transfer was 
achieved by co-culturing the donor and R. jostii RHA 1 on selective LBP plates 
amended with 30 I-1g mr1 nalidixic acid plus 50 I-1g mr1 kanamycin followed by 
sacB counter selection. Confirmation of the removal of the target gene in 
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Table 4-1. Genes and primers used for SYBR Green quantitative peR 
assays. 
Gene 10 Protein Primer Function 
DNA Forward Primer: 5'GACAACAAGTTACGAGCCAAGATC3' 
ro01702 polymerase IV Reverse Primer: 5'CCTCCGTCAGCCGGT AGAT3' 
Forward Primer: 5'AACCGATCACTGCGACTGGATCTT3' 
ro02489 hydroxylase 
Reverse Primer: 5'TTCCGGACGATGATGTCCTTGGAA3' 
ketosteroid-9- Forward Primer: 5'ACCTGGAACTCCATGCTGATCGAA3' 
ro04538 
a-hydroxylase Reverse Primer: 5'TTGAAGTACGTCGGGAACGCGT AA3' 
3-HSA Forward Primer: 5'ACGTCGTA TTCCCGACGATTCCAT3' 
ro04539 hydroxylase Reverse Primer: 5'TGCCAGTTGTGGACACCGATGAT3' 
3,4-DHSA Forward Primer: 5'GCTCCGCAAGAAGGTCAAGATGT3' 
ro04541 dioxygenase Reverse Primer: 5'GGGTCTTCATGTAGAACGACAGCA3' 
cytochrome Forward Primer: 5'AGAAGTTCGACATCATGCGGGAGA3' 
ro04679 P450 CYP125 Reverse Primer: 5'CAGGTGATCCGCAA TCGCA TTGAA3' 
MCE family Forward Primer: 5'ACATGATGTCGCTGATTCCCTCCA3' 
ro04698 protein Reverse Primer: 5' AGACCGTGTTGAACTCGACGGT AA3' 
Forward Primer: 5'TTGTTCAACATGCCGTACTCCTGC3' 
ro05068 hydroxylase 
Reverse Primer: 5'TTCTCCT ATCGCACTGAGCACGT A3' 
Forward Primer: 5'AAGGATGCGTTCATTCCTCAGCAC3' 
ro05802 hydroxylase 
Reverse Primer: 5' AGATGCACGAGAACGGGAAGTTGT3' 
probable Forward Primer: 5'ACCGGATCAAGAGGAACTACGAGA3' 
ro05812 hydroxylase Reverse Primer: 5'TCGTTCCCGCATGAACGTCAAGT A3' 
ketosteroid-9- Forward Primer: 5'CCTGGACGAAGACCTGATCCTGTT3' 
ro05833 
a-hydroxylase Reverse Primer: 5'GTTCGCGT ACACCAGAACGACTTT3' 
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kanamycin-sensitive, sucrose-resistant colonies was verified by colony PCR 
using two sets of primers: the "external" pair matched sequences flanking the 
target gene and "internal" pair matched sequences within the target gene. 
Screening of the hsaA mutant yielded the expected 0.72 kb fragment 
using the external pair and no band using the internal pair. By contrast, wild-type 
RHA 1 yielded fragments of 1.54 and 1.00 kb, respectively. Similarly, screening of 
the cyp12S mutant yielded the expected 1.99 kb fragment using the external pair 
and no band using the internal pair. By contrast, wild-type RHA 1 yielded 
fragments of 3.22 and 1.26 kb, respectively. 
4.2.5. Bioinformatic analysis 
Promoter, gene, terminator, and operon prediction was performed for the 
entire RHA 1 genome using both the fgenesB and PromScan algorithms, and 
through submission to RAST (Rapid Annotation using Subsystem Technology) 
[251]. Annotations were compared to those found at the Rhodococcus Genome 
Project (http://www.rhodococcus.ca). Genes that were both up-regulated on 7KC 
and were differently annotated by RAST versus the previous report were further 
examined using ClustalW multiple sequence alignments with reference 
sequences in order to determine the most probable function for the encoded 
proteins. Comparison was also made using FIGfam data and cluster analysis 
from RAST. Protein localization was performed using a combination of the 
PSortB, SignalP 3.0, and Subloc 1.0 algorithms [252-254]. 
68 
Table 4-2. Strains and plasmid used in this study. 
Strain or Characteristic( s) Source 
plasmid 
Strains 
R. jostii RHA 1 
RHA1 Wild type M. Fukuda 
RHA010 RHA 1 with hsaC replacement [1 ] 
RHA017 RHA 1 with hsaA deletion This study 
RHA018 RHA 1 with cyp 125 deletion This study 
RHA020 RHA 1 with mceABCDEF deletion [1 ] 
RHA021 RHA 1 with supAB deletion [1 ] 
E. coli 
DH5a Host used to clone and maintain conjugative Bethesda 
plasmid Research 
S17-1 Donor strain for conjugation [255] 
Plasm ids 
mobilizable suicide vector used for triple [246] 
pK18mobsacB ligation; sacB a/phil 
pHsaADL pK18mobsacB containing 1.9 kb fusion PCR This study 
fragment flanking hsaA to make strain RHAOXX 
pCYP125DL pK18mobsacB containing 2.0 kb fusion PCR This study 
fragment flanking cyp125 to make strain 
RHAOXX 
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4.2.6. Metabolite Analysis 
RHA 1 and the LlhsaC mutant were grown on 20 mM pyruvate plus 1 mM 
7KC. Apramycin (50 mgll) was also included for the LlhsaC mutant. Exponentially 
growing cells were harvested, washed and suspended in fresh medium with 1 
mM 7KC at a cell density corresponding to 0.33 mg of protein per ml. Cell 
suspensions were incubated for 48 h at 30°C, and samples were periodically 
removed. Samples were centrifuged to remove cells, and the supernatant was 
acidified and extracted with ethyl acetate. The extracts were dried under nitrogen 
and re-dissolved in pyridine. For gas chromatography-mass spectrometry (GC-
MS), the extracts were derivatized using 
bis(trimethylsilyl)trifluoroacetamide/trimethylchlorosilane (99: 1) (Sigma-Aldrich 
Canada, Oakville, Ont.) at room temperature and analyzed with an Agilent 
6890N chromatograph equipped with an HP-5ms capillary column (50 m by 0.25 
mm) and a mass-selective detector. 
To identify catecholic metabolites, a 10-mL sample was extracted as 
described above and suspended in 3 mL sodium phosphate, pH 7.5. Purified 
HsaC from Mycobacterium tuberculosis H37Rv [1] was added to a final 
concentration of 0.1 mg/mL and incubated for 1 min at room temperature. The 
course of the reaction was monitored spectrophotometrically at 397 nm, the 
absorption maximum of the enolate form of the ring-cleaved product of 3,4-
DHSA. The reaction mixture was analyzed by GC-MS as described above. 
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For nuclear magnetic resonance (NMR) analysis, a 100-mL cell 
suspension was prepared, incubated and extracted as described above. The 
dried extract was re-dissolved in 2 mL phosphoric acid/methanol (6:4) for high-
performance liquid chromatography with a Waters 2695 system equipped with a 
Hewlett Packard ODS Hypersil C18 column (5 IJm, 125 x 4 mm). The peak 
corresponding to the metabolite of interest was collected, extracted with ethyl 
acetate, dried under nitrogen and dissolved in D-acetone for proton, (H,H)-
correlation spectroscopy (COSY), Heteronuclear Single Quantum Coherence 
(HSQC) and Heteronuclear Multiple Bond Correlation (HMBC) nuclear magnetic 
resonance (NMR) analyses. 
4.3. Results 
4.3.1. Growth of RHA1 on 7KC 
Under our experimental conditions, RHA 1 grew at a specific growth rates 
(± standard deviation) of 0.23 ± 0.02, 0.023 ± 0.002 and 0.018 ± 0.006 h-1 on 
pyruvate, cholesterol and 7KC, respectively. Both steroids formed precipitate in 
the initial medium, and their low solubility may have been a factor in the slow 
growth on the steroids. The similar growth rates on 7KC versus cholesterol 
suggest that 7KC has no substantial toxicity to RHA 1. 
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4.3.2. Overall transcriptomic analysis 
When growing on 7KC, RHA 1 differentially expressed a large suite of 
genes that were mainly distinct from those differentially expressed during growth 
on cholesterol. Microarray analysis of RHA 1 revealed 1,240 genes differentially 
expressed during growth on 7KC versus pyruvate. Of these, 911 were distinct 
from those differentially expressed during growth on cholesterol versus pyruvate 
(Fig. 4-1, Fig.4-2, Appendix A). Moreover, higher expression ratios were 
observed between 7KC versus pyruvate (range, 148 to 0.12) than between 
cholesterol versus pyruvate (range, 12 to 0.07). However, when expression of 
genes on 7KC versus cholesterol was directly compared, only 363 genes were 
differentially expressed, and the expression ratios were again generally small 
(range, 12 to 0.05). Predictably, a large proportion of genes more highly 
expressed on 7KC versus cholesterol were also among those more highly 
expressed on 7KC versus pyruvate. However, few of the genes more highly 
expressed on cholesterol versus 7KC were among those more highly expressed 
on cholesterol versus pyruvate. The overall analysis indicates that much of the 
difference between the 7KC and cholesterol transcriptomes is due to relatively 
small expression ratios, except for a small subset of differentially expressed 
genes that were substantially more highly expressed on 7KC than on cholesterol. 
4.3.3. Steroid catabolism gene clusters 
Conspicuously, most of the highly up-regulated genes in cells grown on 
7KC are located in three large gene clusters that contain putative steroid 
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catabolism genes. RHA 1 contains four such clusters which are largely defined by 
genes predicted to encode catabolism of steroid rings A and B (Fig. 4-1, 
Appendix B). These genes include kstD, kshA, hsaABCDEFG and their 
homologs. This core set of nine genes is present in each of Clusters 1, 3 and 4, 
while Cluster 2 lacks hsaDEFG. Cluster 3 has two homologs each of kstD and 
hsaA. Cluster 1 additionally contains the mce4 operon and cyp125, neither of 
which have homologs in the other clusters. The mce4 operon encodes an uptake 
system for cholesterol and certain other steroids [243]. The cyp125 gene 
encodes a cytochrome P450 that initiates the oxidative degradation of the 
cholesterol side chain [2]. Each of the four clusters contains a large number of 
additional genes that are predicted to encode steroid catabolic functions, but their 
specific roles remain undefined. 
During growth on 7KC, genes in Clusters 3, 2 and 1 were up-regulated 
(Fig. 4-1, Table 4-3, Appendix B), with average 7KC:pyruvate expression ratios in 
each cluster of 28.7, 8.6 and 3.2, respectively. By contrast, during growth on 
cholesterol, only Cluster 1 genes were up-regulated; the genes of Clusters 3, 2 
and 1 had average cholesterol:pyruvate expression ratios of 1.2, 1.2 and 4.2, 
respectively. The direct microarray comparison of cells grown on 7KC versus 
cholesterol confirmed that most genes in Clusters 2 and 3 were more highly 
expressed on 7KC than on cholesterol (expression ratios> 2.0), while most 
genes in Cluster 1 had similar 
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Figure 4-2. Numbers of genes differentially expressed in microarray 
analyses of RHA1 grown on different substrates. Key: Cho, cholesterol; Pyr, 
pyruvate; j, expression ratio> 2.0; ~, expression ratio < 0.5. 
levels of expression on both steroid substrates (expression ratios between 0.5 
and 2.0). 
While each of the three up-regulated clusters appears to include multiple 
operons, our bioinformatic analysis was only able to predict a small number of 
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transcriptional promoters and transcriptional terminators. Specifically, one 
promoter was putatively identified in Cluster 2, located upstream of the putative 
transcript containing ro02486-ro02487. Terminator sequences were found 
following ro02484 and ro02488-ro02490 in this cluster as well. Promoters were 
predicted in Cluster 3 upstream of ro05815-ro05818 and ro05795. And in Cluster 
3, terminator sequences were found following ro05793-ro05794 as well as 
ro05814. In Cluster 2, hsaA2 and hsaC2 are contiguous, but based on their 
different expression patterns (Table 4-3, Appendix B), it is not clear that they are 
co-transcribed. In Cluster 3, all but one of the hsa genes is in a putative operon, 
hsa03-kst03-hsaE3G3F3A3C3-ro05804, with all eight of these genes up-
regulated to a similar extent. The hsaB3 gene is divergently transcribed from this 
operon and was not up-regulated on 7KC. Similarly, hsaB2 was not up-regulated 
on 7KC. The hsaB and hsaB2 genes encode reductases that putatively function 
with oxygenases encoded by hsaA and hsaA2, respectively. It is not unusual for 
such reductases to be present in lower amounts than their cognate oxygenases 
(unpublished data). 
4.3.4. Other differentially expressed genes 
Of the most highly up-regulated genes during growth on 7KC (versus 
pyruvate), which are not in the above clusters, many are in putative operons or 
larger clusters that were coordinately up-regulated on 7KC (Appendix A). 
Moreover, the majority fall into a few functional groups: 13 involved in signaling 
and transcriptional regulation; 24 in catabolism; 18, arranged in 2 clusters, 
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possibly involved in gas vesicle synthesis; 2 in transport; and 16 in cell wall 
biosynthesis, arranged in a single cluster. The regulatory genes include a cluster 
(ro02115-8) encoding a sigma factor, anti-sigma factor and anti-sigma factor 
antagonist, which were all up-regulated about 10-fold. Unlike the genes in 
Clusters 2 and 3, most of these up-regulated genes were not differentially 
expressed on 7KC versus cholesterol, with expression ratios nearly always 
between 0.5 and 2.0 in the direct microarray comparison. The only exceptions 
were some of the catabolic genes, which were more highly expressed on 7KC 
versus cholesterol, encoding a possible hydroxy-steroid dehydrogenase and a 
short-chain dehydrogenase (ro01882-3), a steroid delta-isomerase (ro03609), a 
probable 3-oxyacyl-(acyl-carrier-protein) reductase (ro03841), an acyl-CoA 
dehydrogenase (ro04283) and a possible bile acid 7-alpha dehydratase 
(ro06638). 
The genes that were most extensively down-regulated during growth on 
7KC (versus pyruvate) are largely involved in energy metabolism and growth 
(Appendix A). Most of these genes were down-regulated three- to five-fold, and 
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Table 4-3 Comparison of RTq-PCR and microarray expression ratios for 
RHA1 grown on either cholesterol or 7KC relative to pyruvate. 
RT -qPCR Expression Microarray Expression 
Gene Name Cholesterol 7KC Cholesterol 7KC 
hsaA2 47.0 (15.5-142.7) 302.3 (42.7-2142.1) 0.8 10.6 
kshA 54.2 (31.7-92.7) 23.3 (8.6-63.0) 4.6 4 
hsaA 124.9 (90.7-172.0) 64.8 (30.3-138.9) 20.3 12 
hsaC 79.8 (54.1-117.6) 56.9 (23.5-137.6) 2.1 2.2 
cyp125 53.9 (22.6-128.3) 40.8 (13.9-119.8) 11 5.7 
mce4A 6.0 (4.2-8.6) 10.3 (4.1-25.9) 2.3 1.6 
hsaAb 10.0 (4.8-20.9) 4.6 (1.9-11.1) 2 2.8 
hsaA3 12.6 (2.9-55.4) 244.4 (75.8-788.0) 1 5.8 
hsaA3b 59.4 (9.5-371.8) 603.1 (181.8-2000.0) 1.8 5.4 
kshB 8.3 (2.3-29.4) 77.1 (18.5-321.0) 1.5 1 
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many are in putative operons that were coordinately down-regulated. The 
functional groups represented by these genes include electron transport (17 
genes in 4 clusters), a H+-driven ATPase (8 genes in 1 cluster), the tricarboxylic-
acid cycle and glycolysis (20 genes, including clusters of 5 and 10 genes), 
translation (49 genes, including clusters of 11 and 33 genes) and cell wall 
synthesis (16 genes, including a cluster of 11 genes). Additional genes down-
regulated on 7KC encode transporters (6 genes, including a cluster of 4 genes 
encoding an ABC transporter) and chaperone proteins (5 genes). Interestingly, 
one gene possibly involved in steroid metabolism, encoding a probable C-5 sterol 
desaturase (ro04159), was down-regulated more than five-fold. With few 
exceptions, the genes down-regulated on 7KC versus pyruvate were not 
differentially expressed on 7KC versus cholesterol. 
4.3.5. RT -qPCR confirmation of gene expression 
The expression of nine of the above mentioned genes known or 
suspected to be involved in steroid degradation or uptake were quantified using 
RT-qPCR. In all cases, the RT-qPCR analysis confirmed up-regulation of genes 
detected by the microarray, and the two methods generally agreed with respect 
to whether 7KC or cholesterol caused greater up-regulation of the particular 
genes (Table 4-3). Four genes, hsaA2, hsaA3, hsaA3b, and kshB, exhibited 
much higher RT-qPCR expression ratios during growth on 7KC versus on 
cholesterol. The expression ratios tended to be higher with RT-qPCR than with 
the microarray, up to 100-fold higher, which is typical [249, 250]. The RT-qPCR 
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assay is probably more quantitatively accurate than the microarray analysis, so it 
appears that the magnitude of up-regulation of steroid catabolism genes ranged 
from approximately 10- to 600-fold. 
4.3.6. Gene deletion analysis 
Unmarked, in-frame gene deletions, and in one case, a gene replacement 
(Table 4-2) were used to determine the roles of several genes in the growth of 
RHA 1 on 7KC. These genes are in Cluster 1 and were previously implicated in 
cholesterol catabolism. Two mutants have deletions of a total of eight genes, 
supAB and mce4ABCDEF, respectively, encoding the Mce4 steroid uptake 
system [243]. Both of these mutants were able to grow on pyruvate, but lost the 
ability to grow on 7KC, indicating that the Mce4 system is essential for uptake of 
7KC. Growth on 7KC was also completely abolished by the replacement of hsaC 
and deletion of cyp125, individually. This strongly implicates the ring-cleavage 
dioxygenase, HsaC, and the cytochrome P450, Cyp125, in the pathway for 
degradation of 7KC. By contrast, deletion of hsaA, encoding the oxygenase of a 
two-component hydroxylase, partially impaired, but did not prevent growth on 
7KC, suggesting that HsaA contributes to 7KC catabolism but is not essential. 
4.3.7. Metabolite Analysis 
When incubated with 7KC, the hsaC mutant cells accumulated several 
potential metabolites, seven of which were not produced by wild-type RHA 1. The 
7KC used for this experiment had no detectable cholesterol impurity, so the 
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metabolites detected are clearly from 7KC. All of these metabolites accumulated 
during the first 20 hours of incubation, and there were no major changes in the 
compounds detectable after that time. Purified HsaC from H37Rv was used to 
transform the mixture of metabolites in order to identify catecholic compounds 
that are transformed by HsaC, and so, likely true intermediates of 7KC 
catabolism. Four metabolites were completely removed from the mixture by 
HsaC. These four metabolites (Fig. 4-4) were identified on the basis of the mass 
spectra of their derivatives. The ability of HsaC_H37Rv to transform these 
compounds strongly suggests that they are structurally similar to one another 
and supports the interpretation of the mass spectra. 
The results of the GC-MS are as follows: 3,4-DHSA, TMS 
derivatized: Rt = 15.91 min EI-MS (70 eV, EI); m/z: 460 ([M+], 74%), 294 (45%), 
281 (36%),267 (8%), 251 (70%),207 (100%), 193 (49%),73 (97%). 3,4,7-THSA, 
TMS derivatized: Rt = 16.25 min EI-MS (70 eV, EI); m/z: 548 ([M+], 25%), 458 
(7%), 382 (12%), 367 (8%),281 (24%),267 (100%), 207 (65%), 73 (73%). 3,4-
DHSAP, TMS derivatized: Rt = 20.60 min EI-MS (70 eV, EI); m/z: 590 
([M+], 70%), 557 (10%),381 (54%),294 (94%), 281 (22%),267 (5%), 207 (48%), 
193 (28%), 73 (100%). 3,4,7-THSAP, TMS derivatized: Rt = 20.46 min EI-MS (70 
eV, EI); m/z: 678 ([M+], 4%), 588 (5%), 397 (60%), 367 (6%), 281 (22%), 253 
(6%),233 (10%), 207 (45%), 161 (11%), 133 (12%),73 (100%). 
NMR analysis of 3,4,7-THSA yielded the following data: 1H NMR 
(500 MHz, CDCI3): 0 = 6.58 (d, J = 8.7 Hz, 1 H, 1), 6.53 (d, J = 8.7 Hz, 1 H, 2), 
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4.27 (ddd, J = 9.8, 3.7, 2.5 Hz, 1 H, 7), 3.01 (dd, J = 13.5, 9.8 Hz, 1 H, 6x), 2.83 
(dd, J = 13.5, 2.5 Hz, 1 H, 6y), 2.82 (dd, J = 14.7, 3.7 Hz, 1 H, 8), 2.50 (dd, J = 
18.4, 8.6 Hz, 1 H, 16x), 2.61 (dd, J = 15.9, 7.6 Hz, 1 H, 11x), 2.48-2.42 (m, 1 H, 
14), 2.37 (dd, J = 15.9, 2.6 Hz, 1 H, 11y), 2.32-2.20 (m, 1 H, 15x), 2.24 (m, 1 H, 
16y), 2.22 (s, 3H, 19), 1.90 (m, 1H, 15y), 1.90-1.63 (m, 2H, 12), 1.12 (s, 3H, 18). 
13C NMR (125.8 MHz, CDCb): 0 = 217.9 (17), 211.9 (9), 144.6 (4), 144.3 (3), 
128.8 (10),126.1 (5), 122.4 (1),112.8 (2), 72.0 (7),55.7 (8), 48.1 (13),46.1 (14), 
38.1 (11),36.4 (16), 32.1 (6),30.1 (12),23.8 (15),19.5 (19),14.0 (18). 
4.4. Discussion 
The current studies demonstrated that three of the four identified steroid 
catabolic gene clusters in RHA 1 were up-regulated during growth on 7KC. Of 
these three, the cholesterol catabolic cluster was much less up-regulated than 
the other two. This was established by both the microarray and RT-qPCR 
results, with the latter demonstrating that genes of Clusters 2 and 3 were up-
regulated up to 600-fold while genes of Cluster 1, encoding cholesterol 
catabolism, were only up-regulated up to 10-fold (Table 4-3). Nevertheless, 
studies using the gene deletion mutants clearly indicated that proteins encoded 
in Cluster 1 are essential for catabolism of 7KC by RHA1, including the Mce4 
transporter, the sidechain-degrading Cyp125, and the ring-cleaving extradiol 
dioxygenase, HsaC (Fig. 4-3). The results do not exclude the possibility that one 
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or more of the 62 genes in Clusters 2 and 3 are essential for growth on 7KC, but 
it is clear that neither cluster encodes a complete pathway for 7KC catabolism. It 
thus appears that 7KC gratuitously induces some, perhaps a large number of 
steroid catabolism genes, neither involved in, nor essential for 7KC metabolism. 
The simultaneous up-regulation of three clusters during growth on 7KC is 
in marked contrast to the previously reported transcriptional response to growth 
on cholesterol [1], in which only Cluster 1 was up-regulated (Fig. 4-1). Despite 
the structural similarity of these two growth substrates, the presence of the 7 -keto 
substituent on the substrate had a major impact on expression of steroid 
catabolism genes, either directly by affecting the function of the molecule as a 
regulatory effector or indirectly by affecting the occurrence of metabolites 
influencing gene regulation. Because of its low abundance, 7KC is unlikely to be 
a major substrate to which RHA 1 is adapted. However, 7KC may resemble one 
or more other steroids that are important substrates. In particular, bile acids are 
abundant steroids with a C-7 substitution, and genes induced by 7KC may playa 
role in their metabolism. 
The requirement of Mce4 transport system for uptake of 7KC by RHA 1 is 
consistent with what is known about the specificity of this ABC transporter [1, 
243]. This system is essential for uptake of cholesterol and other steroids 
supporting growth of RHA 1, including ~-sitosterol, 5-a-cholestanol and 5-a-
cholestanone [243]. 7KC shares structural similarity with the known Mce4 
substrates, particularly a long, hydrophobic side chain. The 7-keto substituent of 
7KC does not appear to impede uptake by Mce4. While the 11-gene operon 
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(ro04696-ro04706) encoding the Mce4 system was not highly up-regulated on 
7KC or cholesterol, according to the microarray analysis, the RT-qPCR assay of 
mce4A indicates that the operon was up-regulated approximately 10-fold on 
7KC. In a previous study [243], the constitutive level of expression of the Mce4 
system on pyruvate was sufficient for measureable cholesterol uptake, so 
extensive up-regulation of the Mce4 system does not appear necessary to 
support growth on steroids. The current results further indicate that an MFS 
transporter encoded by ro05792 in Cluster 3 is not able to transport 7KC. While 
RHA 1 has three additional partial or complete mce operons, the mce4 operon is 
the only one proximal to steroid catabolism genes. 
The current results are consistent with the hypothesis that in RHA 1, 
cholesterol and 7KC are initially transformed by Cyp125 and that the 3~-hydroxy 
substituent is oxidized to a ketone by a cytoplasmic 3~-hydroxysteroid 
dehydrogenase (3~-HSD). Recent work suggests that Cyp125 hydroxylates the 
side chain as an essential early step in catabolism of cholesterol by RHA 1 [2]. 
The inability of the RHA1 ~cyp125 mutant to grow on 7KC suggests that Cyp125 
has the same function in 7KC and cholesterol metabolism (Fig. 4-3). Of the four 
clusters of steroid catabolism genes, Cluster 1 is the only that contains a P450 
gene. Cyp125 is a cytoplasmic enzyme that transforms 3-hydroxy, but not 3-keto-
steroids [2]. These characteristics are inconsistent with an alternate hypothesis 
that 3~-hydroxy substituent of cholesterol is oxidized to a ketone by a secreted 
cholesterol oxidase, as reported for some bacteria [256, 257]. While RHA 1 has 
three genes encoding proteins annotated as secreted cholesterol oxidases 
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(ro03863, ro04305 and ro06201), none was up-regulated on either 7KC or 
cholesterol, and none is proximal to steroid catabolism genes. By contrast, a 
gene encoding a 3~-HSD (ro04707) is part of Cluster 1 and was up-regulated on 
both 7KC and cholesterol (Appendix B). Moreover, Ro04707 is the best 
reciprocal hit for a 3~-HSD from M. tuberculosis, which was demonstrated to 
transform cholesterol to cholest-4-ene-3-one [258]. Other RHA 1 genes encoding 
possible 3~-HSDs, ro04260, ro04612 and ro05893, were not up-regulated on 
either steroid substrate. 
Both HsaA and HsaC play critical roles in cleavage of ring A of 7KC (Fig. 
4-3). Despite the up-regulation of genes in Clusters 2 and 3 encoding isozymes 
of HsaA and HsaC (Fig. 4-1 Appendix B), deletion mutants of hsaA and hsaC 
were partially and completely impaired, respectively, in growth on 7KC. Similarly, 
the growth rate of the l1hsaC mutant on cholesterol was previously found to be 
60% lower than that of the wild-type [1]. The simplest explanation for these 
observations is that the isozymes of HsaA and HsaC have limited or no ability to 
transform intermediates of 7KC degradation. The slow growth of the l1hsaA 
mutant on 7KC could be due to complementation by anyone of several isozymes 
including Ro02489, Ro05068, Ro05802, and Ro05812; however investigation of 
enzyme specificity is necessary to distinguish the relative catalytic abilities of 
isozymes encoded in the steroid catabolism gene clusters. 
The 7KC metabolites accumulated by the l1hsaC mutant indicate that the 
RHA 1 pathways for 7KC and cholesterol metabolism preceding the step 
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catalyzed by HsaC are analogous (Fig. 4-3). Both 3,4-DHSA and 3,4-DHSAP 
were previously found as cholesterol metabolites of the 1J.hsaC mutant [1]. The 
production of these metabolites plus 3,4,7-THSA and 3,4,7-THSAP by the 1J.hsaC 
mutant incubated with 7KC indicates that the 7 -keto substituent is reduced to a 
hydroxyl group prior to the HsaC ring-cleavage step (Fig. 4-4). Nevertheless, it is 
clear that removal of the 7-hydroxy substituent and complete side chain 
degradation are not required for cleavage of ring A to occur. Further, this study 
demonstrated that either or both the 7 -keto and 7 -hydroxyl substituents as well 
as the C-17 propionic acid side chain can be transformed by the enzymes 
preceding the HsaC step and by HsaC of M. tuberculosis. 
No enzymes were identified that are unique to 7KC metabolism and that 
could facilitate the selective degradation of 7KC over cholesterol. The only part of 
the 7KC pathway that is clearly unique is the removal of the 7 -keto substituent, 
putatively via the sequential activities of a reductase and dehydratase. RHA 1 has 
three genes, ro02479, ro06638, and ro05687, encoding proteins similar to bile 
acid 7a-dehydratases, which might catalyze removal of the 7-hydroxy substituent 
during 7KC metabolism. Of these, ro05687 was up-regulated on 7KC but not 
cholesterol (Appendix B). Another, ro02479, was not significantly up-regulated in 
the microarray experiment. However, this may be a false-negative result, as it is 
part of Cluster 2 and appears to be part of a co-transcript that was up-regulated 
on 7KC. That co-transcript also includes ro02478, encoding a reductase. 
Nevertheless, the most promising candidates for the reductase and 7a-
dehydratase appear to be ro06637 and ro06638, respectively, as both were 
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Figure 4-4. Proposed scheme for 7KC metabolism based on metabolites 
accumulated by the RHA1 AhsaC mutant. 1. Degradation of the C-17 side 
chain and 3~-OH dehydrogenation appear to occur concurrently, followed by 
2. degradation of rings A and Band 7-keto reduction. 3. Removal of 7-0H by 
putative dehydratase. 4. Side chain degradation. 5. Reaction catalyzed by 
HsaC. Key: R, side chain intact or in various stages of degradation; 3,4,7-
THSAP, 3,4,7-trihydroxy-9,1 0-seconandrost-1 ,3,5(1 0)-triene-9, 17-dione 
proprionic acid; 3,4-DHSAP, 3,4-dihydroxy-9,1 0-seconandrost-1 ,3,5(10)-
triene-9,17-dione proprionic acid; 3,4,7-THSA, 3,4,7-trihydroxy-9,1 0-
seconandrost-1 ,3,5(1 0)-triene-9, 17-dione. 
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significantly up-regulated on 7KC. These genes and their corresponding protein 
products clearly warrant further investigation for possible selective transformation 
of 7KC. 
Expression patterns of RHA 1 genes outside of the above three steroid 
catabolism gene clusters suggest that general physiological conditions were 
similar in cells growing on the two steroid substrates and distinct from conditions 
in cells growing on pyruvate. Most genes outside of the clusters did not have very 
high or low expression ratios in the 7KC versus cholesterol comparison, and the 
few exceptions to this trend are genes possibly involved in steroid catabolism 
(Appendix A). The lower expression levels, during growth on steroids, of genes 
involved in electron transport, ATP synthesis, central metabolism and translation 
is consistent with the lower growth rates of cells on steroids relative to cells on 
pyruvate. The reason for the reduced expression of chaperone proteins on 
steroids is less obvious but may also be related to growth rates. The observation 
that some cell wall synthesis genes were down-regulated on steroids, while 
others were up-regulated, may reflect remodeling of the cell wall during growth 
on steroids. Finally, the up-regulation of a sigma factor system during growth on 
steroids suggests that a major regulatory network is modulated in order for RHA 1 
to adapt to growth on steroids. 
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Chapter 5 
Isolation and Expression of Selected 
Genes from Rhodococcus jostii RHA 1 
5.1. Introduction 
As discussed in Chapter 4, genomic and transcriptomic analyses of the 
actinomycete Rhodococcus jostii RHA 1 during growth on 7KC revealed the 
presence of four gene clusters encoding putative steroid-degrading enzymes [1]. 
One of these clusters (Cluster 1) was also up-regulated during catabolism of 
cholesterol, while growth on 7KC induced many genes in this cluster as well as in 
Clusters 2 and 3 [38]. No other substrates (i.e., cholic acid, androsterone, or 
cholesterol) significantly up-regulated Cluster 2, though many genes in Cluster 3 
were also highly expressed during growth on cholic acid, which contains a 7a-OH 
group. Furthermore, metabolic screening using a .llhsaC mutant (hsaC deletion) 
determined that reduction of the 7-keto substituent with concomitant removal of 
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the 7-0H moiety could occur prior to the incorporation of dioxygen catalyzed by 
HsaC (Fig. 4-4), an extradiol dioxygenase that is responsible for the meta-
cleavage of ring A of the steroid nucleus during cholesterol degradation (Fig. 4-3) 
[3]. 
Our primary motive for researching the microbial degradation of 7KC is to 
identify enzymes that can transform this oxysterol in a manner that will reduce its 
toxicity or promote its further metabolism or excretion, while simultaneously 
avoiding nonspecific (unintended) transformations. Since cholesterol and most 
endogenous sterols lack a 7 -keto substituent, the most obvious means to 
accomplish this would be through reduction or removal of this group. Reduction 
of 7KC can result in the formation of either 7a- or 7p-hydroxycholesterol (7a/p-
HC) [259], however 7P-HC displays greater cytotoxicity than 7KC while 7a-HC is 
innocuous in comparison [260-262]. 
Cluster 2 contains two significantly up-regulated short chain 
dehydrogenase /reductases (ro02478 and ro02480) that flank a putative 
dehydratase (ro02479). Since removal of the 7-keto group was previously 
indicated, and the likely enzymes involved would consist of a 
reductase/dehydratase pair, these two genes make good candidates for further 
evaluation. Furthermore, these are the only two potential reductases in this 
cluster except for ro02483, which is a 3-ketosteroid-delta-1-dehydrogenase 
homolog. Although not associated with one of the steroid-degrading gene 
clusters, ro06637 and ro06638 were also both significantly up-regulated by 7KC, 
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and encode a reductase/dehydratase pair as well. Additionally, Cluster 3 
contains a large number of reductases, one of which could potentially catalyze 
reduction of the 7-keto substituent. Based on this information we decided to 
clone and express several of these enzymes to assay them for their ability to 
transform 7KC or a downstream metabolite. 
5.2. Materials and Methods 
5.2.1. Bacterial strains and growth 
Rhodococcus jostii RHA 1 and E. coli strains were cultivated aerobically in 
Luria-Bertani (LB) broth or agar plates at 30°C or 37°C, respectively. Liquid 
cultures were also subjected to shaking at 200 rpm. For cloning and plasmid 
propagation, both E. coli TOP10 (Invitrogen, Carlsbad, CA) and E. cloni 10G 
(Lucigen, Middleton, WI) chemically competent cells were used. For protein 
expression, E. coli BL21 Star cells were used. When appropriate, media was 
supplemented with ampicillin (1 00 ~g/ml) or kanamycin (50 ~g/ml) for plasmid 
maintenance. Protein expression was induced using isopropyl ~-D-1-
thiogalactopyranoside (IPTG) (1 00 ~g/ml). All strains were stored as 20% 
glycerol stocks at -80°C. 
92 
5.2.2. Cloning of 7KC up-regulated genes 
Cells from overnight cultures of RHA1 (2 ml) were pelleted (10,000 x g, 30 
s) and extracted using an UltraClean® Microbial DNA Isolation Kit (Mo Bio Labs, 
Inc., Solana Beach, CA) according to the manufacturer's protocol. Briefly, cells 
were resuspended in buffer and SDS prior to mechanical cell lysis by bead 
beating. Cell debris was separated from the supernatant by centrifugation 
(10,000 x g, 30 s) and the supernatant was transferred to a new tube where non-
DNA contaminants were precipitated and separated by further centrifugation. The 
supernatant was passed through a silica column, bound DNA washed with 
ethanol, and eluted with distilled water. All DNA concentrations were determined 
using a NanoDrop 1000 spectrophotometer at 260 nm. The 260/230 and 260/280 
ratios were used to determine DNA purity. 
Primers (IDT, Coralville, IA) were designed for whole gene amplification 
(Table 5-1) without the endogenous stop codon, and the T m and propensity for 
dimer formation were analyzed using OligoAnalyzer (IDT, Coralville, IA). Genes 
were amplified by PCR using a Biometra TGradient thermocycler (Goettingen, 
Germany). Each 20 JJI reaction consisted of 0.2 JJI Phusion® High-Fidelity DNA 
Polymerase (New England Biolabs, Beverly, MA), 4 JJI 5x HF buffer, 0.4 JJI 10mM 
dNTPs, 0.5 JJM each primer, 10-20 ng DNA template, and sterile deionized water. 
Some genes with high GC content were difficult to amplify and required the 
addition of CES, a PCR enhancing solution [263]. Cycling conditions were an 
initial denaturation of 98°C for 1 minute followed by 30 cycles of 98°C for 35 
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seconds, T m - 5°C for 35 seconds, and 72°C for 1 minute, except for plasmid 
linearizations, which required 2 minutes. A final extension time of 5 minutes was 
also included. Cycling times were slightly greater than standard due to our use of 
thick-walled PCR tubes. Product amplification was verified using gel 
electrophoresis followed by staining with SYBR Safe DNA gel stain (Invitrogen, 
Carlsbad, CA). Size was estimated by comparison to a standard DNA ladder 
(Fermentas, Hanover, MD). 
All genes were inserted into pET101/D-TOPO (Invitrogen, Carlsbad, CA) 
(Fig. 5-1), either using the manufacturer's protocol or by circular polymerase 
extension cloning (CPEC) [264]. Briefly, for CPEC cloning, vectors were 
linearized by PCR and gel purified using a Gel Extraction Kit (Qiagen, Valencia, 
CA). Genes were PCR amplified with 15-20 base pair vector-overlapping regions 
added to their 5' and 3' ends, and gel purified as well. 200 ng of the vector was 
then added to an equimolar amount of insert in a 20 IJI reaction volume 
containing Phusion® High-Fidelity DNA Polymerase mix. The DNA was 
denatured at 98°C for 30 seconds, reannealed at 55°C for another 30 seconds, 
and then allowed to extend for 2 minutes. This was repeated for five cycles. For 
either cloning method, 3 IJI of the reaction was subsequently used for 
transformation of chemically competent E. coli TOP1 0 or E. cloni 10G. Cells were 
then plated on ampicillin containing LB agar plates and incubated overnight at 
3rC. Colony PCR with T7 primers was used to verify the presence of the correct 
sized insert. The PCR product from positive colonies was verified by sequencing 
(SeqWright, Houston, TX). 
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Table 5-1. Primers used in the cloning of Rhodococcusjostii RHA1 genes. 
Gene 
10 
ro02478 
ro02480 
ro04707 
ro05790 
ro05791 
ro05810 
ro05819 
ro05821 
ro05832 
ro06637 
Protein Function 
short chain 
dehydrogenase 
short chain 
dehydrogenase 
313-hydroxysteroid 
dehydrogenase 
short chain 
dehydrogenase 
short chain 
dehydrogenase 
short chain 
dehydrogenase 
short chain 
dehydrogenase 
NADPH-dependent 
flavin reductase 
short chain 
dehydrogenase 
short chain 
dehydrogenase 
Primers 
Forward Primer: 5'GACMCAAGTTACGAGCCMGATC3' 
Reverse Primer: 5'CCTCCGTCAGCCGGTAGAT3' 
Forward Primer: 5'MCCGATCACTGCGACTGGATCTI3' 
Reverse Primer: 5'TICCGGACGATGATGTCCTIGGM3' 
Forward Primer: 5'ACCTGGAACTCCATGCTGATCGM3' 
Reverse Primer: 5'TTGMGTACGTCGGGMCGCGT M3' 
Forward Primer: 5'ACGTCGTATTCCCGACGATTCCAT3' 
Reverse Primer: 5'TGCCAGTTGTGGACACCGATGA T3' 
Forward Primer: 5'GCTCCGCMGMGGTCMGATGT3' 
Reverse Primer: 5'GGGTCTTCATGTAGMCGACAGCA3' 
Forward Primer: 5'AGMGTTCGACATCATGCGGGAGA3' 
Reverse Primer: 5'CAGGTGATCCGCM TCGCATTGM3' 
Forward Primer: 5'ACATGATGTCGCTGATTCCCTCCA3' 
Reverse Primer: 5'AGACCGTGTTGMCTCGACGGTM3' 
Forward Primer: 5'TIGTICMCATGCCGTACTCCTGC3' 
Reverse Primer: 5'TICTCCTATCGCACTGAGCACGTA3' 
Forward Primer: 5'MGGATGCGTTCATTCCTCAGCAC3' 
Reverse Primer: 5'AGATGCACGAGMCGGGMGTTGT3' 
Forward Primer: 5'ACCGGATCMGAGGMCTACGAGA3' 
Reverse Primer: 5'TCGTTCCCGCATGMCGTCMGTA3' 
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Figure 5-1. pET101/D-TOPO plasmid map. Vector used for all cloning of 
RHA 1 genes. Genes were inserted without stop codons so they would include 
the 6xHis tag for affinity purification. Insertions were made between base pairs 
305 and 306. 
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5.2.3. Protein expression and purification 
Plasmid DNA from positive clones was extracted from overnight cultures 
using a 6 Minute Mini Plasmid Prep Kit (Mo Bio, Solana Beach, CA) according to 
the manufacturer's instructions. This DNA was used to transform chemically 
competent E. coli BL21 Star cells. Transformed cells were grown overnight in LB 
broth with ampicillin, and 2 ml of this was used to inoculate 100 ml of additional 
media. After 2 hours, cultures were induced with 1 mM IPTG and allowed to grow 
for four more hours, at which time they were split into 50 ml Falcon tubes and 
harvested by centrifugation (5000 rpm, 10 min). Cell pellets were aspirated and 
stored at -80°C. 
Cells were weighed and subsequently lysed with an appropriate amount of 
B-PER protein extraction reagent (Thermo Fisher Scientific, Waltham, MA), 
lysozyme, and DNase I. This was followed by centrifugation (15,000 x g, 5 min) 
and recovery of the supernatant. Crude extracts were split and half subjected to 
Ni-NTA column purification (HisPur Ni-NTA resin, Pierce Biotechnologies, 
Rockford, IL) under native conditions. Columns were loaded with 1.5 ml of resin 
and rinsed once with sterile water and twice with binding buffer (50 mM 
NaH2P04 , 0.5 M NaCI). 8 ml of lysate was then added and allowed to bind under 
gentle agitation for 1 hour. The resin was then washed four times with wash 
buffer (binding buffer with 20 mM imidazole) and then eluted with elution buffer 
(binding buffer with 250 mM imidazole). The eluent was then concentrated and 
desalted using Pierce 9K MWCO protein concentrators and 0.1 M potassium 
97 
phosphate buffer. Proteins were stored at 4°C with the addition of Halt Protease 
Inhibitor (Pierce Biotechnologies, Rockford, IL). 
Protein concentrations were determined using a BCA protein assay 
(Pierce Biotechnologies, Rockford, IL) according to the manufacturer's 
instructions. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
determine the presence of the correct size protein band as well as protein purity. 
Aliquots of protein from different stages in the purification process were mixed 
with equal volumes Laemmli sample buffer (containing 0.5% 2-mercaptoethanol) 
and boiled for 5 minutes in a water bath. 20 IJI was loaded into each well of a 4-
20% ReadyGel Tris-HCI precast gel in a Mini-PROTEAN Tetra Cell (Bio-Rad, 
Richmond, CA). Spectra™ Multicolor Broad Range Protein Ladder (Fermentas) 
was used to monitor the progress of electrophoresis and determine protein size. 
Gels were stained with Coomassie brilliant blue G-250 and allowed to destain 
overnight. 
5.2.4. Enzyme activity assays 
Dehydrogenase activity was assayed by monitoring NAD+ or NADP+ 
reduction at 340 nm using an Ultrospec 2100 Pro UV spectrophotometer 
(Amersham Biosciences, Piscataway, NJ). The standard assay mixture 
contained 100 mM potassium phosphate buffer, 0.1 % Triton X-100, 200 IJM 
NAD+ or NADP+, 20-200 IJM substrate, and an appropriate amount of enzyme in 
a 2 ml reaction volume. Reductase activity was also assayed in a similar manner, 
except that NAD+ and NADP+ were replaced by NADH and NADPH, and a 
98 
decrease in absorbance at 340 nm was used to verify activity. Substrates tested 
were cholesterol, 5-cholestene-26-oic acid-3~-01, cholic acid (CA), 7KC, 7-keto 
dehydroepiandrosterone (7KDHEA), 7-ketodeoxycholic acid (7KDC), and 7-
ketolithocholic acid (7KLC)(Steraloids, Newport, RI). E. coli is known to harbor an 
innate reductase activity against bile acids, so an empty vector control was used 
to determine background activity. Additionally, three bile acid reductases were 
used as positive controls for 7KLC and 7KDC reduction [265-267] (provided by 
Dr. James P. Coleman, ECU). These enzymes were also PCR amplified and 
inserted into pET101/D-TOPO without their stop codons to incorporate the 6xHis 
tag. 
The Michaelis-Menten equation was used to determine enzyme kinetic 
parameters: 
Vmax [5] 
v=---
Km + [5] 
where v is the reaction rate, Vmax is the maximum reaction rate, Km is the 
substrate concentration required to reach one-half of Vmax, and [S] is the 
substrate concentration. This equation was fit to each data set in Matlab R2008b 
(MathWorks Inc., Natick, MA) by nonlinear least squares regression, which uses 
an iterative search algorithm to determine the best-fit values of the hyperbolic 
parameters Km and Vmax. 
HPLC-based assays were also performed with 7KC (absorption maxima = 
235.8 nm) using the same standard assay mixtures and incubating the reactions 
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overnight at room temperature with gentle shaking. Lipids were then extracted 
using the method of Bligh and Oyer [268]. Briefly, 7.5 ml chloroform:methanol 
(1:2 v/v) was added to each 2 ml reaction and vortexed. This was followed by the 
addition of 2.5 ml of chloroform with vortexing. 2.5 ml of water was added and, 
following vortexing, each sample was centrifuged (1000 rpm, 5 mins) to give a 
two phase separation. 1 ml of the bottom organic layer was removed by Pasteur 
pipette, filtered through a 0.22 !-1m ReZist filter (Whatman, Piscataway, NJ), and 
allowed to evaporate to dryness under a nitrogen stream inside an analytical vial. 
Each sample was analyzed by reverse phase HPLC (1.0 ml min-1, 100% 
methanol) using a Waters 2695 Separation Module with a Waters 996 
photodiode array (235 nm) and a Waters NovaPak C18 column (3.9 by 150 mm). 
Chromatographic data was analyzed with the Empower 2 software suite (Waters, 
Milford, MA). 
5.2.5. Protein modeling 
A crystal structure for an E. coli 7a-hydroxysteroid dehydrogenase 
complexed with NAOH and 7 -oxo glycochenodeoxycholic acid (POB code 1 FMC) 
was used to construct a homology model of Bacteroides fragilis 7a-
hydroxysteroid dehydrogenase. ClustalW (Biology Workbench, UCSO) was used 
to perform multiple sequence alignments. The protein homology model was 
created using PRIME (Schrodinger, New York, NY)[269, 270]. Structural figures 
and graphical rendering were done using PyMOL (Schrodinger, New York, NY). 
The three-dimensional structures of 7KC and 7KOC were prepared using the 
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LigPrep module of Maestro v.9.1.207 (Schrodinger, New York, NY). Bond orders 
were fixed and the structures calculated at pH 7. Ligands were then docked into 
the homology model using Glide (Schrodinger, New York, NY)[271] in standard 
precision mode without further minimization. 
5.3. Results 
5.3.1. Cloning of 7KC up-regulated genes 
I n total, 10 dehyd rogenase/red uctases from Rhodococcus jostii RHA 1 
were cloned and expressed in E. coli (Table 5-1). While we were able to PCR 
amplify all the genes from RHA 1, cloning them by the standard protocol was 
problematic. Specifically, many of our cloning reactions contained empty vectors. 
This occurred using several different cloning techniques, such as topoisomerase-
based cloning, CPEC, and restriction-free cloning. All the genes were high GC-
content, which may have contributed to the difficulty we had cloning. Due to an 
additional hydrogen bond (in comparison to AT-bonds), regions of high GC-
content tend to fold in upon themselves causing the formation of secondary 
structures that make certain cloning techniques difficult. To remedy this, and to 
optimize for expression in E. coli, the majority of these genes were synthesized 
(Genscript, Piscataway, NJ). No amino acids were changed, and all the products 
from PCR amplification of the synthesized genes were easily cloned into our 
expression vector. 
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5.3.2. Activity assays 
None of the crude extracts from the recombinant E. coli proved to be 
active against 7KC, though those containing ro02480, ro05819, and ro05832 
were active against 7KLC (after normalization). This activity remained after 
affinity purification. One dehydrogenase, ro04707, proved to be active against 
cholesterol and was purified to homogeneity. This enzyme, a putative 313-
hydroxysteroid dehydrogenase, was determined to have a Km and Vmax of 75±6 
IJM and 6.9±1.2 U/mg respectively when utilizing cholesterol as a substrate (Fig. 
5-2). None of the enzymes proved to be active against 7KDHEA, however 
ro02480, ro05819, and ro5832 displayed activity after oxidation of the 313-0H 
group using a cholesterol oxidase. Unfortunately, we were not able to completely 
purify these enzymes using Ni-NTA affinity chromatography, however control 
reactions were used with an empty vector to establish a baseline for innate 
reductase activity that may have co-purified. 
Three 7a-hydroxysteroid dehydrogenases were also assayed against 7KC 
as well as the bile acids 7KLC and 7KDC. None of the three were active against 
7KC, though they were capable of reducing the two bile acids, as previously 
reported [265-267]. The Bacteroides fragi/is dehydrogenase, which was the most 
active, was successfully purified and assayed against several different 
7KC/phospholipid combinations, but no activity was measured. The Km and Vmax 
for this enzyme were measured as 71.7±10.2 IJM and 13.3±2.0 U/mg 
respectively against 7KLC, and 83.8±9.2 IJM and 6.2±1.5 U/mg for 7KDC (Fig. 
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Figure 5-2. Dehydrogenase and reductase reaction rates. 
Reaction rate data was fit to the Michaelis-Menten equation using 
nonlinear regression for A. R. jostii RHA 1 3~-hydroxysteroid 
dehydrogenase (ro04707) utilizing cholesterol as a substrate, and 
B. B. fragi/is 7a-hydroxysteroid dehydrogenase, utilizing 7KLC 
(solid line) and 7KDC (dotted line) as substrates. 
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5.2}. These numbers differed slightly from previously reported parameters [266], 
however this could possibly be attributed to the fusion of the 6xHis tag and V5 
epitope to the C-terminus of the enzyme. 
5.3.3. 7a-hydroxysteroid dehydrogenase protein model 
Molecular simulations indicated that 7KDC docked into the 7a-
hydroxysteroid dehydrogenase (7a-HSD) active site in proximity to the NADH 
cofactor, and oriented with its 7 -keto substituent able to form a polar contact with 
Tyr158 (Fig 5-3A). This positioning results in reduction of the 7-keto group to 7a-
OH. When 7KC was docked, however, the molecule inserts in a turned and 
flipped orientation with respect to 7KDC (Fig. 5-38). The molecule is therefore 
unable to form a polar contact from its 7 -keto group and reduction does not 
occur. These results are supported by our enzyme activity assays. 
5.4. Discussion 
The failure to identify an RHA 1 enzyme that initiates transformation of 
7KC was unfortunate, but not surprising. The RHA 1 mutants we tested for growth 
on 7KC indicated that neither Cluster 2 or 3 encoded a complete set of 7KC-
degrading enzymes, as evidenced by the failure of the fjhsaC and fjcyp125 
mutants to grow on 7KC [38]. This argument is also supported by the fact that 
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Figure 5-3. Homology model of B. fragi/is 7a-hydroxysteroid 
dehydrogenase. A. Docked with 7 -ketodeoxycholic acid using the 
Glide algorithm in Maestro. B. Docked with 7 -ketocholesterol. 7-
ketocholesterol is oriented flipped and turned with respect to 7-
ketodeoxycholic acid. Substrates are colored red , NADH is colored 
blue. 
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both Cluster 2 and 3 each contain a homolog for hsaC, suggesting that the target 
substrate for the enzymes encoded by these clusters may not be 7KC. It is 
foreseeable that 7KC may gratuitously induce homologs of cholesterol 
catabolism genes in Clusters 2 and 3, but some of these homologs may not 
encode enzymes capable of initiating the catabolism of 7KC or the corresponding 
metabolites. Given the generally low concentrations of 7KC relative to other 
sterols in the environment, this is a reasonable, perhaps likely, scenario. Cluster 
3 was also highly up-regulated by the presence of cholic acid, a compound 
similar in structure to 7KC, but more highly oxidized. While both of these 
compounds harbor functional groups at the C-7 position, bile acids also possess 
hydroxylated side chains and 3a-OH groups. Recently, evidence was found that 
C-26 oxidation may be an obligate first step of cholesterol degradation in RHA 1 
[272]. When we tested our recombinant enzymes on 7KDHEA we failed to detect 
activity, just as we had with 7KC. The steroid nucleus of this substrate is identical 
to that of 7KC, except that 7KDHEA lacks a side chain, having a keto group in its 
place (Fig. 5-4). However, when we first oxidized the 3~-OH groups of 7KDHEA 
with a cholesterol oxidase, three of our enzymes showed activity against this 
metabolite, though we have not determined the structure of the resulting product. 
The same three enzymes that were active against the oxidized 7KDHEA 
(ro02480, ro05819, and ro05832) also were active against 7KLC. This compound 
differs from 7KC in that it possesses both an oxidized side chain and a 3a-OH 
group instead of a 3~-OH (Fig. 5-4). 
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7KC 
7KDHEA 
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OH 
CA 
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Figure 5-4. Substrates used in enzyme activity assays. 7 -ketocholesterol 
(7KC), 7 -ketolithocholic acid (7KLC), and 7 -keto dehydroepiandrosterone 
(7KDHEA) were tested as substrates for several Rhodococcus jostii RHA 
reductases. Cholic acid (CA) was used as a control for reduction reactions and as 
a growth substrate during transcriptomic analysis. 
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In many microbial sterol degradation pathways, oxidation of the 313-0H is 
the first step, often catalyzed by an extracellular cholesterol oxidase [22, 34, 
273]. RHA 1 seems to lack extracellular oxidase activity. However, contrary to 
findings that side chain hydroxylation may be the first step in cholesterol 
degradation in RHA 1 [272], we cloned a putative 313-hydroxysteroid 
dehydrogenase (ro04707) that was active against cholesterol. Though this 
enzyme lacked activity against 7KC, it was also inactive against 5-cholestene-26-
oic acid-313-01. This suggests that oxidation of the 313-0H group may occur prior 
to side chain oxidation, though there may be other enzymes that catalyze 313-0H 
oxidation with differing substrate specificity. Regardless, it appears that the three 
reductases we identified have at least one common requirement for activity: 
isomerization or oxidation of the 313-0H group. They may also require an oxidized 
side chain, though further testing needs to be done to validate this hypothesis. 
This fits wells with our currently proposed cholesterol degradation pathway (Fig. 
4-3) as both of these steps precede the reaction catalyzed by HsaC. 
In a further effort to understand 7KC degradation, and to evaluate the 
potential to alter substrate specificity of the cloned enzymes using mutagenesis, 
we constructed a homology model of the Bacteroides fragi/is 7a-hydroxysteroid 
dehydrogenase (7aHSD). We used this enzyme due to its high similarity to 
another 7aHSD with an available crystal structure complexed with 7-oxo 
glycochenodeoxycholic acid. In comparison to 7KDC, our docking simulation 
showed that 7KC binds to the 7aHSD active site in a turned and flipped 
orientation (Fig. 5-3). This would effectively prevent reduction of the 7-keto group 
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as it removes it from the proximity of the catalytic residues (Tyr158 and Lys 162) 
as well as NADH. The carboxyl group of 7KDC also forms a polar contact, 
potentially stabilizing it in the binding site. 
In searching for 7KC-transforming enzymes, we did not exhaust all of the 
potential candidates that could be responsible for 7-keto reduction. One example 
is ro05789, a putative carveol dehydrogenase. We chose to clone ro02480 over 
this enzyme as they share high identity and ro02480 was much more highly 
expressed during 7KC catabolism. Future work may include investigation of this 
particular gene, especially considering the failure to identify useful RHA 1 
enzymes. On the other hand, it is likely that 7KC needs to be transformed 
sequentially in RHA 1, with ring A and side chain oxidation occurring first. 
Therefore, identifying and expressing active forms of the enzymes responsible 
for these transformations may be of particular importance. 
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Chapter 6 
Strategies for the mitigation of 7KC-
induced cytotoxicity 
6.1. Introduction 
As presented in previous chapters, 7KC is highly cytotoxic to mammalian 
cells and may contribute to the initiation or progression of a number of age-
related diseases. Therefore, it has been suggested that controlling dietary and 
endogenous 7KC levels could help reduce the incidence and severity of these 
diseases [36, 50, 274, 275]. In humans, several enzymes are known to accept 
7KC as a substrate, and may help attenuate some of its effects. Sterol 27-
hydroxylase (CYP27 A 1), a mitochondrial enzyme involved in bile acid synthesis 
and the excretion of excess cholesterol, was previously found capable of 7KC 
side chain oxidation [223]. Additionally, 27-hydroxylation was shown to render 
7KC non-toxic to retinal pigment epithelial cells [210]. Reduction of the 7-keto 
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moiety, producing 7~-hydroxycholesterol (7~-HC), is catalyzed by 11~­
hydroxysteroid dehydrogenase type I (HSD11 ~1) [259, 276]. Reduction of 7KC 
can produce either 7a- or 7~-hydroxycholesterol (7a/~-HC). However, human 
HSD11 ~1 produces only the ~-isomer, as does the HSD11 ~1 from all 
mammalian species studied save the golden hamster (Mesocricetus auratus) 
[259, 276]. This is unusual considering 7~-HC is approximately ten-fold more 
cytotoxic than the a-isomer, and two-fold more than 7KC [150, 260-262]. 
Esterification of 7KC is catalyzed by plasma lecithin:cholesterol acyltransferase 
(LCAT) or, intracellularly, by acyl-coenzyme A:cholesterol acyltransferase 
(ACAT) [277], which has been found to impair the toxicity of oxysterols [278]. 
Finally, the sterol sulfotransferase SUL T2B1 b, which participates in cholesterol 
excretion, also uses 7KC as a substrate [212]. Of these enzymes, only 
SULT2B1b has been overexpressed in cells to test for its ability to attenuate 
7KC-induced cytotoxicity, and though the results suggest some benefit, the effect 
is relatively small; increasing cell survival approximately 20% [212]. Furthermore, 
expression of these enzymes does not seem to be sufficient to reduce 7KC 
levels in vivo [279]. One reason for this apparent lack of effectiveness could be 
the subcellular localization of these enzymes, none of which target to the 
lysosome. 
At micromolar concentrations, 7KC causes lysosomal membrane 
permeabilization (LMP) which precedes mitochondrial destabilization [146]. The 
cellular response to LMP depends on the degree of permeabilization, but 
massive LMP generally leads to necrosis while lesser degrees may induce 
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apoptosis or apoptosis-like cell death [280]. The initiation of lysosomal cell death 
signaling is thought to be due to the release of lysosomal cathepsins into the 
cytosol where they interact with various targets [281]. Lysosomes also receive 
sterols (including oxysterols) from early endosomes after receptor-mediated 
endocytosis of LDL, and are a major site of non-enzymatic oxysterol formation. 
Consequently, 7KC levels are the highest in the endosomai/lysosomal 
compartments [174], and though enzymes exist which may mitigate 7KC 
cytotoxicity, those enzymes are primarily present in the ER, mitochondria, and 
cytoplasm and are not ideally localized to prevent LMP and the subsequent 
signaling cascade. 
In contrast to metabolism in mammalian cells, 7KC is readily mineralized 
by a diversity of bacteria [37], where its only putatively deleterious effect seems 
to be mutagenicity [205]. We previously studied the microbial degradation of 7KC 
in Rhodococcus jostii RHA 1, and partially elucidated its degradation pathway, 
which largely, but not completely, overlaps with that of cholesterol [38]. During 
this investigation we discovered that RHA1 was capable of reducing the 7-keto 
group and removing it downstream of HsaC, the enzyme that catalyzes cleavage 
of ring A of the steroid nucleus. We attempted to identify a reductase that would 
catalyze the reduction of 7KC to 7a-HC, but only isolated reductases from RHA 1 
that were active against more hydrophilic structural analogs, such as 7-
ketolithocholic acid (7KLC). In RHA 1, and many other sterol-degrading bacteria, 
the initial step is either side-chain hydroxylation or oxidation of the 3~-OH group 
(Fig. 4-3). Reduction of the 7-keto moiety also seems to take place downstream 
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of these steps in RHA 1 at least. We determined that the diketone produced from 
313-oxidation of 7KC displays decreased cytotoxicity in 293T cells [39]. It thus 
appears that oxidation of 7KC is sufficient to mitigate its toxicity, at least in cell 
culture, and that the selective oxidation of 7KC could prove useful in reducing its 
toxicity in vivo. However an inability to differentiate between 7KC and cholesterol 
could be problematic. Most cholesterol oxidases, a bacterial enzyme that 
catalyzes 313-oxidation of sterols, also catalyze Ll5-6 to Ll4-5 bond isomerization, 
producing cholest-4-en-3-one from cholesterol. The addition of cholest-4-en-3-
one to membranes in place of cholesterol leads to reduced condensation and 
increased disorder. So while this form of oxidation may reduce the toxicity of 
7KC, it decreases the ability of cholesterol to maintain membrane structure, with 
consequences for cell integrity [282]. 
Recently, a cholesterol oxidase from Chromobacterium sp. OS1 was 
isolated that lacks isomerization activity, forming cholest-5-en-3-one [283, 284] 
(though this compound may undergo further auto-oxidation at C-6 to form 613-
hydroperoxycholest-4-en-3-one) [285]. Unlike cholest-4-en-3-one, cholest-5-en-
3-one does not increase membrane permeability [282]. Additionally, the OS1 
cholesterol oxidase (OS1 ChOx) is extremely stable; maintaining activity in a 
variety of solvents, detergents, and at high temperature. Based on these 
desirable characteristics, we tested the OS 1 ChOx for activity against 7KC, 
assessed the potential to deliver this enzyme to the mammalian lysosome, and 
assayed its potential efficacy to mitigate 7KC-induced cytotoxicity. 
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6.2. Materials and methods 
6.2.1. Molecular cloning 
For protein expression and subsequent purification, DS1 ChOx (obtained 
from Dr. Noriyuki Doukyu, Toyo University) was subcloned into pET101/D-TOPO 
(Invitrogen, Carlsbad, CA)(Fig. 5-1) using Gibson assembly [286]. Briefly, the 
nucleotide sequence for mature DS1 ChOx was PCR amplified using Kapa HiFi 
polymerase (Kapa Biosystems, Woburn, MA) and primers containing 5' additions 
homologous to the ends of the linearized vector (Table 6-1). The insert and 
linearized vector were both gel purified and combined at equimolar 
concentrations in a reaction mixture containing T5 exonuclease, Phusion 
polymerase (New England BioLabs, Beverly, MA), and Taq ligase. Isothermal 
assembly was allowed to proceed for 1 hour at 50°C, and 3 j.J1 of the reaction was 
used to transform chemically competent E. c/oni 10G (Lucigen, Middleton, WI) 
cells. After transformation, cells were plated on LB plates with ampicillin (100 
j.Jg/ml) and incubated overnight at 37°C. The presence of the correct sized insert 
was verified using colony PCR (T7 primers) in conjunction with gel 
electrophoresis. The product from positive colonies was sequenced (Seqwright, 
Houston, TX). 
For use in mammalian transient transfections, the genes for DS1 ChOx, 
HSD11131 (synthesized by Geneart, Regensburg, Germany) were subcloned into 
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Table 6-1. Primers used for vector construction in this study. 
Amplicon Purpose Primers 
F: 5'-MGGGCGAGCTCAATTCGMG-3' 
pET101/D-TOPO vector linearization 
R: 5'-GGTGMGGGCTCCTGM TTCC-3' 
vector linearization F: 5'-GGATCTGACGGTTCACTAMCC-3' pEGFP-
with LAMP1/GFP N3/LAMP1 deletion R: 5'-T AMGCGGCCGCGACTCTA-3' 
vector linearization F: 5'-CTGCTGGACGAGMCAGCAT-3' pEGFP-
with LAMP1 luminal N3/LAMP1 deletion R: 5'-CA TTGCTGCTGACGCACM TG-3' 
F: 5'-CAGGAGCCCTTCACCATGACTTGCAGC 
pET101/D-TOPO CMCCCMTMTTTCC-3' DS1 ChOx insert R: 5'-A TTGAGCTCGCCCTTGAGACCCAGGCT 
GTCCAGC-3' 
F: 5'-GGTTTAGTGMCCGTCAGATCCATGAC 
TTGCAGCCMCCCM TM TTTCC-3' 
DS1 ChOx pEGFP-N3 insert 
R: 5'-TAGAGTCGCGGCCGCTTT AGAGACCCA 
GGCTGTCCAGC-3' 
F: 5'-CATTGTGCGTCAGCAGCMTGACTTGC 
AGCCMCCCMTM TTTCC-3' 
DS1 ChOx LAMP1 insert 
R: 5'-ATGCTGTTCTCGTCCAGCAGGAGACCC 
AGGCTGTCCAGC-3' 
F: 5'-CTGGTTTAGTGMCCGTCAGATCCATGG 
CCTTTATGMGAM TACTTA TTGC-3' 
HSD11131 pEGFP-N3 insert 
R: 5'-TAGAGTCGCGGCCGCTTTACTTATTM 
TGM TCGATCCATGTTAT MGA-3' 
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a variant of pEGFP-N3 (Fig. 6-1) as described above. The variant (obtained from 
Dr. Esteban Dell'Angelica, UCLA) is a construct containing human LAMP1 
cloned in the EcoRI-Sa" sites with a mutant GFP that prevents anti-para"el 
dimerization [287]. The LAMP1 and GFP sequences were deleted during 
linearization for insertion of the HSD11 ~1 gene (pMEV-HSD). For the DS1 ChOx 
sequence, two vectors were created; one in which the LAMP1 and GFP genes 
were also deleted for cytoplasmic targeting (pMEV-COX), and another in which 
only the luminal portion of LAMP1 was deleted (pEGFP-COXL 1). For this latter 
construct, the signal peptide and transmembrane domains of LAMP1 were 
retained for lysosomal targeting of DS1 ChOx. Plasm ids were propagated and 
maintained in E. cloni 10G. After transformation, cells were plated on LB plates 
with kanamycin (50 !-Ig/ml) and incubated overnight at 37°C. All non-competent 
bacterial strains were maintained as 20% glycerol stocks at -80oC. E. coli strains 
were cultivated aerobically in Luria-Bertani (LB) broth or agar plates at 37°C with 
the appropriate antibiotic for plasmid maintenance when necessary. Liquid 
cultures were also shaken at 200 rpm. 
6.2.2. Protein expression 
The purified pET101/D-TOPO construct was used to transform chemically 
competent E. coli BL21 Star cells (Invitrogen, Carlsbad, CA). Transformed cells 
were grown overnight in LB broth with ampicillin, and 2 ml of this was used to 
inoculate 100 ml of additional media. After 2 hours, cultures were induced with 
1 mM IPTG and allowed to grow for four more hours, at which time they were split 
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Figure 6-1. pEGFP-N3 plasmid map. Vector used for construction of 
mammalian expression vectors in this study. For cytoplasmic targeting of 
enzymes, the polylinker and GFP sequences were deleted during peR 
linearization. For lysosomal targeting, the transmembrane domain and signal 
peptide from LAMP1 were utilized, which was inserted between the EcoRI and 
SaIl sites [287]. 
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into 50 ml Falcon tubes and harvested by centrifugation (5000 rpm, 10 min). Cell 
pellets were aspirated and stored at -80°C. 
For protein purification, cells were weighed and subsequently lysed with 
an appropriate amount of B-PER protein extraction reagent 
(Thermo Fisher Scientific, Waltham, MA), lysozyme, and DNase I. This was 
followed by centrifugation (15,000 x g, 5 mins) and recovery of the supernatant. 
Crude extracts were split and half subjected to Ni-NTA column purification 
(HisPur Ni-NTA resin, Pierce Biotechnologies, Rockford, IL) under native 
conditions. Columns were loaded with 1.5 ml of resin and rinsed once with sterile 
water and twice with binding buffer (50 mM NaH2P04, 0.5 M NaCI). 8 ml of lysate 
was then added and allowed to bind under gentle agitation for 1 hour. The resin 
was washed four times with wash buffer (binding buffer with 20 mM imidazole), 
eluted with elution buffer (binding buffer with 250 mM imidazole), and 
concentrated Idesalted using Pierce 9K MWCO protein concentrators and 0.1 M 
potassium phosphate buffer. Proteins were stored at 4°C with the addition of Halt 
Protease Inhibitor (Pierce Biotechnologies, Rockford, IL). 
Protein concentrations were determined using a BCA protein assay 
(Pierce Biotechnologies, Rockford, IL) according to the manufacturer's 
instructions. SOS-polyacrylamide gel electrophoresis (SOS-PAGE) was used to 
determine the presence of the correct size protein band as well as protein purity. 
Aliquots of protein from different stages in the purification process were mixed 
with equal volumes Laemmli sample buffer (containing 0.5% 2-mercaptoethanol) 
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and boiled for 5 minutes in a water bath. 20 1-11 was loaded into each well of a 4-
20% ReadyGel Tris-HCI precast gel in a Mini-PROTEAN Tetra Cell (Bio-Rad, 
Richmond, CA). Spectra™ Multicolor Broad Range Protein Ladder (Fermentas, 
Hanover, MD) was used to monitor the progress of electrophoresis and 
determine protein size. Gels were stained with Coomassie brilliant blue G-250 
and allowed to destain overnight. 
6.2.3. Cholesterol oxidase activity assays 
DS1 ChOx was indirectly assayed for activity against cholesterol and 7KC 
by monitoring oxidation of o-Dianisidine at 500 nm [288]. The reaction buffer 
consisted of 100 mM potassium phosphate buffer containing 0.01 % o-Dianisidine 
(w/v). 10 U of horseradish peroxidase solution and 10 I-Ig of DS1 ChOx were then 
added to 1.8 ml of reaction buffer and allowed to equilibrate. Reactions were 
initiated by the addition 200 1-11 of different concentrations of substrate dissolved 
in 1% Triton X-100, bringing the final volume to 2 ml. Reaction progress was 
monitored by the change in A500 over three minutes. 
HPLC-based assays for DS1 ChOx were also performed with 7KC 
(absorption maxima = 235.8 nm) using 100 mM potassium phosphate as reaction 
buffer and 0.1 % Triton X-100 for detergent micelle formation, and incubating the 
reactions overnight at room temperature with gentle shaking. Lipids were then 
extracted using the method of Bligh and Dyer [268]. Briefly, 7.5 ml 
chloroform:methanol (1:2 v/v) was added to each 2 ml reaction and vortexed. 
This was followed by the addition of 2.5 ml of chloroform with vortexing. 2.5 ml of 
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water was added and, following vortexing, each sample was centrifuged (1000 
rpm, 5 mins) to give a two phase separation. 1 ml of the bottom organic layer 
was removed by Pasteur pipette, filtered through a 0.22 IJm ReZist filter 
(Whatman, Piscataway, NJ), and allowed to evaporate to dryness under a 
nitrogen stream inside an analytical vial. Each sample was analyzed by reverse 
phase HPLC (1.0 ml min-1, 100% methanol) using a Waters 2695 Separation 
Module with a Waters 996 photodiode array (235 nm) and a Waters NovaPak C18 
column (3.9 by 150 mm). Fractions were collected at 30 second intervals for GC-
MS, and chromatographic data was analyzed with the Empower 2 software suite 
(Waters, Milford, MA). 
6.2.4. GC-MS and NMR analysis of DS1 ChOx metabolites 
GC-MS analysis was performed on an Agilent 5973 MSD connected to an 
Agilent 6890 GC system (Agilent, Palo Alto, CA). Samples were injected in 
pulsed splitless mode with an injector temperature of 280°C. The Restek Rtx-
35ms GC column (30 m x 0.25 mm i.d. x 0.1 IJm film thickness) was temperature 
programmed as follows: 110°C (1 min), then 30 °C/min to 240°C, then 1.3 
°C/min to 280°C. MS data were acquired with electron impact (EI) ionization at 
70 eV in full-scan mode (50 to 650 amu) after a 5-min solvent delay. 
Trimethylsilyl (TMS) ether derivatives of sterols were prepared by dissolving each 
sample in 1:1 pyridine/BSTFA, heating the mixture at 60°C for 1 h, and injecting 
2 IJL of the mixture. 
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Proton 1 D NMR spectra were obtained on a 600 MHz Varian (Agilent, 
Palo Alto, CA) Inova NMR spectrometer with an HCN cold probe. Samples were 
dissolved in 99.9% CDCI3 with 0.05% TMS as a proton chemical shift standard. 
The spectrum of the crude reaction mixture was acquired at 25°C with 128 scans 
over a sweep width of 5300 Hz (8.8 ppm). The acquisition time was 6 sec. with a 
relaxation delay of 4 sec.; a 45 degree proton excitation pulse was used. The 
sample was spun at 20 Hz during the acquisition of the spectrum. Since 
resonances from 7KC and the products from its reaction with DS1 ChOx were 
obscured by proton signals from membrane components, the reaction products 
were purified by HPLC. An NMR spectrum of this sample were collected over a 
12-ppm sweep width by taking 640 scans with a 3 sec. acquisition time, a 1 sec. 
relaxation delay, and a 90 degree pulse. Since the HPCL-purified sample was 
less concentrated than the crude reaction mixture, an instrumental artifact from 
the residual protonated chloroform obscured vinyl signals of interest at 5.71 ppm; 
to remedy this, a presaturation pulse of 1 sec was applied at the chemical shift of 
the protonated chloroform (7.26 ppm) to remove this artifact. The spectra 
obtained of the HPLC-purified sample did not allow sufficient time for full 
relaxation; therefore intensity patterns may be skewed due to different relaxation 
rates of different protons. 
6.2.5. Cytotoxicity assays 
WT primary fibroblasts (GM00498) were obtained from Coriell Cell 
Repositories (Camden, NJ). Fibroblasts were grown in minimal essential medium 
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with Earle's salts supplemented with 10% heat-inactivated fetal bovine serum 
and 1 % glutamine-penicillin-strepomycin solution at 3rC in 5% CO2 . Cell 
medium was replaced every 3 or 4 days. Monolayers were passaged upon 
reaching confluency with TrypLE Express (Invitrogen, Carlsbad, CA). 
For cytotoxicity assays, fibroblasts were seeded at approximately 2 x 105 
cells per well in 6-well plates or 5 x 103 cells in 96-well plates containing Eagle's 
minimum essential media (EM EM) with 10% fetal bovine serum and 1 % 
glutamine-penicillin-strepomycin solution, and allowed to recover overnight. Cells 
were exposed to varying concentrations of cholesterol, 7KC, 7KDHEA, or 7KLC 
(ethanol stocks; each well contained a final concentration of 1 % ethanol) for 24 
hours and evaluated for cytotoxicity using an XTT Cell Viability Assay Kit 
(Biotium, Hayward, CA) and monitoring absorbance at 450 nm. Some cells were 
also treated with hydroxypropyl [3-cyclodextrin and 7KC simultaneously. 
Additionally, fibroblasts treated with cholesterol or 7KC were collected and cell 
toxicity tested with the CytoGLO Annexin V-FITC Apoptosis Detection Kit 
(IMGENEX, San Diego, CA) according to the manufacturer's instruction, and 
analyzed by flow cytometry using a FACSCanto II with a 488-nm argon laser 
(Becton Dickinson, Franklin Lakes, NJ). Normal, apoptotic, and dead cell 
percentages were determined for each treatment using 10,000 gated events 
(approximately 10,000 cells). 
To study the effects of heterologous gene expression, fibroblasts were 
seeded in 96-well plates as indicated above, and subsequently transfected with 
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Table 6-2. Plasm ids used in this study. 
Plasmid Product Type Product Source Target 
pcDNA3.1-MC mCherry mammalian cytoplasm Segatori 
pMEV-HSD 11f3-hydroxysteroid mammalian ER This study dehydrogenase 
pEGFP-LAMP1 LAMP1-GFP fusion mammalian lysosome Dell'Angelica [287] 
Chromobacterium Doukyu pBScox sp. DS1 cholesterol E. coli cytoplasm 
oxidase [283] 
DS1 cholesterol 
pET101-COX oxidase with 6xHis E. coli cytoplasm This study 
tag 
pM EV-COX DS1 cholesterol mammalian cytoplasm This study 
oxidase 
Engineered 
pEGFP-COXL 1 cholesterol oxidase- mammalian lysosome This study 
GFP fusion 
pCMV6-XL4- CYP27A1 mammalian mitochondria Origene CYP27 
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plasmid DNA (Table 6-2) using jetPRIME transfection reagent (Polyplus, New 
York, NY) according to the manufacturer's instructions. Fibroblasts were co-
transfected with a small amount of plasmid encoding the fluorescent reporter 
mCherry to evaluate transfection efficiency. After 4 hours, the media was 
exchanged and the cells were allowed to recover for an additional 18 hours 
before the addition of varying concentrations of 7KC. Some non-transfected cell 
populations were amended with either 0.9% or 4.5% hydroxypropyl 13-
cyclodextrin as well. Cell viability was measured after 24 hours using the XTT 
assay as described above. Prior to exposure to 7KC, transfection efficiency was 
gauged by fluorescent plate reader (Excitation 587/Emission 610) as well as 
visualization by fluorescence microscopy. The intracellular expression and 
localization of GFP was observed using an inverted fluorescence microscope (IX-
71, Olympus America, Melville, NY) with a FITC filter set and attached digital 
camera. Images were processed using cellSENS Dimension software. 
6.3. Results 
6.3.1. DS1 cholesterol oxidase is active against 7KC 
The mature form of the DS1 cholesterol oxidase [283] was successfully 
cloned into pET101/D-TOPO using Gibson assembly, expressed in batch, and 
purified to homogeneity using affinity purification. The enzyme was active against 
both cholesterol and 7KC in detergent and mixed micelles. This was supported 
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Figure 6-2. DS1 cholesterol oxidase reaction progress curves. Enzyme 
activity against either A . cholesterol or B. 7KC was measured indirectly by 
monitoring oxidation of o-Dianisidine at 500 nm in 100 mM potassium 
phosphate buffer (pH 7). Substrate mole fraction in detergent micelles (0.10/0 
Triton X-100) varied between 0.05 and 0.50. 
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Figure 6-3. HPLC-based oxidase assays. Purified DS1 cholesterol oxidase 
was incubated for 12 hours with 200 IJM 7KC in 100 mM potassium phosphate 
buffer containing 0.10/0 Triton X-100 (pH 7). Sterols were extracted by the 
method of Bligh and Dyer [268] and separated by reverse phase HPLC. 
Absorbance was monitored at 235 nm. A. Control reaction (no enzyme) showing 
the 7KC peak at 4.5 mins. B. Enzymatic reaction with the peak at 4.5 mins 
completely degraded, and showing two additional peaks at 4.184 and 5.689 
mins. The major product possessed an absorption maximum of 319 nm (peak at 
5.689 mins). 
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by both indirect and HPLC-based assays (Figs. 6-2 and 6-3). Enzyme activity 
against both cholesterol and 7KC increased at higher substrate mole fractions. 
The reaction rate was approximately 8-fold higher for cholesterol than for 7KC at 
a mole fraction of 0.05, and increased to 26-fold higher at a mole fraction of 0.50. 
GC-MS of the HPLC fractions from the 7KC reaction revealed the 
presence of two large peaks, one corresponding to the molecular weight of 7KC 
and the other with a molecular weight two less than that of 7KC (Fig. 6-4). This 
is supportive of 3~-oxidation, which would result in the loss of two hydrogen 
atoms. NMR spectra revealed the presence of two additional shifted peaks at 
approximately 0.7 and 5.7 ppm, which are likely the products of the enzyme 
reaction (Fig. 6-5). Since there is only one additional peak observed during GC-
MS, the two products may be isomers, though we cannot conclusively determine 
this using 1 D NMR. 
6.3.2. 7KC causes necrosis of human fibroblasts 
7KC caused decreased viability of human fibroblasts as determined by the 
XTT assay (Fig. 6-6). 7KC solubilized in ethanol (7KC:EtOH) was more toxic than 
7KC in cyclodextrin (7KC:cyclo) at the same molarity. After 24 hours there was a 
slight decrease in the average viable cell fraction for both treatments at 10 IJM 
(0.96±0.11 for 7KC:EtOH and 0.96±0.02 for 7KC:cyclo). A noticeable divergence 
between treatments occurred at 25 IJM with 7KC:EtOH-treated cells experiencing 
a reduction to 0.15±0.12 viable cell fraction compared to 0.83±0.10 for the 
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Figure 6-4. GC-MS spectra of 7KC metabolite. Fractions from the HPLC-
based assay of DS1 cholesterol oxidase were screen using GC-MS. A. Two 
major peaks were observed with derivitized masses of B. 472 and C. 470. 
These correspond to molecular weights of 400 and 398. The molecular weight 
of 7KC is 400 and that of its 313-oxidized diketone would be 398, providing 
strong evidence for the activity of the DS1 oxidase on 7KC. 
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Figure 6-5. Proton 1 D spectra of the 7KC methyl/methylene (0.65-1.4 ppm) 
and vinyl regions (5.15-5.8 ppm). A. and C. Crude enzymatic reaction, B. and 
D. HPLC-purified reaction mixture. H18 and H19 methyl groups are indicated at 
0.683 and 1.199 ppm of 7 -ketocholesterol (7KC). H6 vinyl proton is indicated at 
5.692 ppm of 7KC. 
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7KC:cyclo-treated cells. At 50 !-1M none of the 7KC:EtOH cells remained, while a 
few of the 7KC:cyclo cells were still viable (0.09±0.04). 
In order to better understand the potential benefits of enzymatically 
transforming 7KC, we also assayed the structurally similar compounds 7KLC and 
7KDHEA (Fig. 5-4) for the ability to reduce fibroblast viability. 7KLC is a more 
highly oxidized molecule that we tested to determine the effect that further 
oxidation of 7KC might have. 7KDHEA possesses the same steroid nucleus as 
7KC, but differs in that the side chain is replaced by a keto group. As expected, 
neither of these compounds showed any toxicity up to 200 !-1M, suggesting that 
oxidation of either the steroid nucleus or side chain is sufficient to reduce 7KC 
toxicity and that further oxidation would not be detrimental. Increasing 
concentrations of both 7KLC and 7KDHEA were actually associated with 
increases in cell viability. While not statistically significant for 7KLC, the effect 
was significant at 50 and 100 !-1M for 7KDHEA, with increases in viable cell 
fraction of 44% and 26% respectively (1.44±0.20 and 1.26±0.1 0, p < 0.05). 
Flow cytometry to assess membrane permeabilization revealed an 
increase in propidium iodide (PI) staining that was positively correlated with 7KC 
concentration (Fig. 6-7). A noticeable PI signal was present at 25 !-1M 7KC, 
indicating a loss of membrane integrity and the presence of dead or necrotic 
cells. No change was apparent in Annexin V-FITC at any concentration, 
suggesting an absence of apoptotic cells. Treatment with the same 
concentrations of cholesterol did not result in increased staining of either PI 
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Figure 6-6. Flow cytometry of cholesterol- and 7KC-treated fibroblasts. 
Cells were treated with either cholesterol or 7KC for 24 hours and then stained 
with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. 
A. Untreated control; B. 50 IJM cholesterol; C. 100 IJM cholesterol ; D. 50 IJM 
7KC; and E. 100 IJM 7KC. A clear increase in PI signal occurs in 7KC 
treatments with no corresponding increase in FITC. This is indicative of PI 
uptake due to membrane permeabilization, likely due to cell necrosis. No 
change occurred in cholesterol-treated cells. 
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Figure 6-7. XTT cell viability assay. Human fibroblasts were treated with 7KC 
(in ethanol), 7KC (in cyclodextrin), 7KLC (in ethanol), or 7KDHEA (in ethanol) at 
concentrations from 0 to 100 jJM. 7KC (in ethanol) displayed the highest toxicity 
while there were slight improvements in cell viability (fraction viable compared to 
untreated) in 7KLC- and 7KDHEA-treated cells. Cells treated with ethanol alone 
showed no change in cell viability (data not shown). 
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or FITC up to 100 IJM. 
6.3.1. 7KC-induced cytotoxicity is attenuated by cyclodextrin or 
transient transfection of lysosomally-targeted cholesterol oxidase 
Transient transfection of fibroblasts with pEGFP-COXL 1, which encodes a 
lysosomally-targeted DS1 ChOx, resulted in significant reduction of the 
cytotoxicity exerted by up to 50 IJM 7KC in comparison to cells transfected with 
pcDNA3.1-MC (control) or pEGFP-LAMP1 (p :5 0.05)(Fig. 6-8). pEGFP-COXL 1 
transfected populations displayed 120% and 160% increased cell viability over 
those transfected with pcDNA3.1-MC at both 25 and 37.5 IJM 7KC, respectively. 
Interestingly, there was also an increase of 44% in cell viability in pEGFP-COXL 1 
transfected, but untreated (no 7KC) cell populations when compared to controls. 
pMEV-COX was also protective to a lesser extent at both 37.5 and 50 IJM. 
However, there was no statistically significant difference compared to pcDNA3.1-
MC at 25 IJM. Additionally, transfection with pEGFP-LAMP1 resulted in an 
average increased cell viability to 50 IJM, although this increase was only 
statistically significant at 37.5 IJM 7KC. GFP expression was verified for both 
pEGFP-COXL 1 and pEGFP-LAMP1 (Fig. 6-9). There was no discernible 
difference between transfection with pCMV6-XL4-CYP27 and the control 
plasmid. However, there was a decrease in cell viability in populations 
transfected with pMEV-HSD. The changes were significant at 0, 37.5, and 50 IJM 
7KC, with 41 %, 38%, and 58% decreases respectively. 
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Figure 6-8. Cytotoxicity analysis of treated human fibroblasts. Both graphs 
show changes in absorbance (450 nm) of XTT due to reduction coupled to 
mitochondrial dehydrogenase that corresponds to differences in cell viability 
(XTT assay). The top panel shows the effect of transfected genes on cell 
viability. Significant differences existed amongst treatments up to 50 j.JM 7KC, 
with transfection by lysosomally-targeted DS1 ChOx being the most 
cytoprotective. The bottom panel shows the effect of either 0.9% or 4.5% 
HP~CD on cell viability. The lower concentration of HP~CD proved to be 
significantly protective from 50 to 1 00 ~M 7KC, while the higher dose was toxic 
by itself. Asterisks (*) denote statistical significance (p :5 0.05). 
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Figure 6-9. Micrographs of transiently transfected fibroblasts. Brightfield 
micrographs taken at 10X of human fibroblasts transfected with 7KC-active 
enzymes (or mCherry control) and incubated for 24 hours in either a or 50 lJM 
7KC. Also, a micrograph of non-transfected cells treated with 0.9% cyclodextrin . 
The two images to the right were taken using fluorescence microscopy to show 
GFP expression in the DS1 ChOx-LAMP1-GFP and LAMP1-GFP constructs (25 
lJM 7KC). 
135 
Concurrent amendment of non-transfected cells with 7KC (ethanol stock) 
and 0.9% hydroxypropyl l3-cyclodextrin provided a high degree of cytoprotection 
against 7KC-induced toxicity up to 1 00 ~M, though this was only significant at 
50 ~M and 1 00 ~M (Fig. 6-8). Changes in cell morphology were not apparent by 
microscopy at 50 ~M (Fig. 6-9), though they were at 1 00 ~M. The addition of 
4.5% was toxic to the fibroblasts without 7KC and at all concentrations. 
6.4. Discussion 
Although oxysterols are potent initiators of apoptosis and necrosis [146, 
156, 209, 260, 279], very few studies have considered methods to control their 
levels in vivo. Overexpression of cholesterol sulfotransferase impairs LXR 
signaling by reducing oxysterol levels [289], and the same enzyme was found to 
reduce 7KC toxicity in 293T cells [212]. To our knowledge, this is the only case 
besides this study of an enzyme being overexpressed in vivo for the purpose of 
reducing oxysterol toxicity. Oxysterols are subject to esterification by ACAT, 
which has been shown to attenuate their toxicity [290]. This is supported by 
reports that ACAT deficiency, though facilitating a reduction in atherosclerotic 
plaque size, also results in increased cell death [291-293]. Similar to ACAT 
deficiency, overexpression of cholesteryl ester hydrolase (CEH) in macrophages 
was found to reduce atherosclerotic plaque size [292], although without a 
concomitant increase in cell death. CEH is known to hydrolyze oxysterol esters 
[294], which should have an adverse effect given the resultant increase in the 
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active oxysterol pool, but in this particular case it appears that the combination of 
enhanced efflux and re-esterification is sufficiently rapid to prevent detrimental 
effects. When re-esterification is inhibited, as in ACAT deficiency, toxicity ensues. 
Hydrolysis of steryl esters also takes place in the lysosome. This is catalyzed by 
lysosomal acid lipase (LAL), which has been shown to reduce coronary and 
aortic atheromatous lesions when introduced intravenously in LDL receptor 
deficient mice [227]. However, this results in an increased oxysterol pool which 
may be cytotoxic and could inhibit sterol efflux [136, 277, 295]. 
All of these pathways serve to either promote the efflux of sterols or their 
esterification outside of the endosomai/lysosomal compartments. No enzymes 
exist in the lysosome that are capable of detoxifying oxysterols, though reactive 
oxygen species generated oxysterols are primarily formed and stored there. In 
oxLDL-loaded macrophage foam cells, approximately 54% of the 7KC is stored 
in the endosomaillysosomal system, with another 40% being stored in the 
plasma membrane [174]. It was for this reason that we investigated the effect of 
targeting a 7KC-transforming enzyme to the lysosome. Most other enzymes that 
are capable of transforming oxysterols are localized to the ER, cytoplasm, or 
mitochondria, making it unlikely they would be capable of preventing lysosomal 
membrane permeabilization. Our results suggest that this is true; transient 
transfection of fibroblasts with plasmid expressing CYP27 A 1, a mitochondrially-
localized hydroxylase, did not display increased viability. 
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The lysosome-associated membrane proteins (LAMP) are transmembrane 
proteins that possess short cytoplasmic tails and highly glycosylated intraluminal 
domains thought to protect the lysosomal membrane from hydrolytic attack. 
Though their function is still not entirely understood, they seem to have roles in 
both lysosome dynamics [287, 296] and stability. Knockdown of either LAMP1 or 
LAMP2 sensitized cells to siramesine-induced cell death and photooxidation-
induced lysosomal destabilization, while overexpression was found to be 
protective [297]. Our results extend the protective effect of LAMP1 to oxysterol-
induced cytotoxicity. The largest increases in cell viability were observed in 
transfections with pEGFP-COXL 1 and pEGFP-LAMP1, and for treatment with 
hydroxypropyl l3-cyclodextrin (HPI3CD). Both of the former appeared to be 
successfully expressed and lysosomally targeted as indicated by fluorescence 
microscopy. Additionally, it has recently been discovered that the ability of 
HPI3CD to facilitate cholesterol efflux from Niemann-Pick type C fibroblasts 
occurs within late endosomes or Iysosomes, and is not due to extraction from the 
cytoplasmic membrane [298, 299]. 
The efficacy of our DS1 ChOx/LAMP1 construct to protect fibroblasts from 
7KC-mediated cell death (which performed better than other treatments) is 
supportive of our main hypothesis that lysosomally-targeted enzymes are 
necessary for the greatest protection against oxysterol-induced toxicity. 
Furthermore, cytoplasmically-targeted DS1 ChOx, though showing some 
cytoprotective benefit, was inferior to lysosomal DS1 ChOx or LAMP1. 
Overexpression of HSD11131 actually resulted in increased cell death (due to 
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formation of 7~-HC), though the effect was of a lower magnitude and statistical 
significance than our lysosomal treatments, which we feel further supports our 
conclusion. Moreover, HP~CD treatment, which showed the greatest overall 
benefit (but which is not directly comparable to transfected cells), is believed to 
increase 7KC efflux from the lysosome to the ER [298-300], where it is capable 
of being esterified by ACA T. 
In summary, we identified a 7KC-active bacterial cholesterol oxidase and 
targeted it to the mammalian lysosome by fusion to the LAMP1 signal sequence 
and transmembrane domain. When transfected in human fibroblasts, this 
construct was superior to other treatments in protecting against 7KC-induced cell 
death. Taken together, these results indicate that the lysosome should be the 
target for treatment of oxysterol-mediated toxicity, and support the utility of using 
microbial enzymes for therapeutic benefit. 
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Chapter 7 
Conclusions and Recommendations 
7.1. Conclusions 
This thesis investigated the microbial degradation of 7 -ketocholesterol, its 
toxicity in cell culture, and potential strategies for mitigating its effects. The 
following points highlight our findings relative to specific objectives: 
1. Determine whether bacteria capable of metabolizing 7KC exist in the 
environment and assess their diversity. 
a. Seven species of bacteria from the Proteobacteria and 
Actinobacteria phyla were isolated from three soil samples and one 
activated sludge sample from a wastewater treatment plant based 
on their ability to exploit the biodegradation of 7KC as a metabolic 
niche. Carbon dioxide evolution in incubations with 7KC (but not in 
unamended controls) indicated extensive mineralization. Growth on 
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7KC as sole carbon source was also demonstrated by monitoring 
substrate degradation over time using HPLC. This suggests that 
oxysterol degradation is a commonly occurring microbial trait. 
2. Determine the genetic basis of 7-ketocholesterol degradation in a 
microorganism. 
a. 7KC degradation was studied in Rhodococcus jostii RHA 1 using a 
whole genome microarray as well as RT-qPCR. Growth on 7KC up-
regulated two large gene clusters of homologs of sterol-catabolizing 
enzymes, in addition to a previously identified cluster required for 
cholesterol deg radation. 
b. Growth on 7KC was completely abolished by the replacement of 
hsaC and deletion of cyp125, individually. This strongly implicates 
the ring-cleavage dioxygenase, HsaC, and the cytochrome P450, 
Cyp125, in the pathway for degradation of 7KC. Deletion of hsaA, 
encoding the oxygenase of a two-component hydroxylase, partially 
impaired, but did not prevent growth on 7KC, suggesting that HsaA 
contributes to 7KC catabolism but is not essential. 
c. Metabolic screening using GC-MS and NMR analysis of culture 
media identified four accumulating metabolites in a LlhsaC mutant, 
providing evidence that reduction and removal of the 7-keto 
substituent occurs prior to the step catalyzed by HsaC. 
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3. Characterize candidate enzymes for their ability to transform 7KC, and 
assess their feasibility for use in controlling oxysterol levels. 
a. While we identified several enzymes in Rhodococcus jostii RHA 1 
involved in 7KC degradation, we were not successful in determining 
which enzymes initiated transformation, though this is likely 
CYP125 and an unidentified 3~-hydroxysteroid dehydrogenase. 
CYP125 was determined to be critical for 7KC catabolism, and was 
capable of initiating transformation of cholesterol [272]. Additionally, 
we were able to clone and express three reductases active against 
analogs structurally similar to 7KC, and likely involved in catalysis 
against a downstream metabolite. 
b. We determined that oxidation of either the 3~-hydroxyl group or 
side chain of 7KC is sufficient to reduce its toxicity in cell based 
culture. We expressed Chromobacterium sp. OS1 cholesterol 
oxidase and found it capable of oxidizing the 3~-hydroxyl group of 
7KC based on indirect assays, NMR, and GC-MS. 
c. Lysosomally-targeted OS 1 cholesterol oxidase was successful in 
partially attenuating 7KC cytotoxicity and provided a higher degree 
of protection than either LAMP1, cytoplasmically-targeted OS1 
oxidase, or CYP27A1 overexpression. 
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7.2. Recommendations 
During the course of this thesis we investigated methods of oxysterol 
transformation, with a particular interest in enzymatic transformations that 
attenuate 7KC toxicity. We discovered several microbial species that may 
become sources of enzymes for future work, and we identified catabolic 
pathways in Rhodococcus jostii RHA 1 that helped us elucidate how bacteria 
catabolize oxysterols. However, the ultimate objective of our work is to develop a 
method of reducing cytotoxic oxysterol levels in vivo, either for therapeutic use, 
or to use as a tool to further study oxysterol formation and effects. In an advance 
toward this, we assayed a 7KC-active cholesterol oxidase from 
Chromobacterium sp. DS 1 for its ability to protect human fibroblasts against 7KC 
cytotoxicity. Our preliminary results are promising and indicate that 
overexpression of our construct may be useful in accomplishing this, however 
much work also remains. 
Our cytotoxicity assays were done using human fibroblasts transiently 
transfected with constitutively expressed plasmids. While this proved useful as 
an initial screening method, the process of transfection is itself toxic and may 
interfere with results. More definitive conclusions could be made utilizing stably 
transfected cell lines with inducible expression. And while we were able to 
determine protein expression by the presence of GFP (in the case of pEGFP-
COXL 1), we cannot assume that enzyme activity was present inside the 
lysosome. LAMP1, the protein we used to target the DS1 oxidase, is itself 
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protective against 7KC, so the possibility cannot be excluded that the effect 
comes from other properties of the construct than its catalytic activity. 
Nevertheless, our results are strongly suggestive that intralysosomal 
transformation of 7KC is cytoprotective, and that targeting treatments to the 
lysosome is the best way to attenuate the detrimental effects of oxysterols in 
vivo. 
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Appendix A 
Functional groups of differentially 
expressed genes in Rhodococcus jostii 
Expression ratio 
GenelD Product CHOI 7KCI 7KCI 
PYR PYR CHO 
Signaling and transcriptional regulation 
ro01881 possible tyrosine protein phosphatase 1.2 15.7 4.1 
ro02115 anti-sigma factor antagonist 1.6 10.1 1.3 
ro02116 conserved hypothetical protein 0.9 1.6 0.7 
ro02117 possible anti-sigma factor NO 11.0 0.9 
ro02118 sigma factor, sigma 70 type, group 3 NO 9.1 0.8 
ro02829 possible transcriptional regulator 1.4 4.5 0.8 
ro03251 possible transcriptional regulator, WhiB family NO 3.7 0.7 
ro04316 possible transcriptional regulator, WhiB family 1.9 6.4 1.0 
ro04454 transcriptional regulator, GntR family 1.6 3.9 0.6 
ro05371 probable transcriptional regulator, ArsR family 1.5 7.8 0.8 
ro05735 possible protein-tyrosine kinase, G-terminal 0.7 35.7 0.9 
ro06593 hypothetical protein NO 141.9 0.7 
ro06594 possible transcriptional regulator, AraG family 1.2 24.1 0.6 
ro10163 transcriptional regulator 0.4 5.8 0.5 
ro10389 protein kinase/ transcriptional regulator, LuxR family 0.9 5.0 0.6 
Catabolism 
ro01882 short chain dehydrogenase 1.1 9.1 4.8 
ro01883 short chain dehydrogenase 1.1 22.7 5.0 
ro03609 steroid delta-isomerase 2.6 6.8 2.2 
ro03841 probable 3-oxoacyl-[ acyl-carrier -protein 1 red uctase 0.6 2.8 2.4 
ro04283 possible acyl-GoA dehydrogenase 1.3 10.2 4.7 
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ro04427 conserved hypothetical protein 1.8 2.6 0.9 
ro04428 probable thiocyanate hydrolase gamma subunit 2.8 16.3 0.6 
ro04429 probable thiocyanate hydrolase alpha subunit 1.5 8.1 0.5 
ro04430 probable thiocyanate hydrolase beta subunit 1.1 2.2 0.6 
ro04431 conserved hypothetical protein 1.4 9.1 0.6 
ro04432 possible dithiol-disulfide isomerase 0.8 1.2 1.2 
ro04433 hypothetical protein 0.6 0.8 1.6 
ro04434 conserved hypothetical protein 1.3 2.7 1.3 
ro04601 hydrogenase nickel incorporation protein HypA 1.5 2.0 0.6 
ro04602 hydrogenase nickel incorporation protein HypB 1.0 1.7 0.4 
ro04603 Ni-Fe hydrogenase small subunit 1.2 4.1 0.6 
ro04604 Ni-dependent hydrogenase large subunit 7.5 24.8 0.6 
ro04605 possible nitrogen fixation protein 0.9 0.9 1.0 
ro04606 conserved hypothetical protein 1.1 1.8 0.8 
ro04607 conserved hypothetical protein NO 4.6 0.9 
ro04608 conserved hypothetical protein 0.9 2.4 0.9 
ro04609 hydrogenase maturation protease 1.7 14.5 0.6 
ro06637 3-oxoacyl-[acyl-carrier-protein] reductase 1.2 4.0 1.9 
ro06638 conserved hypothetical protein NO 9.6 5.7 
Possible gas vesicle synthesis 
ro00203 conserved hypothetical protein 0.9 12.5 0.2 
ro00204 conserved hypothetical protein 1.4 3.2 0.4 
ro00205 gas vesicle synthesis protein 1.1 1.8 0.3 
ro00206 probable gas vesicle synthesis protein 3.1 6.8 0.5 
ro00207 possible gas vesicle synthesis protein 1.5 2.1 0.7 
ro00208 probable gas vesicle synthesis protein NO 3.0 0.6 
ro00209 gas vesicle synthesis protein 0.6 0.6 1.0 
ro0021 0 probable gas vesicle synthesis protein 1.5 2.2 0.6 
ro00211 probable gas vesicle protein 0.9 2.0 1.1 
ro00705 conserved hypothetical protein 1.3 3.0 2.4 
ro00706 conserved hypothetical protein NO 5.6 0.5 
ro00707 gas vesicle structural protein NO 1.1 0.4 
ro00708 possible gas vesicle synthesis protein NO 1.7 1.0 
ro00709 possible gas vesicle synthesis protein NO 1.1 0.8 
ro0071 0 possible gas vesicle synthesis protein NO 4.6 0.7 
ro00711 gas vesicle protein NO 2.3 0.8 
ro00712 probable gas vesicle protein NO 1.4 1.1 
ro00713 possible gas vesicle synthesis protein 1.2 1.2 1.0 
Transport 
roOO071 multidrug resistance transporter, MFS superfamily 0.7 14.2 5.2 
ro00301 metabolite transporter, MFS superfamily 0.4 0.2 1.0 
ro01597 possible transcriptional activator TenA 0.3 0.3 1.0 
ro01598 probable ABC transporter, permease component 0.3 0.3 1.1 
ro01599 ABC transporter, permease component 0.4 0.3 1.0 
ro01600 ABC transporter, ATP-binding component 1.1 0.4 1.4 
ro05372 conserved hypothetical protein 1.9 10.0 1.0 
ro06547 metabolite transporter, MFS superfamily 0.5 0.2 1.0 
Cell wall synthesis 
ro01087 UOP-N-acetylmuramate--L-alanine ligase 0.7 0.8 1.5 
ro01088 beta-N-acetylglucosaminyltransferase 0.7 0.7 1.0 
ro01089 cell division protein, FtsW 0.8 0.7 0.9 
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ro01090 UDP-N-acetylmuramoylalanine--D-glutamate ligase 1.6 1.0 0.8 
ro01091 phospho-N-acetylmuramoyl-pentapeptide-transferase 0.6 0.7 1.5 
ro01092 UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase 0.6 0.4 1.6 
ro01093 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate 1.1 0.4 1.7 
ligase 
ro01094 peptidoglycan glycosyltransferase 9.0 0.6 1.0 
ro01095 possible conserved membrane protein 0.9 0.5 1.3 
ro01096 S-adenosyl-methyltransferase 0.5 0.4 0.8 
ro01097 possible protein MraZ 0.6 0.4 0.5 
ro01921 elongation factor EF1A 0.3 0.3 1.4 
ro01922 elongation factor G 0.4 0.4 1.5 
ro04058 probable mycolyltransferase 0.6 0.5 1.8 
ro04059 probable antigen 85 complex protein 0.3 0.2 0.9 
ro04060 probable antigen 85 complex protein 0.4 0.4 1.3 
ro05733 conserved hypothetical protein 1.2 3.1 0.9 
ro05734 possible mannuronan epimerase 1.1 15.5 1.0 
ro05736 hypothetical protein 5.3 47.0 0.4 
ro05737 conserved hypothetical protein 1.3 8.8 0.6 
ro05738 probable O-antigen transporter, MOP superfamily 1.1 2.9 0.8 
ro05739 possible glycosyltransferase 1.3 6.4 1.1 
ro05740 probable glycosyltransferase 1.0 8.1 0.8 
ro05741 possible glycosyl transferase 1.2 3.6 0.7 
ro05742 sugar transferase 2.2 11.2 0.7 
ro05743 possible transferase ND 26.9 1.1 
ro05744 dTDP-4-dehydrorhamnose 3,5-epimerase 1.3 1.5 1.2 
ro05745 probable UDP-glucose 4-epimerase 1.4 3.3 0.7 
ro05746 conserved hypothetical protein 2.2 19.4 0.8 
ro05747 probable glucose-1-phosphate cytidylyltransferase 0.7 1.3 0.7 
ro05748 probable methyltransferase 1.5 2.3 0.9 
Electron transport 
ro01133 ubiquinol-cytochrome c reductase cytochrome b subunit 0.7 1.2 0.8 
ro01134 possible transport protein 0.7 1.3 0.9 
ro01135 probable transcriptional regulator, TetR family 1.2 1.8 0.8 
ro01136 conserved hypothetical protein 0.9 0.7 1.0 
ro01137 probable cytochrome c oxidase subunit II 0.4 0.2 1.3 
ro02032 cytochrome c assembly membrane protein 0.3 0.3 0.9 
ro02033 possible cytochrome c biogenesis membrane protein 0.7 1.0 1.0 
ro02034 cytochrome c biogenesis membrane protein 0.7 0.6 1.6 
ro02035 possible thioredoxin 0.8 0.7 1.5 
ro02036 conserved hypothetical protein 0.6 0.4 1.3 
ro04847 cytochrome bd ubiquinol oxidase subunit I 0.6 0.3 1.0 
ro04848 cytochrome bd ubiquinol oxidase subunit II 0.4 1.0 
ro04849 transport ATP-binding protein CydD 0.9 0.6 1.4 
ro04850 transport ATP-binding protein CydC 1.2 0.7 1.2 
ro06461 probable 3-demethylubiquinone-9 3-0-methyltransferase 0.4 0.3 0.9 
ro06462 electron transfer flavoprotein beta-subunit 0.5 0.2 1.7 
ro06463 electron transfer flavoprotein alpha-subunit 0.6 0.3 1.1 
H+-driven ATPase 
ro01471 H(+)-transporting two-sector ATPase epsilon subunit 1.0 0.6 1.3 
ro01472 H(+)-transporting two-sector ATPase beta subunit 0.3 0.1 1.3 
ro01473 H(+)-transporting two-sector ATPase gamma subunit 0.3 0.2 1.2 
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ro01474 H(+)-transporting two-sector ATPase alpha subunit 0.2 0.1 1.2 
ro01475 ATP synthase delta subunit 0.3 0.2 1.1 
ro01476 H(+)-transporting two-sector ATPase subunit B 0.7 0.4 0.8 
ro01477 H(+)-transporting two-sector ATPase subunit C 0.3 0.2 1.1 
ro01478 probable H(+)-transporting two-sector ATPase subunit A 0.4 0.2 1.7 
Tricarboxylic-acid cycle and glycolysis 
ro02070 phosphoglycerate mutase 0.4 0.2 0.9 
ro02122 isocitrate lyase 0.3 0.2 0.9 
ro02123 conserved hypothetical protein 1.1 0.8 
ro06238 isocitrate dehydrogenase (NADP+) 0.4 0.2 1.5 
ro06244 malate dehydrogenase 0.4 0.7 1.4 
ro06245 succinate dehydrogenase Fe-S protein 0.3 0.3 1.1 
ro06246 succinate dehydrogenase 0.3 0.3 1.5 
ro06247 probable succinate dehydrogenase hydrophobic membrane 0.6 0.3 1.1 
anchor protein 
ro06248 probable succinate dehydrogenase hydrophobic membrane 0.3 0.2 1.2 
anchor protein 
ro07177 glyceraldehyde 3-phosphate dehydrogenase 0.3 0.2 0.9 
ro07178 phosphoglycerate kinase 0.4 0.5 1.2 
ro07179 triose-phosphate isomerase 1.0 0.4 1.0 
ro07180 possible protein-export membrane protein 0.4 0.4 1.0 
ro07181 phosphoenolpyruvate carboxylase 0.8 0.9 0.8 
ro07182 6-phosphogluconolactonase 0.9 0.8 1.2 
ro07183 conserved hypothetical protein 0.4 0.5 0.9 
ro07184 glucose-6-phosphate 1-dehydrogenase 0.4 0.6 0.9 
ro07185 transaldolase 0.4 0.5 1.2 
ro07186 transketolase 0.5 0.7 1.1 
ro07207 aconitate hydratase 0.3 0.2 0.9 
Translation 
ro01923 30S ribosomal protein S7 0.5 0.3 1.2 
ro01924 30S ribosomal protein S12 0.6 0.4 1.1 
ro01975 50S ribosomal protein L7/L 12 0.3 0.2 1.1 
ro01976 50S ribosomal protein L 10 0.2 0.2 1.8 
ro01977 possible antibiotic efflux protein 1.4 1.5 0.6 
ro01978 50S ribosomal protein L 1 0.4 0.2 0.6 
ro01979 50S ribosomal protein L 11 0.9 1.3 0.5 
ro01980 transcription antitermination protein 0.3 0.4 1.0 
ro01981 probable protein translocation complex preprotein translocase 0.6 0.9 1.0 
subunit 
ro01982 tRNA-Trp (CCA) 0.6 0.9 
ro01983 possible fatty acid synthase beta subunit 0.6 0.7 0.8 
ro01984 conserved hypothetical protein 0.4 0.4 1.1 
ro01985 50S ribosomal protein L33 type 2 0.4 0.4 2.1 
ro05085 possible translation initiation factor 0.8 0.3 0.8 
ro06132 30S ribosomal protein S10 0.5 0.6 2.1 
ro06133 50S ribosomal protein L3 0.4 0.3 2.4 
ro06134 50S ribosomal protein L4 0.6 0.6 1.9 
ro06135 50S ribosomal protein L23 0.5 0.4 1.7 
ro06136 50S ribosomal protein L2 0.4 0.4 1.8 
ro06137 30S ribosomal protein S 19 0.5 0.3 1.6 
ro06138 50S ribosomal protein L22 0.4 0.2 2.1 
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ro06139 30S ribosomal protein S3 0.4 0.3 1.4 
ro06140 50S ribosomal protein L 16 0.4 0.2 1.4 
ro06141 50S ribosomal protein L29 0.4 0.3 2.1 
ro06142 30S ribosomal protein S17 0.4 0.4 1.4 
ro06143 50S ribosomal protein L 14 0.4 0.3 1.2 
ro06144 50S ribosomal protein L24 0.3 0.3 1.6 
ro06145 50S ribosomal protein L5 0.4 0.3 1.5 
ro06146 30S ribosomal protein S14 0.3 0.3 1.8 
ro06147 30S ribosomal protein S8 0.3 2.0 
ro06148 50S ribosomal protein L6 0.3 0.3 1.5 
ro06149 50S ribosomal protein L 18 0.3 0.2 1.3 
ro06150 30S ribosomal protein S5 0.3 1.4 
ro06151 50S ribosomal protein L30 0.3 0.3 2.4 
ro06152 50S ribosomal protein L 15 0.5 0.3 1.6 
ro06153 preprotein translocase 0.6 0.4 1.6 
ro06154 adenylate kinase 0.4 0.4 1.1 
ro06155 methionyl aminopeptidase 0.4 0.4 1.2 
ro06156 D-tyrosyl-tRNA(Tyr) deacylase 1.0 1.0 0.7 
ro06157 translation initiation factor IF1 0.4 1.7 
ro06158 50S ribosomal protein L36 0.4 2.1 
ro06159 30S ribosomal protein S13 0.3 1.0 
ro06160 30S ribosomal protein S11 0.4 0.6 2.0 
ro06161 30S ribosomal protein S4 0.4 0.2 1.3 
ro06162 DNA-directed RNA polymerase alpha subunit 0.3 0.3 1.6 
ro06163 50S ribosomal protein L 17 0.3 0.3 2.1 
ro06164 pseudouridylate synthase 1.2 0.5 1.3 
ro06165 conserved hypothetical protein 2.3 3.1 0.5 
ro06166 conserved hypothetical protein 0.1 1.4 
ro06167 probable transcriptional regulator, AsnC family 1.2 1.3 
ro06168 conserved hypothetical protein 2.0 1.7 1.0 
ro06169 ornithine--oxo-acid transaminase 1.1 0.9 1.3 
ro06170 50S ribosomal protein L 13 0.7 0.4 0.9 
ro06171 30S ribosomal protein S9 0.5 0.3 1.3 
Chaperones 
ro02146 60 kDa chaperonin GroEL 0.3 0.1 0.6 
ro05497 heat shock protein Hsp70 0.8 0.2 0.5 
ro05498 heat shock protein GrpE 1.2 0.3 1.0 
ro05892 chaperone protein HtpG (heat shock protein HtpG) 0.4 0.3 0.8 
ro06190 chaperone protein 0.4 0.1 1.2 
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Appendix 
B 
Expression ratios of Rhodococcus jostii 
RHA1 steroid degradation clusters 
Ex~ression ratio 1 
CHO 7KC 7KC 
GenelD Product versus versus versus 
PYR PYR CHO 
Cluster 1 
ro04531 possible MaoC family protein 3.2 3.7 0.9 
ro04532 probable succinate dehydrogenase flavoprotein 3.3 2.4 0.8 
ro04533 hydratase 2.0 1.5 1.3 
ro04534 acetaldehyde dehydrogenase 3.2 4.3 1.2 
ro04535 4-hydroxy-2-oxovalerate aldolase 5.1 1.8 1.0 
ro04536 conserved hypothetical protein 1.5 1.7 0.8 
ro04537 conserved hypothetical protein 2.6 2.3 1.4 
ro04538 probable terminal oxygenase fot steroid degradation 4.6 4.0 0.4 
ro04539 possible hydroxylase 20.3 12.0 0.6 
ro04540 alpha/beta-fold C-C bond hydrolase 9.2 4.9 0.8 
ro04541 extradiol dioxygenase, type I 2.1 2.2 1.3 
ro04542 oxidoreductase 9.3 2.0 1.0 
ro04679 cytochrome P450 CYP125 11.0 5.7 0.9 
ro04680 possible erythromycin esterase 3.2 1.8 0.8 
ro04681 conserved hypothetical protein 2.4 5.7 1.2 
ro04682 conserved hypothetical protein 1.0 1.4 0.8 
ro04683 probable nonspecific lipid carrier protein 3.7 2.6 0.9 
ro04684 probable thiolase 1.3 1.2 1.5 
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ro04685 conserved hypothetical protein 3.4 4.1 1.1 
ro04686 reductase 1.8 2.3 0.9 
ro04687 conserved hypothetical protein 1.5 1.5 1.7 
ro04688 probable enoyl-CoA hydratase 1.8 2.5 0.5 
ro04689 AMP-binding CoA ligase 12.5 11.1 0.5 
ro04690 probable 2-nitropropane dioxygenase 5.5 4.0 0.6 
ro04691 probable long-chain fatty-acid--CoA ligase 3.6 2.2 1.2 
ro04692 CoA dehydrogenase 1.7 0.7 1.1 
ro04693 probable acyl-CoA dehydrogenase 9.5 8.5 0.8 
ro04694 possible ferredoxin 7.1 0.5 
ro04695 probable 3-oxoacyl-[ acyl-carrier -protei n] red uctase 7.2 3.2 0.9 
ro04696 conserved hypothetical protein 3.6 2.7 0.9 
ro04697 conserved hypothetical protein 2.7 1.1 1.3 
ro04698 possible Mce family protein 2.3 1.6 0.6 
ro04699 possible Mce family protein 2.2 2.7 0.8 
ro04700 possible Mce family protein 2.5 1.7 0.5 
ro04701 possible Mce family protein 1.7 1.4 1.0 
ro04702 possible Mce family protein 3.0 1.7 0.9 
ro04703 possible Mce family protein 0.8 1.0 1.2 
ro04704 conserved hypothetical protein 1.7 1.6 0.8 
ro04705 conserved hypothetical protein 0.8 0.7 1.3 
ro04706 conserved hypothetical protein 0.8 1.0 1.5 
ro04707 reductase 5.0 2.1 0.7 
Cluster 2 
ro02478 short-chain dehydrogenase 2.0 3.4 1.0 
ro02479 conserved hypothetical protein 1.5 1.8 1.1 
ro02480 carveol dehydrogenase 0.9 69.6 7.9 
ro02481 carveol dehydrogenase 1.3 6.5 5.6 
ro02482 conserved hypothetical protein 0.9 29.4 8.0 
ro02483 3-ketosteroid-delta-1-dehydrogenase 0.9 12.8 2.9 
ro02484 probable nitrilotriacetate monooxygenase component B 0.6 1.3 2.4 
ro02485 transcriptional regulator, PadR family 0.3 0.8 1.1 
ro02486 probable sterase / lipase 2.1 38.0 6.4 
ro02487 transcriptional regulator, IclR family 0.8 2.6 2.7 
ro02488 extradiol dioxygenase, type I 1.1 42.9 10.4 
ro02489 pigment production hydroxylase 0.8 10.6 11.5 
ro02490 probable dioxygenase Rieske iron-sulfur component 2.2 148.4 7.3 
ro02491 hypothetical protein 1.0 2.8 3.1 
ro02492 cyclohexanone monooxygenase 0.8 59.3 11.8 
Cluster 3 
ro05787 probable transcriptional regulator, AraC family 1.1 1.7 2.4 
ro05788 probable transcriptional regulator, MarR family 1.0 2.1 1.3 
ro05789 (+)-trans-carveol dehydrogenase 1.6 9.1 2.9 
ro05790 probable 3-oxoacyl-[acyl-carrier-protein] reductase 6.0 19.5 6.5 
ro05791 dehydrogenase 0.9 8.4 4.1 
ro05792 multidrug transporter, MFS superfamily 0.9 18.4 7.4 
ro05793 conserved hypothetical protein 1.2 5.2 2.2 
ro05794 conserved hypothetical protein 1.1 5.6 2.9 
ro05795 probable transcriptional regulator, IclR family 0.7 20.0 3.5 
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ro05796 probable oxidoreductase 0.5 0.9 1.3 
ro05797 alpha/beta-fold C-C bond hydrolase 1.4 5.1 3.7 
ro05798 possible dehydrogenase 1.8 5.7 5.9 
ro05799 2-keto-4-pentenoate hydratase, bphE homolog 1.4 15.7 4.8 
ro05800 acetaldehyde dehydrogenase (acetylating) 0.8 3.1 2.9 
ro05801 4-hydroxy-2-oxovalerate aldolase, bphF homolog 2.2 1.6 
ro05802 hydroxylase 1.0 5.8 3.3 
ro05803 extradiol dioxygenase, type I 1.6 2.2 1.2 
ro05804 conserved hypothetical protein 0.6 29.7 5.9 
ro05805 conserved hypothetical protein 1.3 1.1 1.4 
ro05806 conserved hypothetical protein 1.0 1.7 1.3 
ro05807 possible transmembrane protein 0.5 0.9 2.0 
ro05808 conserved hypothetical protein 0.5 2.7 1.3 
ro05809 probable 3-oxoacyl-[acyl-carrier-protein] reductase 0.7 1.7 0.9 
ro05810 probable dehydrogenase 1.1 6.2 3.6 
ro05811 probable dioxygenase Rieske iron-sulfur component 1.7 53.2 9.8 
ro05812 probable hydroxylase 1.8 5.4 2.1 
ro05813 probable 3-oxosteroid 1-dehydrogenase 1.2 22.0 3.4 
ro05814 probable transcriptional regulator, TetR family 1.3 4.2 2.9 
ro05815 probable thiolase 0.9 31.6 4.8 
ro05816 possible acyl-CoA dehydrogenase 1.0 27.9 6.6 
ro05817 possible MaoC family dehydratase 0.8 5.9 7.1 
roO!;i818 conserved hypothetical protein 0.6 4.4 6.1 
ro05819 probable (+ )-trans-carveol dehydrogenase 1.6 13.2 7.2 
ro05820 CoA ligase 1.6 3.9 1.3 
ro05821 probable NADH-dependent flavin oxidoreductase 18.4 5.8 
ro05822 acyl-CoA synthetase 1.0 2.8 1.9 
ro05823 conserved hypothetical protein 1.1 1.9 2.0 
ro05824 conserved hypothetical protein 2.1 2.9 2.1 
ro05825 acyl-CoA dehydrogenase 1.8 4.6 1.8 
ro05826 conserved hypothetical protein 0.5 3.5 4.9 
ro05827 acyl-CoA dehydrogenase 0.8 3.2 2.4 
ro05828 conserved hypothetical protein 4.2 1.7 
ro05829 conserved hypothetical protein 1.0 4.0 2.9 
ro05830 conserved hypothetical protein 0.6 1.1 1.7 
ro05831 0.7 
ro05832 reductase 1.4 2.2 2.1 
ro05833 probable oxidoreductase 1.5 1.0 0.9 
Cluster 4 
ro09002 oxygenase reductase KshB 1.5 1.6 1.1 
ro09003 terminal oxygenase KshA 6.2 45.1 8.2 
ro09004 probable hydroxylase 1.3 0.9 1.0 
ro09005 extradiol ring-cleavage dioxygenase, BphC homolog 1.1 2.5 2.4 
ro09006 conserved hypothetical protein 1.8 0.8 0.8 
ro09007 probable short-chained dehydrogenase 1.0 1.2 0.8 
ro09008 conserved hypothetical protein 1.2 1.0 0.8 
ro09009 probable transposase 1.0 0.9 1.0 
ro09010 probable lipase/esterase 1.3 0.9 0.7 
ro09011 hypothetical protein 1.2 1.1 
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ro09012 possible flavoprotein oxidoreductase 1.5 1.0 
ro09013 conserved hypothetical protein 1.6 1.2 
ro09014 alpha/beta-fold C-C bond hydrolase 0.8 1.0 
ro09015 conserved hypothetical protein 0.9 
ro09016 conserved hypothetical protein 1.6 1.1 
ro09017 transcriptional regulator, PadR family 1.0 
ro09018 acetaldehyde dehydrogenase 1.8 0.2 
ro09019 4-hydroxy-2-oxovalerate aldolase 0.7 0.9 
ro09020 hypothetical protein 1.0 
ro09021 0.9 
ro09022 transcriptional regulator, IclR family 1.9 2.4 
ro09023 probable fumarate reductase 1.1 1.5 
ro09024 fragment of 3-ketosteroid-1-dehydrogenase 2.5 1.4 
ro09025 fragment of 3-ketosteroid-1-dehydrogenase 1.0 1.1 
ro09026 probable lipase/esterase 0.8 0.7 
ro09027 transcriptional regulator, GntR family 0.9 0.8 
ro09028 possible CoA-transferase 0.7 1.0 
ro09029 acyl-CoA dehydrogenase 1.3 0.9 
ro09030 probable acyl-CoA dehydrogenase 1.4 
ro09031 possible enoyl-CoA hydratase 0.9 
ro09032 short-chained dehydrogenase 0.6 1.6 
ro09033 hypothetical protein 0.6 
ro09034 transcriptional regulator, IclR family 1.4 1.1 
ro09035 monooxygenase 1.3 1.1 
ro09036 lipase/esterase 1.5 0.9 
ro09037 possible short-chained dehydrogenase 1.0 0.7 
ro09038 probable short-chained dehydrogenase 1.6 1.0 
ro09039 probable monooxygenase 0.7 0.9 
ro09040 3-ketosteroid delta( 1 )-dehydrogenase 1.5 1.0 
2 
Expression ratios that are statistically significant (p ~ 0.05) are bolded. 
Data adapted from Van der Geize et al. (37) 
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